Protac degraders of MLLT1 and / or MLLT3

Abstract

The invention relates to a compound which is a Proteolysis Targeting Chimera (PROTAC) or a pharmaceutically acceptable salt thereof, wherein the PROTAC has the structure (AA) wherein U is an E3 ubiquitin ligase binding moiety, LINK is a moiety that covalently links M and U, and M is an MLLT1 and / or MLLT3 binder of formula (I) wherein Z1, Z2, Y1, Y2, Y3, R1, R2, R8, X, L and Hy are as defined herein, and either R8 is a bond to LINK, or M is bonded to LINK via a C or N atom within group R8 or ring Hy such that a hydrogen atom on the C or N atom within group R8 or ring Hy is replaced with a bond to LINK. The compounds are useful in the treatment of cancer.

Description

[0001] PROTAC DEGRADERS OF MLLT1 AND / OR MLLT3 Field of the Invention The present invention relates to compounds that find use in the treatment of cancer by inducing selective degradation of MLLT1 and / or MLLT3. The invention also provides such compounds per se, pharmaceutical compositions comprising such compounds, and methods of treating cancer by administering such compounds. Background The processes controlling gene transcription are highly regulated during development and normal homeostasis. Dysregulation of gene transcription is a common driver of cancer with somatic defects in proteins that control gene transcription a frequent occurrence (Cell, 2013, 153, 17; Cell, 2017, 168, 629). Transcriptional elongation is a central step in gene transcription, carried out by the RNA polymerase II (PolII), which itself is kept under tight control by regulatory protein complexes. During development PolII is recruited to sites of the genome proximal to the transcription start site for target genes and is kept in a paused state. Such target genes are often immediate response genes such as heat-shock genes and key developmental genes. Productive elongation is initiated by the coordinated interplay of regulatory protein complexes including the super elongation complex (SEC). The SEC includes multiple proteins with diverse functions including protein phosphorylation, histone reader, histone modification and regulatory activities. Critical to the recruitment of the SEC to target genes are the histone reader proteins MLLT1 (mixed lineage leukaemia translocated to 1, also known as eleven- nineteen leukaemia, ENL) and MLLT3 (mixed lineage leukaemia translocated to 3, also known as AF-9). MLLT1 and 3 contain essential YEATS domains that bind acetylated histones. Mutations in the YEATS domains reduce loading of PolII on to SEC target genes and suppression of gene transcription. (Cell Mol Life Sci 2018, 75, 3931; Nat Rev Mol Cell Biol 2012, 13, 543). Gain-of-function mutations in the MLLT1 Yeats domain have been causally associated with Wilm’s tumor (also known as nephroblastoma) a kidney cancer most commonly observed in children (Nature 2020, 577, 121). Additionally, it has been shown that for certain acute leukaemias MLLT1 represents a critical dependency (Nature 2017, 543, 270). Such leukaemias include mixed-lineage leukaemia (MLL) rearranged leukaemia. MLL rearrangements arise from in frame fusions of the MLL gene with more than 80 different partner genes, many of which are involved in the regulation of transcription elongation including components of the SEC (Front. Pediatr.5:4. doi: 10.3389 / fped.2017.00004). MLL rearrangements are observed in approximately 10% of all acute leukaemias including a high frequency in infantile ALL where it accounts for 70-80% of all cases (Front. Pediatr.5:4. doi: 10.3389 / fped.2017.00004). Notably it is reported that patients with MLL rearranged leukaemias have an especially poor prognosis (New Engl J Med 2016, 374, 2209). Target genes for MLL-SEC complexes include potent oncogenes such as BCL-2, Myc and CDK6 along with many other genes implicated in maintaining cancer cell self-renewal, growth and survival, such as the HOX family genes and MEIS1 (Front. Pediatr.5:4. doi: 10.3389 / fped.2017.00004). Consistent with a role in the regulation of multiple oncogenes, it has been demonstrated that the SEC can play a critical role in the transcriptional addiction of both hematopoietic and solid cancers. For example, data supports potential in non-MLL rearranged leukaemia (Cancer Disc 2022, 12, 2684) and it is reported that with some breast cancer cells, growth and survival is dependent on a SEC mediated transcription of the Myc oncogene (Cell Rep.2021 Feb 16;34(7):108749. doi: 10.1016 / j.celrep.2021.108749. PMID: 33596420; PMCID: PMC8006859). Taken together the evidence supports MLLT1 and / or MLLT3 as an attractive therapeutic target across acute leukaemias and solid cancers. Proteolysis targeting chimeras (PROTACs) have been proposed as a small molecule-based platform technology capable of inducing proteolysis of a target protein in the body. The PROTAC is a bifunctional compound in which a molecule that binds to a disease-related target protein and an E3 ubiquitin ligase binding moiety are linked by a chemical linker. Theoretically, the PROTAC compound is capable of inducing degradation of the target protein by placing the disease-related target protein near the E3 ubiquitin ligase. Drug discovery efforts have resulted in agents that either bind the YEATS domain to block the MLLT1 and / or MLLT3 protein to histone interaction or that result in degradation of the MLLT1 and / or MLLT3 protein (using a PROTAC approach). In all cases however, the reported activity has been weak (ACS Cent Sci 2021, 7, 815; Cancer Disc 2022, 12, 2684; Angew. Chem. Int. Ed.2018, 57, 16302). Accordingly, there remains a high need to identify potent modulators of MLLT cell function. Summary of the Invention The inventors have discovered a series of compounds that induce selective degradation of MLLT1 and / or MLLT3. Accordingly, the invention provides a compound which is a Proteolysis Targeting Chimera (PROTAC) or a pharmaceutically acceptable salt thereof, wherein the PROTAC has the structure: wherein U is an E3 ubiquitin ligase binding moiety, LINK is a moiety that covalently links M and U, and M is an MLLT1 and / or MLLT3 binder of formula (I): wherein: one of Z1and Z3is -N(H)- and the other is N or -C(R4)-, Y1is N, Y2is N or -C(R6)-, and Y3is N or -C(R5)-; Hy is a 4- to 7-membered heterocyclic ring containing X and at least one N atom, wherein: ring Hy is linked to ring A via a C atom within ring Hy, said C atom also being linked to R2; a N atom within ring Hy is substituted by R1; X is a bond, -N(R11)-, O, S, -S(O)2-, -S(O)(NR11)-, or - C(R11)2-; and the rest of ring Hy is unsubstituted or substituted by one or two R3; L is –C(O)N(H)-, wherein the C atom of L is bonded to R8, and the N atom of L is bonded to ring B; R1is H, C1-4cycloalkyl, or C1-4alkyl which is itself unsubstituted or substituted with one C1-4alkoxy or one, two or three halo; R2is H or methyl; each R3is independently selected from C1-4alkyl, C1-4alkoxy, phenyl, a 5- to 6-membered heteroaryl ring and halo, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring; R4and R6are independently selected from H, halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R5is selected from H, halo, C1-4alkoxy, C3-5cycloalkyl and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R8is an 8- to 10-membered heteroaryl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two R9; each R9is independently selected from halo and C1-4alkoxy; R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 6-membered heterocyclyl ring, and a phenyl ring, the group R10being unsubstituted or substituted by one or two substituents independently selected from C1-4alkyl, C1-4alkoxy, and halo; and each R11is independently selected from H, C1-4alkyl, and C1-4cycloalkyl; wherein M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK. In a preferred embodiment, M is of formula (II): wherein: Z1, Z3, Y1, Y2, Y3, R1, R2, R8, X and L are as defined herein; R3aand R3bare independently selected from H, C1-4alkyl, phenyl, a 5- to 6-membered heteroaryl ring and C1-4alkoxy, or R3aand R3bform, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring, R3cand R3dare independently selected from H, C1-4alkyl, halo, phenyl, a 5- to 6-membered heteroaryl ring and C1-4alkoxy, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring, or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, with the proviso that when X is -N(R11)-, O, S, -S(O)2- or -S(O)(NR11)-, then neither R3cnor R3dare halo; wherein at least two of R3a, R3b, R3cand R3dare H; and wherein M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK. In a more preferred embodiment, M is of formula (III): wherein: R1is H or C1-4alkyl which is itself unsubstituted or substituted with one C1-4alkoxy or one, two or three halo, preferably with one C1-4alkoxy; R2is H or methyl; R3aand R3bare independently selected from H, C1-4alkyl, and C1-4alkoxy, or R3aand R3bform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, with the proviso that when X is -N(Me)- or O, then neither R3cnor R3dare halo; wherein at least two of R3a, R3b, R3cand R3dare H; X is a bond, -N(Me)-, O or -CH2-; R4is selected from H, CN, halo, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R5and R6are independently selected from H, halo, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R8is an 8- to 10-membered heteroaryl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two R9; each R9is independently selected from halo and C1-4alkoxy; R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 6-membered heterocyclyl ring, and a phenyl ring, the group R10being unsubstituted or substituted by one or two substituents independently selected from C1-4alkyl, C1-4alkoxy, and halo; and wherein M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK. In a particularly preferred embodiment, M is of formula (IV): wherein R8is an 8- to 10-membered heteroaryl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkyl and R10; R10is a 3-membered cycloalkyl ring; wherein M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK. As discussed elsewhere herein, the stereochemistry of the compounds of the invention at the ring Hy is preferably such that the bond from ring Hy to the core ring A is in the “up” position and the bond from ring Hy to R2is the down position. Thus, formula (IV) preferably has the stereochemistry depicted below:

[0002] The inventors have also surprisingly found that compounds of formula (I’) are potent inhibitors of MLLT1 and MLLT3. Accordingly, the invention provides a compound which is a bicyclic compound of formula (I’) or a pharmaceutically acceptable salt thereof: wherein: one of Z1and Z3is -N(H)- and the other is N or -C(R4)-, Y1is N, Y2is N or -C(R6)-, and Y3is N or -C(R5)-; Hy is a 4- to 7-membered heterocyclic ring containing X and at least one N atom, wherein: ring Hy is linked to ring A via a C atom within ring Hy, said C atom also being linked to R2; a N atom within ring Hy is substituted by R1; X is a bond, -N(R11)-, O, S, -S(O)2-, -S(O)(NR11)-, or - C(R11)2-; and the rest of ring Hy is unsubstituted or substituted by one or two R3; L is –C(O)N(H)-, wherein the C atom of L is bonded to R8, and the N atom of L is bonded to ring B; R1is H, C1-4cycloalkyl, or C1-4alkyl which is itself unsubstituted or substituted with one C1-4alkoxy or one, two or three halo; R2is H or methyl; each R3is independently selected from C1-4alkyl, C1-4alkoxy, phenyl, a 5- to 6-membered heteroaryl ring and halo, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring; R4and R6are independently selected from H, halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R5is selected from H, halo, C1-4alkoxy, C3-5cycloalkyl and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; at least one of R4, R5and R6is not H; R8is an 8- to 10-membered heteroaryl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two R9; each R9is independently selected from halo and C1-4alkoxy; R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 6-membered heterocyclyl ring, and a phenyl ring, the group R10being unsubstituted or substituted by one or two substituents independently selected from C1-4alkyl, C1-4alkoxy, and halo; each R11is independently selected from H, C1-4alkyl, and C1-4cycloalkyl. In a preferred embodiment, the compound is a bicyclic compound of formula (II’) or a pharmaceutically acceptable salt thereof: wherein: Z1, Z3, Y1, Y2, Y3, R1, R2, R8, X and L are as defined in any one of claims 1 to 18; R3aand R3bare independently selected from H, C1-4alkyl, phenyl, a 5- to 6-membered heteroaryl ring and C1-4alkoxy, or R3aand R3bform, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring, R3cand R3dare independently selected from H, C1-4alkyl, halo, phenyl, a 5- to 6-membered heteroaryl ring and C1-4alkoxy, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring, with the proviso that when X is - N(R11)-, O, S, -S(O)2- or -S(O)(NR11)-, then neither R3cnor R3dare halo; or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring; wherein at least two of R3a, R3b, R3cand R3dare H. In a more preferred embodiment, the compound is a bicyclic compound of formula (III’) or a pharmaceutically acceptable salt thereof: wherein: X, Y1, R1, R2, R4, R5, R6, R3a, R3b, R3c, R3dand R8are as defined herein. The present invention also provides a compound as described herein for use in a method of treating cancer in a subject in need thereof. Also provided is a method for treating cancer in a subject, which method comprises administering to said subject an effective amount of a compound as described herein. Further provided is the use of a compound as described herein in the manufacture of a medicament for use in treating cancer in a subject. Brief Description of the Drawings Figure 1: Graph showing reduction in tumour growth in in vivo mouse model of human AML, following oral administration of the compound of Example 1, following the procedure described in Example 112. Detailed Description of the Invention Definitions As used herein, a C1-4alkyl group is a linear or branched alkyl group containing from 1 to 4 carbon atoms. A C1-4alkyl group is often a C1-3alkyl group. Examples of C1-4alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, and tert-butyl. A C1-3alkyl group is typically a C1-2alkyl group. A C1-2alkyl group is methyl or ethyl, typically methyl. For the avoidance of doubt, where multiple alkyl groups are present, the alkyl groups may be the same or different. As used herein, a C1-4alkoxy group is typically a said C1-4alkyl group which is joined to the rest of the molecule via an oxygen atom. Typically, a C1-4alkoxy group is a C1-3alkoxy group. Examples of C1-4alkoxy groups include methoxy, ethoxy, propoxy and butoxy. Typically, a C1-3alkoxy group is a C1-2alkoxy group such as a methoxy or ethoxy group. For the avoidance of doubt, where two alkoxy groups are present, the alkoxy groups may be the same or different. As used herein, a C1-30alkylene group is a linear or branched divalent alkyl group that contains from 1 to 30 carbon atoms. A C1-30alkylene group is sometimes a C1-20alkylene group, and often a C1-10 alkylene group. C1-30 alkylene groups, C1-20 alkylene groups and C1-10 alkylene groups are preferably linear. A C1-30alkylene group is sometimes a C1-6alkylene group, typically a C1-4alkylene group or a C1-3alkylene group. Examples of C1-4alkylene groups include methylene, ethylene, n- propylene, iso-propylene, n-butylene, sec-butylene, and tert-butylene. A C1-3alkylene group is typically a C1-2alkylene group. A C1-2alkylene group is methylene or ethylene, typically methylene. For the avoidance of doubt, where multiple alkylene groups are present, the alkylene groups may be the same or different. As used herein, a C2-6alkenylene group is a linear or branched divalent alkenyl group containing from 2 to 6 carbon atoms and having one or more, e.g. one or two, typically one double bonds. Typically, a C2-6alkenylene group is a C2-4alkenylene group. Examples of C2-4alkenylene groups include divalent ethenylene, propenylene and butenylene. For the avoidance of doubt, where multiple alkenylene groups are present, the alkenylene groups may be the same or different. An alkyl, alkoxy, alkylene or alkenylene group as used herein may be unsubstituted or substituted. Unless otherwise stated, substituted alkyl, alkoxy, alkylene or alkenylene groups typically carry one or more, e.g. one, two or three e.g. one, or two, e.g. one substituent selected from halo, OH, and unsubstituted C1-4alkoxy. Preferred substituents are halo and C1-4alkoxy unless otherwise stated. The substituents on a substituted alkyl, alkoxy, alkylene or alkenylene group are typically themselves unsubstituted. Where more than one substituent is present, these may be the same or different. As used herein, a halo typically refers to chlorine, fluorine, bromine or iodine, preferably chlorine, bromine or fluorine, more preferably chorine or fluorine, most preferably fluorine unless otherwise stated. A C3-8cycloalkyl ring is a cyclic hydrocarbon containing from 3 to 8 carbon atoms. A cycloalkyl ring may be saturated or partially unsaturated, but is typically saturated. A C3-8cycloalkyl ring is typically a C3-6cycloalkyl ring. A partially unsaturated cycloalkyl ring is a cyclic hydrocarbon containing 1 or 2, e.g.1 double bond. C3-6cycloalkyl and C5-6cycloalkyl rings may also be referred to herein as 3- to 6-membered cycloalkyl rings and 5- to 6-membered cycloalkyl rings respectively. A C3-6 cycloalkyl ring may be a saturated C3-6 cycloalkyl ring. A C3-6 cycloalkyl ring may be a C5-6cycloalkyl ring, in particular a saturated C5-6cycloalkyl ring. Examples of C3-6cycloalkyl rings are cyclopropyl, cyclobutyl cyclopentyl and cyclohexyl groups. A C3-8cycloalkyl ring may be a C7-8cycloalkyl ring, in particular a saturated C7-8cycloalkyl ring. Examples of C7-8cycloalkyl rings are cycloheptanly, cyclooctanyl, bicyclo[2.2.1]heptanyl and bicyclo[2.2.2]octanyl groups. A 5- to 10-membered heterocyclyl ring is a cyclic group containing from 5 to 10 atoms selected from C, O, N and S in the ring, including at least one heteroatom, and typically one or two heteroatoms unless otherwise stated. The heteroatom or heteroatoms are typically selected from O, N, and S, most typically from S and N, especially N. For example, where the heterocyclyl ring is denoted a nitrogen-containing heterocyclyl group, it contains one nitrogen atom and optionally a further heteroatom selected from O, N and S. A heterocyclyl ring may be saturated or partially unsaturated, but is typically saturated. A 5- to 10- membered partially unsaturated heterocyclyl ring is a cyclic group containing from 5 to 10 atoms selected from C, O, N and S in the ring and containing 1 or 2, e.g.1 double bond. Typically, in the compounds described herein, a heterocyclyl ring is saturated unless otherwise specified. A 5- to 10- membered heterocyclyl ring is typically a 4- to 7- membered heterocyclyl ring or a 5- to 6-membered ring. A 4- to 7- membered heterocyclyl ring is typically a monocyclic ring and may be a monocyclic 5- or 6- membered heterocyclyl ring. Alternatively, a 5- to 10- membered heterocyclyl ring may be a 9- or 10- membered fused bicyclic heterocyclyl ring (i.e. a fused heterobicyclic group). In some compounds described herein, a 5- to 10- membered heterocyclyl group is a 4- to 7- membered nitrogen-containing heterocyclyl ring which is unsubstituted or is substituted as described herein. Preferred 4- to 7- membered nitrogen- containing heterocyclyl rings include morpholine, pyrrolidine, piperidine and piperazine. Examples of 5- and 6- membered saturated heterocyclyl rings include piperazine, piperidine, morpholine, diazinane and pyrrolidine. Diazinane is typically 1,4-diazinane. Examples of 9- and 10- membered bicyclic heterocyclyl rings include azaspiro[4.4]nonane and octahydro-1H-indole. Preferably, the bicyclic heterocyclyl ring comprises 1, 2 or 3, preferably 1 or 2 nitrogen atoms. For the avoidance of doubt, references to a heterocyclyl ring also include fused polycyclic ring systems, including for instance fused bicyclic systems in which a heterocyclyl ring is fused to an aryl group. When the heterocyclyl ring is such a fused heterocyclyl group, preferred examples are fused ring systems wherein a 5- to 6-membered heterocyclyl group is fused to a phenyl group. As used herein, a 6- to 10-membered aryl ring is a substituted or unsubstituted, monocyclic or fused polycyclic aromatic group containing from 6 to 10 carbon atoms in the ring portion. Examples include monocyclic groups such as phenyl and fused bicyclic groups such as naphthyl and indenyl. Phenyl (benzene) is preferred. As used herein, a 5- to 10- membered heteroaryl ring is a substituted or unsubstituted monocyclic or fused polycyclic aromatic group containing from 5 to 10 atoms in the ring portion, including at least one heteroatom, for example 1, 2 or 3 heteroatoms, typically selected from O, S and N. A heteroaryl ring is typically a 5- or 6-membered heteroaryl ring or an 8- to 10- membered heteroaryl ring. Preferably, the heteroaryl ring comprises 1, 2 or 3, preferably 1 or 2 nitrogen atoms. Examples of 5- and 6- membered heteroaryl rings include thiazole, pyrazole, pyrimidine, triazole, 1,2,4-oxadiazole and pyrazine. Examples of 8-, 9- and 10- membered heteroaryl rings include indazole, thieno[2,3-c]pyrazole, imidazo[4,5-b]pyridine, pyrazolo[3,4-b]pyridine, furo[2,3-c]pyridine, indole, benzoxazole, benzothiazole, [1,2,4]triazolo[4,3-a]pyridine, thieno[2,3-d]pyrimidine, 1,2,3-benzotriazole, imidazo[1,5-a]pyridine, imidazo[1,2-a]pyrazine, oxazolo[5,4-b]pyridine, quinoline, naphthyridine, isoquinoline, quinazoline, and quinoxaline. 8-, 9- and 10- membered heteroaryl rings as used herein are typically fused bicyclic groups. For the avoidance of doubt, references to a heteroaryl ring also include fused polycyclic ring systems, including for instance fused bicyclic systems in which a heteroaryl ring is fused to an aryl group. When the heteroaryl ring is such a fused heteroaryl group, preferred examples are fused ring systems wherein a 5- to 6-membered heteroaryl group is fused to a phenyl group. Indazole is preferred. As used herein, a fused bicyclic group is a group comprising two cyclic moieties sharing a common bond between two atoms. A cycloalkyl, heterocyclyl, aryl or heteroaryl ring may be unsubstituted or substituted as described herein unless otherwise stated. For example, a cycloalkyl, heterocyclyl, aryl or heteroaryl ring may be unsubstituted or substituted with 1, 2 or 3, typically 1 or 2 such as e.g.1 substituent. Suitable substituents include halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl, wherein R10is as defined herein). The substituents on a substituted cycloalkyl, heterocyclyl, aryl or heteroaryl ring are typically themselves unsubstituted, unless otherwise stated. The compounds described herein comprise at least one heterocyclyl ring comprising at least one nitrogen atom. Said nitrogen atom(s) are independently selected from secondary, tertiary and quaternary nitrogen atom(s). A quaternary nitrogen atom is present when the compound comprises a quaternised derivative of one or more monocyclic groups or fused bicyclic groups. As used herein, a quaternised derivative of a moiety such as a cyclic moiety is formed by bonding an additional alkyl group to a nitrogen atom in the moiety such that the valency of the said nitrogen atom increases from 3 to 4 and the nitrogen atom is positively charged. The compounds described herein comprise a heterocyclyl ring identified as ring Hy, which is a 4- to 7-membered heterocyclyl ring. Ring Hy contains X and at least one N atom in the ring portion, wherein X is a bond, -N(R11)-, O, S, -S(O)2-, -S(O)(NR11)-, or -C(R11)2-, and R11is as defined herein. Ring Hy is linked to ring A (as identified in formula (I) above) via a C atom within ring Hy, said C atom also being linked to R2which is as defined herein. A N atom within ring Hy is substituted by R1which is as defined herein. The rest of ring Hy is unsubstituted or substituted by one or two R3. Each R3is independently selected from C1-4alkyl, C1-4alkoxy and halo, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring, as defined herein. In option (ii), the skilled person would understand that the C atom to which the two R3are attached is a spiro atom (i.e. the common atom that connects the two rings of a spiro compound). As used herein, the terms “monovalent” or “monovalent moiety” are used to describe a chemical group obtainable by removing a hydrogen atom from the corresponding compound. As used herein, the terms “divalent” or “divalent moiety” are used to describe a chemical group obtainable by removing a hydrogen atom from the corresponding monovalent moiety. Thus, as used herein, the terms “divalent” and “divalent moiety” are used to describe a chemical group obtainable by removing two hydrogen atoms from the corresponding compound. It is to be understood that each individual atom present in the formulae depicted herein may be present in the form of any of its naturally occurring isotopes, with the most abundant isotope(s) being preferred. Thus, by way of example, each individual hydrogen atom present in the formulae depicted herein may be present as a 1H, 2H (deuterium) or 3H (tritium) atom, preferably 1H. Similarly, by way of example, each individual carbon atom present in the formulae depicted herein may be present as a 12C, 13C or 14C atom, preferably 12C. In the compounds of the invention, the stereochemistry is not limited. In particular, where moiety M of formula (I) and / or moiety U contains one or more chiral centre, the compounds may be used in enantiomerically or diastereoisomerically pure form, or in the form of a mixture of isomers. Further, for the avoidance of doubt, the compounds of the invention may be used in any tautomeric form. Typically, the agent or substance described herein contains at least 50%, preferably at least 60, 75%, 90% or 95% of a compound which is enantiomerically or diasteriomerically pure. Thus, the compound is preferably substantially optically pure. The moiety M of formula (I) typically contains at least one chiral centre at the carbon atom of ring Hy which is linked to R2and to ring A. Moiety M may be provided in the form of the R- enantiomer at said carbon atom, in the form of the S-enantiomer at said carbon atom, or in the form of a mixture of the two enantiomers. The substance or agent described herein may contain at least 50%, preferably at least 60, 75%, 90% or 95% of a compound which is enantiomerically or diasteriomerically pure at moiety M. A pure enantiomeric form of either the R- or the S- enantiomer may be preferred. In some embodiments, the R-enantiomer at said carbon atom is preferred, and in particular when R2is H then the R-enantiomer at said carbon atom is preferred. The preferred stereochemistry at said carbon atom is also depicted by the following illustrative structure of formula (I) where the bond from ring Hy to the core ring A is in the “up” position and the bond from ring Hy to R2is the down position: This steroechemsitry at the carbon atom of ring Hy which is linked to R2and to ring A, where the bond from ring Hy to the core ring A is in the “up” position and the bond from ring Hy to R2is the down position (as depicted above), is also preferred for the moiety M of formulae (II), (III), (IV), and for the compounds of formulae (I’), (II’) and (III’). As discussed further herein, where the compounds of the invention contain a chiral centre, and in particular where moiety M and / or moiety U contains a chiral centre, the individual stereoisomers may be obtained by chiral synthesis, or by separation of stereoisomers. Stereoisomers may be separated, for example, using chiral chromatography. The individual stereoisomers may be identified using the IUPAC labels R and S as appropriate. Alternatively, the individual stereoisomers may be identified by the order in which they elute, for example the first, second, third or fourth stereisomer respectively, as obtained by separation using chiral chromatography. Where two or more stereocentres are present in a compound or moiety, a combination of IUPAC nomenclature for stereocentres where absolute stereochemistry has been defined, and rate of elution, may be used. For example, where two or more individual stereoisomers are unidentified by IUPAC nomenclature, these stereoisomers may be identified as the first- and second-eluting isomers, as obtained by separation using chiral chromatography. Therefore, the stereoisomers at a chiral carbon atom of ring Hy which is linked to R2and to ring A may be defined as the first-eluting and second-eluting stereoisomers, as obtained by separation using chiral chromatography. Chiral chromatography is typically reverse phase HPLC or SFC. The compounds of the present invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. A compound of the present invention can be converted into a pharmaceutically acceptable salt thereof, and a salt can be converted into the free compound, by conventional methods. For instance, a compound of the present invention can be contacted with a pharmaceutically acceptable acid to form a pharmaceutically acceptable salt. A pharmaceutically acceptable salt is a salt with a pharmaceutically acceptable acid or base. Pharmaceutically acceptable acids include both inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic or nitric acid and organic acids such as oxalic, citric, fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic, methanesulphonic, ethanesulphonic, benzenesulphonic or p-toluenesulphonic acid. Pharmaceutically acceptable bases include alkali metal (e.g. sodium or potassium) and alkali earth metal (e.g. calcium or magnesium) hydroxides and organic bases such as alkyl amines, aralkyl amines and heterocyclic amines. Hydrochloride salts and acetate salts are preferred, in particular hydrochloride salts. Proteolysis Targeting Chimera (PROTAC)s The compounds of the invention comprise a binder of MLLT1 and / or MLLT3 (M) that is covalently attached via a linker moiety (LINK) to an E3 ubiquitin ligase binding moiety (U). The inventors have surpisingly discovered that such compounds may have substantially enhanced efficacy compared with a corresponding MLLT1 and / or MLLT3 inhibitor that is not attached to an E3 ubiquitin ligase binding moiety. For example, the antiproliferative effects of the compounds may be substantially enhanced by covalent attachment to the E3 ubiquitin ligase binding moiety. Such compounds may induce selective degradation of MLLT1 and / or MLLT3. For instance, such compounds may induce selective degradation of MLLT1 and / or MLLT3 without inducing degradation of other proteins, such as FLT3 (fms like tyrosine kinase 3). Such compounds may also not inhibit FLT3. Thus, the invention provides a compound which is a Proteolysis Targeting Chimera (PROTAC) or a pharmaceutically acceptable salt thereof, wherein the PROTAC has the structure: wherein U is an E3 ubiquitin ligase binding moiety, LINK is a moiety that covalently links M and U, and M is an MLLT1 and / or MLLT3 binder of formula (I) as defined herein. In the compounds of the present invention, the MLLT1 and / or MLLT3 binder is covalently attached to the E3 ubiquitin ligase binding moiety via the moiety labelled LINK. LINK is either a single bond or a chemical group that covalently attaches the MLLT1 and / or MLLT3 binder to the E3 ubiquitin ligase binding moiety. The MLLT1 and / or MLLT3 binder is attached to LINK via a C or N atom within group R8or ring Hy (as described herein) such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. A hydrogen atom on the C or N atom within group R8or ring Hy is replaced by either a direct single bond to the E3 ubiquitin ligase binding moiety or by a chemical group that covalently attaches the MLLT1 and / or MLLT3 binder to the E3 ubiquitin ligase binding moiety. It is preferred for the MLLT1 and / or MLLT3 binder to be attached to LINK via a C or N atom within group R8. The description herein discusses the substitution of group R8and ring Hy by various chemical groups aside from LINK. For completeness, the skilled person would readily appreciate that where group R8and / or ring Hy are defined as being unsubstituted, this is intended as a reference to the absence of substituents other than a bond to LINK. Therefore, such a definition retains the option that group R8or ring Hy is attached to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. Furthermore, the skilled person would readily appreciate that where group R8and / or ring Hy are defined as being substituted by one or more chemical groups (suitable such chemical groups are defined herein), this is intended as a reference to substituents other than a bond to LINK. Therefore, such a definition includes group R8or ring Hy being attached to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. Therefore, where group R8and / or ring Hy are defined as being unsubstituted or substituted by one or more chemical groups (suitable such chemical groups are defined herein), then one of group R8or ring Hy may also be attached to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. A bond to LINK may optionally be positioned on a carbon atom which carries a further substituent (where chemically possible). Typically, a carbon or nitrogen atom which is bonded to LINK does not carry a further substituent. For the avoidance of doubt, where group R8and / or ring Hy are defined as being substituted by a hydrogen atom (e.g. where R1, R2, R11, R3a, R3b, R3cand R3dare defined as being a hydrogen atom), then a reference herein to a hydrogen atom within group R8or ring Hy being replaced with a bond to LINK, includes the option that said hydrogen atom (e.g. a hydrogen atom at R1, R2, R11, R3a, R3b, R3cand R3d) is replaced with a bond to LINK. Therefore, where R1, R2, R11, R3a, R3b, R3cand R3dare defined as being a hydrogen atom, then said hydrogen atom may be replaced with a bond to LINK. For the avoidance of doubt, where ring Hy or group R8is substituted, a C or N atom which is bonded to LINK may be within the aryl, heteroaryl, heterocyclyl, or cycloalkyl ring of ring Hy or group R8, or it may be a C or N atom of a substituent on ring Hy or group R8. Preferably, a C or N atom which is bonded to LINK is a C or N atom on the heterocyclyl ring of ring Hy (i.e. directly to the ring and not via a substituent), a C or N atom of the heteroaryl ring of group R8, or the heteroaryl, cycloalkyl, heterocyclyl or phenyl ring of R10in the case that a group R10is present as, or as part of, a substituent on R8. As the skilled person would readily appreciate, methods for preparation of compounds (in which two discrete chemical entities contribute discrete biological functions to the overall compound) are very well known in the art. A hugely diverse range of techniques for covalently attaching the respective chemical entities, via a vast number of chemical linker moieties, is well established. Such is the ubiquity of these methodologies, that standard text books devoted entirely to this topic have long been available. One such textbook is “Bioconjugate Techniques” (Greg T. Hermanson, Academic Press Inc., 1996), the content of which is herein incorporated by reference in its entirety. MLLT1 and / or MLLT3 binder group M In the compounds of the invention, the MLLT1 and / or MLLT3 binder M is a monovalent moiety of formula (I) as defined herein. In the description that follows, the skilled person will readily understand that M is a monovalent moiety that is bonded to LINK via a C or N atom within group R8or ring Hy (as described herein) such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. Thus, in the description that follows, any of the hydrogen atoms on any of the C or N atoms within group R8or ring Hy may be removed to form the point of attachment of the monovalent moiety M to LINK. Typically, ring Hy is a 5- to 6- membered heterocyclyl ring containing X and at least one N atom, for instance one or two N atoms. X is typically a bond, -N(R11)-, O or -C(R11)2-. Preferably, X is a bond, -N(Me)-, O or -CH2-, most preferably X is a bond. In particular, when ring Hy is a 4- or 5-membered heterocyclyl ring, X is most preferably a bond. For example, ring Hy may be selected from a pyrrolidinyl, piperidinyl, morpholinyl or diazinanyl ring. Preferably, ring Hy is a 5-membered heterocyclyl ring containing X and at least one N atom, for instance one N atom. For example, ring Hy may be a pyrrolidinyl ring. Ring Hy is linked to ring A via a C atom within ring Hy, said C atom also being linked to R2. A N atom within ring Hy is substituted by R1. Typically, the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A. A C or N atom within ring Hy may be bonded to LINK by a hydrogen atom on that C or N atom being replaced by a bond to LINK. Typically, where ring Hy is bonded to LINK, this is via a C atom on Hy. Preferably, the bond to LINK is via replacement of a hydrogen atom on a C or N within group R8, i.e. the bond to LINK is preferably not via ring Hy. Typically, R1is H, C1-4cycloalkyl, or C1-4alkyl which is itself unsubstituted or substituted with one C1-4alkoxy or one, two or three halo, preferably with one C1-4alkoxy, for example R1may be H or C1-2alkyl which is unsubstituted or substituted with one C1-2alkoxy or one, two or three halo, preferably with one C1-2alkoxy, or R1may be H or C1-2alkyl which is unsubstituted or substituted with one C1-2alkoxy. Preferably, R1is H, methyl, ethyl or methoxyethyl, more preferably methyl or ethyl. Most preferably, R1is methyl. R2is H or methyl. Preferably, R2is H. Typically, each R11is independently selected from H and methyl. When X is -N(R11)- or - S(O)(NR11)-, R11is preferably methyl. When X is -C(R11)2-, optionally one R11is replaced with a single bond to LINK and the other R11is H. When X is -C(R11)2-, each R11is preferably H. Aside from groups R1and R2, ring Hy may further be unsubstituted or substituted by one or two R3. Typically, each R3is independently selected from C1-4alkyl, C1-4alkoxy and halo, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a C3-6cycloalkyl ring. More typically, each R3is independently selected from methyl, ethyl, t-butyl methoxy and fluoro, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a cyclohexyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a cyclopentyl ring. Preferably, ring Hy is substituted by no R3groups. In another typical emobidment, each R3is independently selected from methyl, ethyl, t-butyl, methoxy and fluoro, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a cyclohexyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a cyclopropyl ring or a cyclopentyl ring. Preferably, ring Hy is substituted by two R3groups which are both C1-4 alkyl, for instance both being methyl, or one R3group which is C1-4alkyl, for instance methyl, ethyl or t-butyl. Typically, therefore, ring Hy is a 5- to 6- membered heterocyclyl ring containing X and at least one N atom, for example a pyrrolidinyl, piperidinyl, morpholinyl or diazinanyl ring; the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A; R1is H or C1-2alkyl which is unsubstituted or substituted with one C1-2alkoxy or one, two or three halo, preferably with one C1-2alkoxy; R2is H or methyl; X is a bond, -N(R11)-, O or - C(R11)2-; R11is H or methyl; ring Hy is further unsubstituted or substituted by one or two R3; and each R3is independently selected from C1-4alkyl, C1-4alkoxy and halo, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a C3-6cycloalkyl ring. Preferably, ring Hy is a pyrrolidinyl ring; the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A; R1is methyl or ethyl, more preferably methyl; R2is H; and ring Hy is substituted by no R3groups, i.e. ring Hy is not further substituted and carries substituent R1only. In this embodiment, ring Hy may be referred to as being an unsubstituted pyrrolidine ring, wherein the skilled person would understand that ring Hy still carries substituent R1. Alternatively, ring Hy is a pyrrolidinyl ring; the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A; R1is H, methyl, ethyl or methoxyethyl, more preferably methyl; R2is H; and ring Hy is further substituted by two R3groups which are both C1-4alkyl, for instance both being methyl, or one R3group which is C1-4alkyl, for instance methyl, ethyl or t-butyl. Typically, no more than two of Y1, Y2and Y3are N. Preferably Y1is N, Y2is -C(R6)-, and Y3is -C(R5)-. Typically, Z1is -C(R4)-, Z3is -N(H)-, and Y1is N. Thus, the bicyclic structure formed by rings A and B has the structure: In one preferred embodiment, Z1is -C(R4)-, Z3is -N(H)-, Y1is N, Y2is -C(R6)-, and Y3is - C(R5)-, such that the bicyclic structure formed by rings A and B has the structure: Typically, R4, R5and R6are independently selected from H, CN, halo, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo, with the proviso that R5and R6are not CN. Typically, R4, R5and R6are independently selected from H, CN, halo (e.g. fluoro), methoxy, and methyl, with the proviso that R5and R6are not CN. Preferably, either R4, R5and R6are H, or one of R4, R5and R6is selected from halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo, and the rest are H, with the proviso that R5and R6are not CN. More preferably, either R4, R5and R6are H, or one of R4, R5and R6is selected from halo (e.g. fluoro), CN, methoxy, and methyl, and the rest are H, with the proviso that R5and R6are not CN. More preferably, R4, R5and R6are H. In one preferred embodiment, R5and R6are as defined herein and R4is selected from H, halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo. More preferably, R5and R6are as defined herein and R4is selected from H, halo, CN, C1-4alkyl and CF3. Most preferably, R5and R6are as defined herein and R4is selected from H, F, Cl, CN, Me and CF3. In one preferred embodiment, R5is selected from H, cyclopropyl, C1-4alkoxy, and C1-4alkyl, for example from H, C1-4alkoxy, and C1-4alkyl. More preferably, R5is selected from H, cyclopropyl, methoxy and methyl, for example H, methoxy and methyl. In one preferred embodiment, R6is H. Typically, therefore, in formula (I): - R4is selected from H, halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo, and R5and R6when present are H; or - R5is selected from H, cyclopropyl, C1-4alkoxy, and C1-4alkyl, typically from H, C1-4alkoxy, and C1-4alkyl, and R4and R6when present are H; or - R4, R5and R6are H. Preferably, in formula (I): - R4is selected from H, F, Cl, Me, CN and CF3, and R5and R6when present are H; - R5is selected from H, cyclopropyl, methoxy and methyl, typically from H, methoxy and methyl, and R4and R6when present are H; or - R4, R5and R6are H. In one alternative preferred embodiment, R5and R6are as defined herein and R4is selected from halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo. More preferably, R5and R6are as defined herein and R4is selected from halo, CN, C1-4alkyl and CF3. More preferably, R5and R6are as defined herein and R4is selected from halo, and CF3. Most preferably, R5and R6are as defined herein and R4is selected from F, Cl, and CF3. L is -C(O)N(H)-, wherein the C atom of L is bonded to R8, and the N atom of L is bonded to ring B. R8is an 8- to 10-membered heteroaryl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two R9. R9and R10are as defined herein. Typically, R8is selected from indazolyl, thieno[2,3-c]pyrazolyl, imidazo[4,5-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, furo[2,3-c]pyridinyl, indolyl, benzoxazolyl, benzothiazolyl, [1,2,4]triazolo[4,3-a]pyridinyl, thieno[2,3-d]pyrimidinyl, 1,2,3-benzotriazolyl, imidazo[1,5- a]pyridinyl, imidazo[1,2-a]pyrazinyl, oxazolo[5,4-b]pyridinyl, quinolinyl, naphthyridinyl, isoquinolinyl, quinazolinyl, and quinoxalinyl. Preferably, R8is a 9- to 10-membered heteroaryl ring containing one, two or three N atoms. More preferably, R8is an indazolyl group. In some preferred embodiments, R8is a group selected from the following structures. For the avoidance of doubt, the following structures may be unsubstituted or substituted by one, two or three substituents as defined herein. [see below]

[0003] A C or N atom within group R8may be bonded to LINK by a hydrogen atom on that C or N atom being replaced by a bond to LINK. Typically, where group R8is bonded to LINK, this is via a C atom on R8. Preferably, a C or N atom within group R8is bonded to LINK such that a hydrogen atom on that C or N atom is replaced by a bond to LINK. Preferably, the C or N atom that is bonded to LINK is a C or N atom of the heteroaryl ring of R8or a C or N atom of the heteroaryl, cycloalkyl, heterocyclyl or phenyl ring of R10. More preferably, the C or N atom that is bonded to LINK is a C or N atom of the heteroaryl ring of R8. In addition to any bond to LINK (where present) R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents. Typically, each substituent is independently selected from halo, C1-4alkoxy, R10, -(CH2)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo and C1-2alkoxy. More typically, each substituent is independently selected from fluoro, chloro, methoxy, R10, -(CH2)-R10, =O, -CN, and C1-2alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo (e.g. fluoro) and methoxy. Preferably, each substituent is independently selected from fluoro, R10and methyl. Most preferably, each substituent is independently selected from fluoro and methyl. R10is as defined herein. Typically, R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 5-membered heterocyclyl ring, and a phenyl ring. The cycloalkyl, heteroaryl and heterocyclyl rings are as defined herein. Preferably, R10is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, oxadiazolyl, oxetanyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, thiazinyl, thiazolyl and triazolyl, more preferably pyrazolyl. Typically, in addition to any bond to LINK (where present), R10is unsubstituted or substituted by one or two substituents independently selected from fluoro, methyl and methoxy. Preferably, R10is unsubstituted. Typically, therefore, R8is an 8- to 10-membered heteroaryl ring; the group R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents, each independently selected from halo, C1-4alkoxy, R10, -(CH2)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo and C1-2alkoxy; wherein R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6- membered cycloalkyl ring, a 4- to 5-membered heterocyclyl ring, and a phenyl ring; and R10is unsubstituted or substituted by one or two substituents independently selected from fluoro, methyl and methoxy. Typically, where a C or N atom within group R8is bonded to LINK, the C or N atom that is bonded to LINK is a C or N atom of the heteroaryl ring of R8or a C or N atom of the heteroaryl, cycloalkyl, heterocyclyl or phenyl ring of R10. Preferably, R8is an 8- to 10-membered heteroaryl ring containing one, two or three N atoms, for example an indazolyl group; the group R8is unsubstituted or substituted by one or two substituents, each independently selected from fluoro, R10and methyl; R10is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, oxadiazolyl, oxetanyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, thiazinyl, thiazolyl and triazolyl; and R10is unsubstituted. Preferably, a C or N atom within group R8is bonded to LINK, wherein the C or N atom that is bonded to LINK is a C or N atom of the heteroaryl ring of R8. In a typical embodiment of formula (I), the bicyclic structure formed by rings A and B has the structure: and: ring Hy is a 5- to 6- membered heterocyclyl ring containing X and at least one N atom, for example a pyrrolidinyl, piperidinyl, morpholinyl or diazinanyl ring; wherein the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A; R1is H or C1-2 alkyl which is unsubstituted or substituted with one C1-2 alkoxy or one, two or three halo, preferably with one C1-2alkoxy; R2is H or methyl; X is a bond, -N(Me)-, O or -CH2-; ring Hy is further unsubstituted or substituted by one or two R3; wherein each R3is independently selected from C1-4alkyl, C1-4alkoxy and halo, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a C3-6cycloalkyl ring; R4is selected from H, halo (e.g. fluoro or chloro), methoxy, methyl and trifluoromethyl; R5and R6are independently selected from H, halo (e.g. fluoro or chloro), methoxy, methyl and trifluoromethyl; the C atom of L is bonded to R8, and the N atom of L is bonded to ring B; R8is an 8- to 10-membered heteroaryl ring; wherein the group R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents, each independently selected from halo, C1-4alkoxy, R10, -(CH2)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two groups selected from halo and C1-2alkoxy; and R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 5-membered heterocyclyl ring, and a phenyl ring; wherein R10is unsubstituted or substituted by one or two substituents independently selected from fluoro, methyl and methoxy; wherein M is bonded to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. In a preferred embodiment of formula (I), the bicyclic structure formed by rings A and B has the structure: and: ring Hy is a pyrrolidinyl ring; wherein the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A; R1is H, methyl, ethyl or methoxyethyl, more preferably methyl; R2is H; and ring Hy is substituted by no R3groups; either R4, R5and R6are H, or one of R4, R5and R6is selected from halo (e.g. fluoro or chloro), CN, methoxy, methyl and trifluoromethyl, and the rest are H, with the poviso that R5and R6are not CN; the C atom of L is bonded to R8, and the N atom of L is bonded to ring B; R8is an 8- to 10-membered heteroaryl ring containing one, two or three N atoms, for example an indazolyl group; the group R8is unsubstituted or substituted by one or two substituents, each independently selected from fluoro, R10and methyl; R10is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, oxadiazolyl, oxetanyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, thiazinyl, thiazolyl and triazolyl; and R10is unsubstituted; wherein M is bonded to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. In a particular embodiment of the compounds of the invention, the MLLT1 and / or MLLT3 binder group M is a monovalent moiety of formula (II): wherein: Z1, Z3, Y1, Y2, Y3, R1, R2, R8, X and L are as defined herein; R3aand R3bare independently selected from H, C1-4alkyl, phenyl, a 5- to 6-membered heteroaryl ring and C1-4alkoxy, or R3aand R3bform, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring, R3cand R3dare independently selected from H, C1-4alkyl, halo, phenyl, a 5- to 6-membered heteroaryl ring and C1-4alkoxy, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring, or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, with the proviso that when X is -N(R11)-, O, S, -S(O)2- or -S(O)(NR11)-, then neither R3cnor R3dare halo; wherein at least two of R3a, R3b, R3cand R3dare H; and wherein M is bonded to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. Typically, in formula (II): R3aand R3bare independently selected from H and methyl; R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, in particular from H, methyl, ethyl, fluoro, methoxy and t-butyl, or R3cand R3dform, together with the C atom to which they are attached, a C5-6cycloalkyl ring (in particular a cyclopentyl ring), with the proviso that when X is -N(R11)-, O, S, -S(O)2- or -S(O)(NR11)-, then neither R3cnor R3dare fluoro; or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring (in particular a cyclohexyl ring); wherein at least two of R3a, R3b, R3cand R3dare H. In an alternative typical embodiment: R3aand R3bare independently selected from H and methyl; R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, in particular from H, methyl, ethyl, fluoro, methoxy and t-butyl, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring (in particular a cyclopropyl or cyclopentyl ring), with the proviso that when X is NR11, O, or S, then neither R3cnor R3dare fluoro; or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring (in particular a cyclohexyl ring); wherein at least two of R3a, R3b, R3cand R3dare H. Optionally, one of R3a, R3b, R3cand R3dis replaced with a single bond to LINK. Preferably, in formula (II), R3a, R3b, R3cand R3dare all H, or one of R3a, R3b, R3cand R3dis methyl, ethyl or t-butyl and the rest are H, or R3cand R3dare methyl and the rest are H. More prefereably, R3a, R3b, R3cand R3dare all H. In a typical embodiment of formula (II), the bicyclic structure formed by rings A and B has the structure: and: R1is H or C1-2alkyl which is unsubstituted or substituted with one C1-2alkoxy or one, two or three halo, preferably with one C1-2alkoxy; R2is H or methyl; X is a bond, -N(Me)-, O or -CH2-; R3aand R3bare independently selected from H and methyl; R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, in particular from H, methyl, ethyl, fluoro, methoxy and t-butyl, or R3cand R3dform, together with the C atom to which they are attached, a C5-6cycloalkyl ring (in particular a cyclopentyl ring), with the proviso that when X is NR11or O, then neither R3cnor R3dare fluoro; or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring (in particular a cyclohexyl ring); wherein at least two of R3a, R3b, R3cand R3dare H; R4is selected from H, CN, halo (e.g. fluoro or chloro), methoxy, methyl and trifluoromethyl; R5and R6are independently selected from H, halo (e.g. fluoro or chloro), methoxy, methyl and trifluoromethyl; the C atom of L is bonded to R8, and the N atom of L is bonded to ring B; R8is an 8- to 10-membered heteroaryl ring; wherein the group R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents, each independently selected from halo, C1-4alkoxy, R10, -(CH2)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo and C1-2alkoxy; and R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 5-membered heterocyclyl ring, and a phenyl ring; wherein R10is unsubstituted or substituted by one or two substituents independently selected from fluoro, methyl and methoxy; wherein M is bonded to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. In a preferred embodiment of formula (II), the bicyclic structure formed by rings A and B has the structure: and: X is absent; R1is H, methyl, ethyl or methoxyethyl, more preferably methyl; R2is H; R3a, R3b, R3cand R3dare all H; either R4, R5, and R6, are H, or one of R4, R5, and R6is selected from fluoro, CN, methoxy, methyl and trifluoromethyl, and the rest are H, with the proviso that R5and R6are not H; the C atom of L is bonded to R8, and the N atom of L is bonded to ring B; R8is an 8- to 10-membered heteroaryl ring containing one, two or three N atoms, for example an indazolyl group; the group R8is unsubstituted or substituted by one or two substituents, each independently selected from fluoro, R10and methyl; R10is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, oxadiazolyl, oxetanyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, thiazinyl, thiazolyl and triazolyl; and R10is unsubstituted; and wherein M is bonded to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. In a particularly preferred embodiment of the compounds of the invention, the MLLT1 and / or MLLT3 binder M is a monovalent moiety of formula (III): wherein R1, R2, R3a, R3b, R3c, R3d, X, R4, R5, R6and R8are as defined herein. Typically, in the compounds of formula (III): R1is H or C1-4alkyl which is itself unsubstituted or substituted with C1-4alkoxy; R2is H or methyl; R3aand R3bare independently selected from H, C1-4alkyl, and C1-4alkoxy, or R3aand R3bform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, with the proviso that when X is -N(Me)- or O, then neither R3cnor R3dare halo; wherein at least two of R3a, R3b, R3cand R3dare H; X is a bond, -N(Me)-, O or -CH2-; R4is selected from H, CN, halo C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R5and R6are independently selected from H, halo C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R8is an 8- to 10-membered heteroaryl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two R9; each R9is independently selected from halo and C1-4alkoxy; and R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 6-membered heterocyclyl ring, and a phenyl ring, the group R10being unsubstituted or substituted by one or two substituents independently selected from C1-4alkyl, C1-4alkoxy, and halo; wherein M is bonded to LINK via a C or N atom within group R8or ring Hy (as described herein) such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. Typically, in formula (III), R1is H, or C1-4alkyl which is itself unsubstituted or substituted with one C1-4alkoxy or one, two or three halo, preferably with one C1-4alkoxy, for example R1may be H or C1-2alkyl which is unsubstituted or substituted with one C1-2alkoxy or one, two or three halo, preferably with one C1-2alkoxy. Preferably, R1is H, methyl, ethyl or methoxyethyl. Most preferably, R1is methyl. In formula (III), R2is H or methyl. Preferably, R2is H. Typically, in formula (III), X is a bond, -N(R11)-, O or -C(R11)2-. Preferably, X is a bond, - N(Me)-, O or -CH2-, most preferably X is a bond. Typically, in formula (III), each R11is independently selected from H and methyl. When X is - N(R11)-, R11is preferably methyl. When X is -C(R11)2-, one R11is optionally replaced with a single bond to LINK and the other R11is H. When X is -C(R11)2-, each R11is preferably H. Typically, in formula (III), R3aand R3bare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, in particular from H and methyl; R3cand R3dare independently selected from H, methyl, ethyl, fluoro, methoxy and t-butyl, or R3cand R3dform, together with the C atom to which they are attached, a C5-6cycloalkyl ring (in particular a cyclopentyl ring), with the proviso that when X is NR11or O, then neither R3cnor R3dare fluoro; or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring (in particular a cyclohexyl ring); wherein at least two of R3a, R3b, R3cand R3dare H. Preferably, in formula (III), R3a, R3b, R3cand R3dare all H. Alternatively, one of R3a, R3b, R3cand R3dis methyl, ethyl or t-butyl, and the rest are H, or R3cand R3dare methyl and the rest are H. In all embodiments of formula (III) described herein, when X is -N(R11)- or O then neither R3cnor R3dare halo (e.g. fluoro). Typically, in formula (III), R4is selected from H, CN, halo, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo. Preferably, R4is selected from H, CN, F, Cl, Me and CF3. Typically, in formula (III), R5is selected from H and C1-4 alkyl. Preferably, R5is selected from H and methyl, more preferably H. Typically, in formula (III), R6is H. Typically, therefore, in formula (III): - R4is selected from H, CN, halo, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo, and R5and R6are H; or - R5is selected from H and C1-4alkyl, and R4and R6when present are H; or - R4, R5, and R6when present are H. Preferably, in in formula (III): - R4is selected from selected from H, CN, F, Cl, Me and CF3, and R5and R6are H; or - R5is selected from H and methyl, and R4and R6when present are H; or - R4, R5, and R6when present are H. In one alternative preferred embodiment, R5and R6are as defined herein and R4is selected from halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo. More preferably, R5and R6are as defined herein and R4is selected from halo, CN, C1-4alkyl and CF3. More preferably, R5and R6are as defined herein and R4is selected from halo, and CF3. Most preferably, R5and R6are as defined herein and R4is selected from F, Cl, and CF3. In one preferred embodiment of formula (III), R8is a group selected from indazolyl, thieno[2,3- c]pyrazolyl, imidazo[4,5-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, furo[2,3-c]pyridinyl, indolyl, benzoxazolyl, benzothiazolyl, [1,2,4]triazolo[4,3-a]pyridinyl, thieno[2,3-d]pyrimidinyl, 1,2,3- benzotriazolyl, imidazo[1,5-a]pyridinyl, imidazo[1,2-a]pyrazinyl, oxazolo[5,4-b]pyridinyl, quinolinyl, naphthyridinyl, isoquinolinyl, quinazolinyl, and quinoxalinyl. Preferably, R8is an 8- to 10-membered heteroaryl ring containing one, two or three N atoms. Most preferably, R8is an indazolyl group. Typically, in formula (III), R8is a group selected from the following structures. For the avoidance of doubt, the following structures may be unsubstituted or substituted by one, two or three substituents as defined herein. [see below]

[0004] Preferably, R8is an indazolyl group. Typically, in formula (III), R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents, independently selected from halo, C1-4alkoxy, R10, -(CH2)- R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo and C1-2alkoxy. More typically, each substituent is independently selected from fluoro, chloro, methoxy, R10, -(CH2)-R10, =O, -CN, and C1-2alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo (e.g. fluoro) and methoxy. Preferably, each substituent is independently selected from fluoro, R10and methyl. Most preferably, each substituent is independently selected from fluoro and methyl. R10is as defined herein. Typically, in formula (III), R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 5-membered heterocyclyl ring, and a phenyl ring. The aryl, heteroaryl and heterocyclyl rings are as defined herein. Preferably, R10is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, oxadiazolyl, oxetanyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, thiazinyl, thiazolyl and triazolyl, more preferably pyrazolyl. Typically, in in formula (III), R10is unsubstituted or substituted by one or two substituents independently selected from fluoro, methyl and methoxy. Preferably, R10is unsubstituted. In typical embodiments of formula (III): R1is H or C1-2alkyl which is unsubstituted or substituted with one C1-2alkoxy or one, two or three halo, preferably with one C1-2alkoxy; R2is H or methyl; X is a bond, -N(Me)- O or -C(H)2-; R3aand R3bare independently selected from H and methyl; R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, in particular from H, methyl, ethyl, fluoro, methoxy and t-butyl, or R3cand R3dform, together with the C atom to which they are attached, a C5-6cycloalkyl ring (in particular a cyclopentyl ring), with the proviso that when X is NR11or O, then neither R3cnor R3dare fluoro; or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring (in particular a cyclohexyl ring); wherein at least two of R3a, R3b, R3cand R3dare H; one of the following options applies: R4is selected from H, CN, halo, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo, and R5and R6are H; or R5is selected from H and C1-4alkyl, and R4and R6when present are H; or R4, R5, and R6when present are H; the group R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents, each independently selected from halo, C1-4alkoxy, R10, -(CH2)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo and C1-2alkoxy; and R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 5-membered heterocyclyl ring, and a phenyl ring; wherein R10is unsubstituted or substituted by one or two substituents independently selected from fluoro, methyl and methoxy; and R8is a group selected from the following structures:

[0005] wherein M is bonded to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. In preferred embodiments of formula (III), X is absent; R1is H, methyl, ethyl or methoxyethyl, more preferably methyl; R2is H; R3a, R3b, R3cand R3dare all H; R5and R6are H, and R4is selected from H, CN, F, Cl, Me and CF3, preferably H or Cl, more preferably H; R8is an 8- to 10-membered heteroaryl ring containing one, two or three N atoms, for example an indazolyl group; the group R8is unsubstituted or substituted by one or two substituents, each independently selected from fluoro, R10and methyl; R10is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, oxadiazolyl, oxetanyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, thiazinyl, thiazolyl and triazolyl, preferably pyrazolyl; and R10is unsubstituted; wherein M is bonded to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. In a most preferred embodiment of the compounds of the invention, the MLLT1 and / or MLLT3 binder M is a monovalent moiety of formula (IV): wherein R8is as defined herein. In particular in formula (IV), the group R8may be unsubstituted or substituted by one, two or three substituents independently selected from R10, halo and C1-4alkyl; wherein M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK. Typically, in formula (IV), R8is a group selected from indazolyl, thieno[2,3-c]pyrazolyl, imidazo[4,5-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, furo[2,3-c]pyridinyl, indolyl, benzoxazolyl, benzothiazolyl, [1,2,4]triazolo[4,3-a]pyridinyl, thieno[2,3-d]pyrimidinyl, 1,2,3-benzotriazolyl, imidazo[1,5-a]pyridinyl, imidazo[1,2-a]pyrazinyl, oxazolo[5,4-b]pyridinyl, quinolinyl, naphthyridinyl, isoquinolinyl, quinazolinyl, and quinoxalinyl. More typically, in formula (IV), R8is a group selected from the following structures. For the avoidance of doubt, the following structures may be unsubstituted or substituted by one, two or three substituents as defined herein. [see below] Preferably, R8is an indazolyl group. Typically, in formula (IV), R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents, independently selected from halo and C1-4alkyl. Preferably, each substituent is independently selected from fluoro and methyl. In a particularly preferred embodiment, in formula (IV), R8is selected from one of the following structures: wherein: represents the point of attachment of R8to the rest of moiety M; and represents the point of attachment of R8to LINK. For the avoidance of doubt, the group R8is further unsubstituted or substituted as described above. Preferably, the group R8is further unsubstituted or substituted by one or two substituents independently selected from fluorine and methyl, for instance fluorine. For example, the group R8may be selected from one of the following structures: wherein: represents the point of attachment of R8to the rest of moiety M; and represents the point of attachment of R8to LINK. For the avoidance of doubt, R8may be selected from any one of the above structures defined herein (including structures A, B and C) in any of formulae (I), (II) and (III). In another preferred embodiment of the compounds of the invention, the MLLT1 and / or MLLT3 binder M is a monovalent moiety: wherein R4and R8are as defined herein. In some of these preferred embodiments, R4is selected from H and halo (such as flouro or chloro). In one such embodiment, R4is H. In another such embodiment, R4is halo (such as flouro or chloro). E3 ubiquitin ligase binding moieties The presence of the E3 ubiquitin ligase binding moiety U in the compound of the invention means that the compound is a so-called “PROTAC”. The term PROTAC is an acronym for proteolysis targeting chimera. In general, PROTACs are, as is known in the art, heterobifunctional molecules that comprise two active moieties attached covalently by a linker group. In a PROTAC, the first active moiety (the MLLT1 and / or MLLT3 binder M in the compound of the present invention) binds to a target protein that is intended for degradation (target proteins for the compound of the present invention are MLLT1 and / or MLLT3). The second active moiety (U in the compound of the present invention) is capable of binding to an E3 ubiquitin ligase, thereby inducing selective intracellular proteolysis. Recruitment of the E3 ligase to the target protein results in ubiquitination and subsequent degradation of the target protein by the proteasome. E3 ubiquitin ligase moities are known in the art. Substantially any such moiety can be used. The sole limitation on the moiety is that it be capable of binding to an E3 ubiquitin ligase. Those skilled in the art would appreciate that entirely routine laboratory methods can be used to determine whether a given substance binds to an E3 ubiquitin ligase (including but not limited to any of those disclosed specifically herein). Thus, those skilled in the art would have no difficulty in identifying E3 ubiquitin ligase moieties, nor in establishing whether any existing chemical moiety falls within the bounds of this definition. In certain embodiments, the moiety shows activity or binds to the E3 ubiquitin ligase with an IC50of less than about 200 mM. The IC50can be determined according to any method known in the art, e.g., a fluorescent polarization assay. Merely by way of example of the extensive disclosure in the field concerning PROTACs, and hence E3 ubiquitin ligase binding moieties, reference can be made to Gu et al. (BioEssays 2018, 40, 1700247), Sun et al. (Signal Transduction and Targeted Therapy (2019) 4:64), WO 2020 / 041331, and WO 2019 / 140003, the contents of all of which are herein incorporated by reference in their entireties. Any of the numerous E3 ubiquitin ligase binding moieties disclosed in these documents can be used as an E3 ubiquitin ligase binding moiety in the compounds of the present invention. For the avoidance of doubt, Gu et al. refer to such moieties as ligands to recruit E3 ubiquitin ligase, Sun et al. refer to such moieties as E3 ubiquitin ligase (E3) recruiting ligands, in WO 2020 / 041331 such moieties are referred to as a “ULM” or (small molecule) E3 ubiquitin ligase binding moiety (that binds an E3 ubiquitin ligase) (and noting that the term “ULM” includes each of “ILM”, “CLM”, “VLM” and “MLM”, any of which can be used in the present compounds), and in WO 2019 / 140003 such moieties (labelled “B” in WO 2019 / 140003’s formula (I)) are referred to as a ubiquitin ligase ligand / binder. Further examples of documents disclosing suitable moieties that can be used in the compounds of the present invention are WO2013 / 106643, US2016 / 0045607, WO2014187777, US20140356322 and US 9,249, 153, US2016 / 0058872, US2015 / 0291562 and Winter et al (Science, June 19, 2015, p.1376), the contents of all of which are herein incorporated by reference in their entireties. Thalidomide, lenalidomide, pomalidomide and analogs thereof are still further examples of suitable moieties. Examples of E3 ubiquitin ligases include von Hippel-Lindau (VHL) and cereblon (CRBN). Preferably the E3 ubiquitin ligase binding moiety (U) is capable of binding to CRBN or VHL. Such moieties are referred to herein as CRBN or VHL E3 ubiquitin ligase binding moieties. In one embodiment, U is a CRBN E3 ubiquitin ligase binding moiety. In another embodiment, U is a VHL E3 ubiquitin ligase binding moiety. In some embodiments, the E3 ubiquitin ligase binding moiety (U) is: (a) a CRBN E3 ubiquitin ligase binding moiety of formula (U1): wherein: RU1is H; Q is selected from -CH(RU6)-, -N(RU6)-, -O-, -C(O)-, -NH-CH(RU6)-, -N=C(RU6)-, or -N=N-; RU6is H or C1-4alkyl; RU2and RU5are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; RU3and RU4are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU2, RU3, RU4and RU5is a single bond to LINK; (b) a CRBN E3 ubiquitin ligase binding moiety of formula (U4): wherein: RU1’is H; W is N or CRU16; Q’ is N and LUis a single bond, or Q’ is CH and LUis selected from a single bond or - C(O)N(H)-, wherein either (i) the C atom of LUis bonded to phenyl, and the N atom of LUis bonded to Q’; or (ii) the C atom of LUis bonded to Q’, and the N atom of LUis bonded to phenyl; RU12, RU13and RU14are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU12, RU13and RU14is a single bond to LINK; RU15and RU16are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN and CF3; (c) a CRBN E3 ubiquitin ligase binding moiety of formula (U5):

[0006] wherein: RU17is H; RU18, RU19, RU20and RU21are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU18, RU19, RU20and RU21is a single bond to LINK; or (d) a VHL E3 ubiquitin ligase binding moiety of formula (U2): wherein: RU7is a group selected from phenyl, a 5- to 6-membered heteroaryl ring, a 5- to 6-membered heterocyclyl ring, and a 5- to 6-membered cycloalkyl ring, the group RU7being unsubstituted or substituted by C1-4alkyl; RU11is H or C1-4 alkyl; RU8is selected from C1-4alkyl, phenyl and a 3- to 8-membered cycloalkyl ring; and RU9is a single bond to LINK. For the avoidance of doubt, in formula (U1), when Q is -NH-CH(RU6)- or -N=C(RU6)-, the N atom of Q is bonded to the phenyl ring in U, and the C atom of Q (not including any C atom that may be in RU6) is bonded to the N atom in U that is adjacent to group Q. In some embodiments, the E3 ubiquitin ligase binding moiety (U) is preferably a CRBN E3 ubiquitin ligase binding moiety of formula (U1). Typically, in formula (U1), Q is selected from -CH(RU6)- and -C(O)-. Preferably, Q is selected from -CH2- and -C(O)-. Most preferably, Q is -CH2-. Typically, in formula (U1), RU6is H or methyl. Preferably, RU6is H. Typically, in formula (U1), RU2and RU5are each independently selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK. Preferably, RU2and RU5are each independently selected from H and a single bond to LINK. Most preferably, RU2is H, and RU5is a single bond to LINK. Typically, in formula (U1), RU3and RU4are each independently selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN, CF3 and a single bond to LINK. Preferably, RU3and RU4are each independently selected from H and a single bond to LINK. Typically, in formula (U1), two or three of RU2, RU3, RU4and RU5are H. Preferably, three of RU2, RU3, RU4and RU5are H. More preferably, RU2and RU3are H, one of RU4and RU5is a single bond to LINK, and the other of RU4and RU5is H. Most preferably, RU2, RU3and RU4are H, and RU5is a single bond to LINK. Typically, therefore, in formula (U1): Q is selected from -CH(RU6)- and -C(O)-; RU6is H or methyl; RU2and RU5are each independently selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; RU3and RU4are each independently selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN, CF3and a single bond to LINK; and two or three of RU2, RU3, RU4and RU5are H. Preferably, in formula (U1): Q is selected from -CH2- and -C(O)-; RU6is H; one of RU2, RU3, RU4and RU5is a single bond to LINK, and the rest are H, for instance wherein RU2and RU3are H, one of RU4and RU5is a single bond to LINK, and the other of RU4and RU5is H. Most preferably, in formula (U1): Q is -CH2-; RU6is H; RU2, RU3and RU4are H, and RU5is a single bond to LINK. Typically, in formula (U4), Q’ is N and LUis a single bond, or Q’ is CH and LUis -C(O)N(H)-. Preferably, Q’ is N and LUis a single bond. Typically, in formula (U4), when LUis -C(O)N(H)-, then the C atom of LUis bonded to phenyl, and the N atom of LUis bonded to Q’. Typically, in formula (U4), RU12, RU13and RU14are each independently selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK (wherein one and only one of RU12, RU13and RU14is a single bond to LINK). Preferably, one of RU12, RU13and RU14is a single bond to LINK, one of RU12, RU13and RU14is H and the other of RU12, RU13and RU14is selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN, CF3, preferably from H, fluoro and methyl. More preferably, one of RU12, RU13and RU14is a single bond to LINK and the other two are H, for instance wherein RU12and RU14are H, and RU13is a single bond to LINK. Typically, in formula (U4), RU15and RU16(when present) are each independently selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN and CF3. Preferably, RU15and RU16(when present) are each independently selected from H, F and Me. In one embodiment of formula (U4), RU15and RU16(when present) are H, and two of RU12, RU13and RU14are H. Preferably, RU13, RU14and RU15are H, RU12is a single bond to LINK, and RU16(when present) is selected from H, F and Me. Typically, therefore, in formula (U4): Q’ is N and LUis a single bond, or Q’ is CH and LUis -C(O)N(H)-; RU12, RU13and RU14are each independently selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; and RU15and RU16(when present) are each independently selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN and CF3; wherein one and only one of RU12, RU13and RU14is a single bond to LINK. Preferably, in formula (U4): Q’ is N and LUis a single bond; one of RU12, RU13and RU14is a single bond to LINK and the other two are H, for instance wherein RU12and RU14are H, and RU13is a single bond to LINK, or RU13, RU14and RU15are H, RU12is a single bond to LINK, and RU16(when present) is selected from H, F and Me. Typically, in formula (U5), RU18, RU19, RU20and RU21are each independently selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK (wherein one and only one of RU18, RU19, RU20and RU21is a single bond to LINK). Preferably, one of RU18, RU19, RU20and RU21is a single bond to LINK, one or two, preferably two of RU18, RU19, RU20and RU21are H and the other one or two, preferably one of RU18, RU19, RU20and RU21are selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN, CF3, preferably from H, fluoro and methyl. More preferably, one of RU18, RU19, RU20and RU21is a single bond to LINK and the other three are H, for instance wherein RU19, RU20and RU21are H, and RU18is a single bond to LINK. Typically, in formula (U2), RU7is a 5- to 6-membered heteroaryl ring. Preferably, RU7is a 5- membered heteroaryl ring containing one S atom and optionally one N atom. Typically, in formula (U2), RU7is unsubstituted or substituted by C1-4alkyl. Preferably, RU7is unsubstituted or substituted by methyl. Typically, in formula (U2), RU11is H or methyl. Preferably, RU11is H. Typically, in formula (U2), RU8is C1-4alkyl or phenyl. Preferably, RU8is t-butyl or phenyl, more preferably t-butyl. Typically, therefore, in formula (U2), RU7is a 5- to 6-membered heteroaryl ring, the group RU7being unsubstituted or substituted by C1-4alkyl, RU11is H or methyl, and RU8is C1-4alkyl or phenyl. Preferably, in formula (U2), RU7is a 5-membered heteroaryl ring containing one S atom and optionally one N atom, the group RU7being unsubstituted or substituted by methyl, RU11is H, and RU8is t-butyl or phenyl, more preferably t-butyl. In a preferred embodiment, the E3 ubiquitin ligase binding moiety (U) is a VHL E3 ubiquitin ligase binding moiety of formula (U3): V is S or O; W is N or CH; RU10is H or C1-4alkyl; RU11is H or C1-4alkyl; RU8is selected from C1-4alkyl, phenyl and a 3- to 8-membered cycloalkyl ring; and RU9is a single bond to LINK. Typically, in formula (U3), V is S. Typically, in formula (U3), W is N or CH. Preferably, W is N. Typically, in formula (U3), RU10is H or methyl. Preferably, RU10is methyl. Typically, in formula (U3), RU11is H or methyl. Preferably, RU11is H. Typically, in formula (U3), RU8is C1-4alkyl or phenyl. Preferably, RU8is t-butyl or phenyl, more preferably t-butyl. Typically, therefore, in formula (U3), V is S, W is N or CH, RU10is H or methyl, RU11is H or methyl, and RU8is C1-4alkyl or phenyl. Preferably, V is S, W is N, RU10is methyl, RU11is H, RU8is t-butyl or phenyl, more preferably t-butyl. The moieties U of formulae (U1), (U4) when Q’ is CH and (U5) typically contain at least one chiral centre at the carbon atoms marked with an asterisk as depicted below: Moiety U may therefore be provided in the form of the R-enantiomer at said carbon atom, in the form of the S-enantiomer at said carbon atom, or in the form of a mixture (for example a 1:1 mixture) of the two enantiomers. A pure enantiomeric form of either the R- or the S-enantiomer may be preferred. In some embodiments, the S-enantiomer at said carbon atom is preferred. In other embodiments, the R-enantiomer at said carbon atom is preferred. The substance or agent described herein may contain at least 50%, preferably at least 60%, 75%, 90% or 95% of a compound which is enantiomerically or diasteriomerically pure at moiety U. Unless otherwise stated, the moiety U may typically be provided in the form of a 1:1 mixture of the two enantiomers. In some embodiments, the S-enantiomer at said carbon atom is preferred. The preferred stereochemistry at said carbon atom is also depicted by the following illustrative structure of formula (U1): . where LINK is attached to moiety U at the RU5position. In some preferred embodiments, the E3 ubiquitin ligase binding moiety (U) has the following structure: . Linkers As discussed herein, in the compounds of the invention, the binder of MLLT1 and / or MLLT3 (M) is covalently attached to an E3 ubiquitin ligase binding moiety (U). This covalent attachment is labelled LINK and may be a direct single bond or a divalent chemical linker group that forms covalent bonds both to the binder of MLLT1 and / or MLLT3 (M), and to the E3 ubiquitin ligase binding moiety (U). Typically, LINK is a divalent chemical linker group that forms covalent bonds both to the binder of MLLT1 and / or MLLT3 (M), and to the E3 ubiquitin ligase binding moiety (U). There is no particular limitation on the nature of LINK in the compounds of the present invention (beyond that the respective active moieties, e.g., U and M, are able to exert their desired function and LINK is capable of covalently attaching them together). Those skilled in the art would recognise that chemical linker groups are routinely used in the construction of bifunctional molecules and would be able routinely to provide appropriate chemical linker groups for attaching particular U and M moieties together. Typically, a chemical linker group for use in the present invention is an organic group. When LINK is a divalent chemical linker group, it may be represented by formula (L): wherein: LINK is attached to M via L1; LINK is attached to U via L3; L1 and L3 are each independently selected from a single bond, -N(R’)-, -C(O)N(R’)-, -O-, - N(R’)C(O)-, -C(O)-, -S(O2)N(R’)-, -N(R’)S(O2)-, -(C1-6alkylene)-, ethynylene, -(C2-6alkenylene)-, -C=C=C-, phenylene, a divalent 3- to 6-membered cycloalkyl ring and a divalent 4- to 7-membered heterocyclyl ring, the phenylene, cycloalkyl and heterocyclyl rings being unsubstituted or substituted by one or two C1-4alkyl; L2 is represented by the formula -(L4)m-;each L4 is independently a unit of formula: or each XLis independently selected from a single bond, -N(R’)-, -O-, -C(O)-, -S-, -SO-, -SO2-, - C(R”)=C(R”)- and -C≡C-; each YLis independently selected from a divalent 3- to 6-membered cycloalkyl ring, a divalent 4- to 7-membered heterocyclyl ring, or one of the following structures: , the cycloalkyl and heterocyclyl rings being unsubstituted or substituted by one or two C1-4alkyl; n is selected from 0 to 4; n’ is selected from 0 or 1; n + n’ ≥ 1; m is selected from 1 to 30; each R’ is independently selected from H and C1-4alkyl; and each R” is independently selected from H and halo. When m is not 1 (i.e. when there are two or more L4 groups present), then the XLgroup of any L4 group is not directly bonded to the XLgroup of any other L4 group that is present. When the phenylene, cycloalkyl or heterocyclyl rings referred to herein are substituted, they are prefereably substituted by one methyl group. In a preferred embodiment, L1 and L3 are each independently selected from a single bond, - C(O)N(R’)-, -O-, -N(R’)C(O)-, -C(O)-, -S(O2)N(R’)-, -N(R’)S(O2)-, -(C1-6alkylene)-, ethynylene, -(C2-6alkenylene)-, -C=C=C-, phenylene, a divalent 3- to 6-membered cycloalkyl ring and a divalent 4- to 7-membered heterocyclyl ring, the phenylene, cycloalkyl and heterocyclyl rings being unsubstituted or substituted by one methyl group. Typically, in formula (L), L1 is selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -C(O)N(R’)-, -N(R’)C(O)-, -O-, -S(O2)N(R’)-, -N(R’)S(O2)-, and a divalent 4- to 7- membered heterocyclyl ring which is unsubstituted or substituted by one or two C1-4alkyl. When present, the divalent 4- to 7-membered heterocyclyl ring of L1 typically contains at least one N atom, for instance one or two N atoms. Preferably, when L1 is a divalent 4- to 7- membered heterocyclyl ring, it is a divalent 5- to 6-membered heterocyclyl ring, more preferably a saturated divalent 5- to 6-membered heterocyclyl ring, for instance a divalent moiety of piperidine or diazinane. Preferably, in formula (L), L1 is selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -C(O)N(H)-, -N(H)C(O)-, and a divalent moiety of piperidine or diazinane which is unsubstituted or substituted by one methyl group. For instance, L1 may be a single bond. Typically, in formula (L), L3 is selected from a single bond, -N(R’)-, -C(O)N(R’)-, -O-, - N(R’)C(O)-, -S(O2)N(R’)-, -N(R’)S(O2)-, ethynylene, -C=C=C-, phenylene and a divalent 4- to 7-membered heterocyclyl ring, the phenylene and heterocyclyl rings being unsubstituted or substituted by one or two C1-4alkyl. When present, the divalent 4- to 7-membered heterocyclyl ring of L3 typically contains at least one N atom, for instance one or two N atoms. Preferably, when L3 is a divalent 4- to 7-membered heterocyclyl ring, it is a divalent 5- to 6-membered heterocyclyl ring, more preferably a saturated divalent 5- to 6-membered heterocyclyl ring, preferably a divalent moiety of piperidine or diazinane. Preferably, in formula (L), L3 is selected from a single bond, -C(O)N(H)-, -O-, -N(H)C(O)-, ethynylene, -C=C=C-, phenylene and a divalent moiety of piperidine or diazinane, the phenylene and divalent moiety of piperidine or diazinane being unsubstituted or substituted by one methyl group. Most preferably, L3 is selected from a single bond, ethynylene and a divalent moiety of piperidine or diazinane. L2 is represented by the formula -(L4)m-. In formula (L), each L4 is independently a unit offormula described above. Typically, each XLis independently selected from a single bond, -O-, -S-, -C(R”)=C(R”)- and - C≡C-, for example a single bond, -O- and -S-. Preferably, each XLis independently selected from a single bond and -O-. Typically, each YLis independently selected from a divalent moiety of piperidine or diazinane, or one of the following structures: the divalent moiety of piperidine or diazinane being unsubstituted or substituted by one methyl group. In formula (L), n is selected from 0 to 4; n’ is selected from 0 or 1; and n + n’ ≥ 1. In one embodiment, each L4 is the same. Alternatively, L2 may comprise two or more blocks, wherein in each block, each L4 is the same. For instance, L2 may be represented by the formula -(L4’)p-(L4’’)q-(L4’’’)r-, wherein L4’, L4’’ and L4’’’ are selected from those moieties described above for L4, and wherein each L4’ is the same, each L4’’ is the same and each L4’’’ is the same. Preferably, L4’, L4’’ and L4’’’ are selected from -CH2-, -CH2CH2O-, -OCH2CH2-, - CH2CH2S- and -SCH2CH2-. More preferably, L4’, L4’’ and L4’’’ are selected from -CH2-, - CH2CH2O- and -OCH2CH2-. p, q and r are integers of from 0 to 30, wherein p+q+r=m. In one embodiment, each L4 unit is the same. For instance, each L4 in formula (L) may be - CH2-, each L4 in formula (L) may be -CH2CH2O-, each L4 in formula (L) may be -OCH2CH2-, each L4 in formula (L) may be -CH2CH2S-, or each L4 in formula (L) may be -SCH2CH2-. More preferably, each L4 in formula (L) is -CH2-, each L4 in formula (L) is -CH2CH2O- or each L4 in formula (L) is -OCH2CH2-. Most preferably, each L4 in formula (L) is -CH2-. Typically, in formula (L), m is selected from 1 to 10. For instance, m may be selected from 1 to 8, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1. Typically, in formula (L), each R’ is independently selected from H and methyl. Preferably, each R’ is H. Typically, in formula (L), each R” is independently selected from H, fluoro and chloro. Preferably, each R” is H and chloro, for example H. When L2 comprises one or more divalent 4- to 7-membered heterocyclyl rings, typically L2 comprises only one or two, e.g. one divalent 4- to 7-membered heterocyclyl rings. Typically, therefore, L2 comprises none, one or two divalent 4- to 7-membered heterocyclyl rings, for example none or one divalent 4- to 7-membered heterocyclyl rings. When L2 comprises one or more divalent 4- to 7-membered heterocyclyl rings, then in one embodiment L1 and L3 do not contain a divalent 4- to 7-membered heterocyclyl ring. Typically, therefore, in formula (L): L1 is selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -C(O)N(R’)-, - N(R’)C(O)-, -O-, -S(O2)N(R’)-, -N(R’)S(O2)-, and a divalent 4- to 7-membered heterocyclyl ring which is unsubstituted or substituted by one or two C1-4alkyl, the divalent 4- to 7- membered heterocyclyl ring typically containing at least one N atom, for instance one or two N atoms; L3 is selected from a single bond, -N(R’)-, -C(O)N(R’)-, -O-, -N(R’)C(O)-, -S(O2)N(R’)-, - N(R’)S(O2)-, ethynylene, -C=C=C-, phenylene and a divalent 4- to 7-membered heterocyclyl ring, the phenylene and heterocyclyl rings being unsubstituted or substituted by one or two C1-4alkyl, the divalent 4- to 7-membered heterocyclyl ring typically containing at least one N atom, for instance one or two N atoms; each XLis independently selected from a single bond, -O-, -S-, -C(R”)=C(R”)- and -C≡C-, for example a single bond, -O- and -S-; each YLis independently selected from a divalent moiety of piperidine or diazinane, or one of the following structures: the divalent moiety of piperidine or diazinane being unsubstituted or substituted by one methyl group; n is selected from 0 to 4; n’ is selected from 0 or 1; and n + n’ ≥ 1; m is selected from 1 to 10, preferably from 1 to 4 (for example 1, 2 or 3); each R’ is independently selected from H and methyl; and each R” is independently selected from H, fluro and chloro, for instance H and chloro. Preferably, in formula (L): L1 is selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -C(O)N(H)-, - N(H)C(O)-, and a divalent moiety of piperidine or diazinane which is unsubstituted or substituted by one methyl group; L3 is selected from a single bond, -C(O)N(H)-, -O-, -N(H)C(O)-, ethynylene, -C=C=C-, phenylene and a divalent moiety of piperidine or diazinane, the phenylene and divalent moiety of piperidine or diazinane being unsubstituted or substituted by one methyl group; each XLis independently selected from a single bond and -O-; each YLis independently selected from a divalent moiety of piperidine or diazinane, or one of the following structures: the divalent moiety of piperidine or diazinane being unsubstituted or substituted by one methyl group; n is selected from 0 to 4; n’ is selected from 0 or 1; and n + n’ ≥ 1; m is selected from 1 to 4 (for example 1, 2 or 3); each R’ is H; and each R” is H or chloro, for instance H. In a typical embodiment, L2 is -(C1-10alkylene)- or -(C1-10alkylene)-C(O)-, preferably -(C1-10alkylene)-. In this embodiment, L1 is preferably selected from a single bond, -C(O)N(H)-, - N(H)C(O)-, -O-, and a divalent moiety of piperidine or diazinane. In this embodiment, L3 is preferably selected from a single bond, -C(O)N(H)-, -O-, -N(H)C(O)-, ethynylene and a divalent moiety of piperidine or diazinane. More preferably, L1 and L3 are selected from the following options: - L1 is -C(O)N(H)- or -N(H)C(O)-, and L3 is -C(O)N(H)- or -N(H)C(O)-; - L1 is a divalent moiety of piperidine and L3 is a divalent moiety of diazinane; - L1 is -C(O)N(H)- or -N(H)C(O)-, and L3 is a divalent moiety of diazinane; - L1 is a single bond and L3 is a divalent moiety of diazinane; - L1 is a single bond and L3 is a divalent moiety of piperidine; - L1 is a single bond and L3 is -O-; - L1 is a single bond and L3 is ethynylene; - L1 is a single bond and L3 is a single bond; and - L1 is -C(O)N(H)- or -N(H)C(O)-, and L3 is -O-. In particularly preferred embodiments: - L1 is a divalent moiety of piperidine, L2 is -(C1-10alkylene)- and L3 is a divalent moiety of diazinane; - L1 is a single bond, L2 is -(C1-10alkylene)- and L3 is -O-; - L1 is a single bond, L2 is -(C1-10alkylene)- and L3 is a divalent moiety of piperidine or diazinane; - L1 is a single bond, L2 is -(C1-10alkylene)- and L3 is ethynylene; - L1 is a divalent moiety of piperidine, L2 is -(C1-10alkylene)- and L3 is ethynylene; - L1 is a divalent moiety of diazinane, L2 is -(C1-10alkylene)- and L3 is ethynylene; - L1 is a divalent moiety of diazinane, L2 is -(C1-10alkylene)- and L3 is a divalent moiety of piperidine; - L1 is a single bond, L2 is a divalent moiety of piperidine and L3 is phenylene; - L1 is a divalent moiety of piperidine or diazinane, L2 is is -(C1-10alkylene)- and L3 is phenylene; - L1 is -O-, L2 is -(C1-10alkylene)- and L3 is ethynylene; - L1 is a divalent moiety of piperidine, L2 is -(C1-10alkylene)-O- and L3 is a divalent moiety of piperidine. In one preferred embodiment, LINK has the following structure: wherein T is -O- or –(CH2)-, and t is selected from 1 to 10, preferably 1 to 5, more preferably 2. In another preferred embodiment, L1 is a single bond, L2 is -(C1-10alkylene)- and L3 is ethynylene or a divalent moiety of piperidine (for instance ethynylene), preferably wherein L2 is -(C3-8alkylene)-, more preferably wherein L2 is -(C7alkylene)-. Alternatively, when LINK is a divalent chemical linker group, it may be represented by formula (L’): wherein: LINK is attached to M via L1; LINK is attached to U via L3; L1 and L3 are each independently selected from a single bond, -N(R’)-, -C(O)N(R’)-, -O-, - N(R’)C(O)-, -C(O)-, -S(O2)N(R’)-, -N(R’)S(O2)-, -(C1-6alkylene)-, ethynyl, -(C2-6alkenylene)-, a divalent 3- to 6-membered cycloalkyl ring and a divalent 4- to 7-membered heterocyclyl ring; L2 is represented by the formula -(L4)m-; each L4 is independently selected from a divalent 3- to 6-membered cycloalkyl ring, a divalent4- to 7-membered heterocyclyl ring and a unit of formula: each XLis independently selected from a single bond, -N(R’)-, -O-, -C(O)-, -S-, -SO-, -SO2-, - C(R”)=C(R”)- and -C(H)≡C(H)-; n is selected from 1 to 4; m is selected from 1 to 30; each R’ is independently selected from H and C1-4alkyl; and each R” is independently selected from H and halo. In one embodiment of formula (L’), L1 and L3 are each independently selected from a single bond, -N(R’)-, -C(O)N(R’)-, -O-, -N(R’)C(O)-, -C(O)-, -S(O2)N(R’)-, -N(R’)S(O2)-, -(C1-6alkylene)-, -(C2-6alkenylene)-, ethynyl, a divalent 3- to 6-membered cycloalkyl ring and a divalent 4- to 7-membered heterocyclyl ring; L2 is represented by the formula -(L4)m-; and each L4 is independently selected from a divalent 3- to 6-membered cycloalkyl ring, a divalent4- to 7-membered heterocyclyl ring and a unit of formula: .When m is not 1 (i.e. when there are two or more L4 groups present), then the XLgroup of any L4 group is not directly bonded to the XLgroup of any other L4 group that is present. Typically, in formula (L’), L1 is selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -C(O)N(R’)-, -N(R’)C(O)-, -O-, -S(O2)N(R’)-, -N(R’)S(O2)-, and a divalent 4- to 7- membered heterocyclyl ring. When present, the divalent 4- to 7-membered heterocyclyl ring of L1 typically contains at least one N atom, for instance one or two N atoms. Preferably, when L1 is a divalent 4- to 7-membered heterocyclyl ring, it is a divalent 5- to 6-membered heterocyclyl ring, more preferably a saturated divalent 5- to 6-membered heterocyclyl ring, for instance a divalent moiety of piperidine or diazinane. Preferably, in formula (L), L1 is selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -C(O)N(H)-, -N(H)C(O)-, and a divalent moiety of piperidine or diazinane. Typically, in formula (L’), L3 is selected from a single bond, -N(R’)-, -C(O)N(R’)-, -O-, - N(R’)C(O)-, -S(O2)N(R’)-, -N(R’)S(O2)-, ethynyl and a divalent 4- to 7-membered heterocyclyl ring. When present, the divalent 4- to 7-membered heterocyclyl ring of L3 typically contains at least one N atom, for instance one or two N atoms. Preferably, when L3 is a divalent 4- to 7- membered heterocyclyl ring, it is a divalent 5- to 6-membered heterocyclyl ring, more preferably a saturated divalent 5- to 6-membered heterocyclyl ring, for instance a divalent moiety of piperidine or diazinane, preferably 1,4-diazinane. Preferably, in formula (L), L3 is selected from a single bond, -N(H)-, -C(O)N(H)-, -O-, -N(H)C(O)-, ethynyl and a divalent moiety of piperidine or diazinane. L2 is represented by the formula -(L4)m-. Typically, in formula (L’), each L4 is independently selected from a divalent 4- to 7-membered heterocyclyl ring and a unit of formula described above. Typically, each XLis independently selected from a single bond, -O-, -S-, -C(R”)=C(R”)- and - C(H)≡C(H)-, for example a single bond, -O- and -S-, and n is selected from 1 or 2. In one embodiment, each L4 is the same. Alternatively, L2 may comprise two or more blocks, wherein in each block, each L4 is the same. For instance, L2 may be represented by the formula -(L4’)p- (L4’’)q-(L4’’’)r-, wherein L4’, L4’’ and L4’’’ are selected from those moieties described above for L4, and wherein each L4’ is the same, each L4’’ is the same and each L4’’’ is the same. Preferably, L4’, L4’’ and L4’’’ are selected from -CH2-, -CH2CH2O-, -OCH2CH2-, -CH2CH2S- and -SCH2CH2-. More preferably, L4’, L4’’ and L4’’’ are selected from -CH2-, -CH2CH2O- and -OCH2CH2-. p, q and r are integers of from 0 to 30, wherein p+q+r=m. In one embodiment of formula (L’), each L4 unit is the same. For instance, each L4 in formula (L’) may be -CH2-, each L4 in formula (L’) may be -CH2CH2O-, each L4 in formula (L’) may be -OCH2CH2-, each L4 in formula (L’) may be -CH2CH2S-, or each L4 in formula (L’) may be -SCH2CH2-. More preferably, each L4 in formula (L’) is -CH2-, each L4 in formula (L’) is - CH2CH2O- or each L4 in formula (L’) is -OCH2CH2-. Most preferably, each L4 in formula (L’) is -CH2-. Typically, in formula (L’), m is selected from 1 to 10. Typically, in formula (L’), each R’ is independently selected from H and methyl. Preferably, each R’ is H. Typically, in formula (L’), each R” is independently selected from H, fluoro and chloro. Preferably, each R” is H and chloro, for example H. When one or more L4 is a divalent 4- to 7-membered heterocyclyl ring, typically only one or two, e.g. one L4 is a divalent 4- to 7-membered heterocyclyl ring. Typically, therefore, none, one or two L4 is a divalent 4- to 7-membered heterocyclyl ring, for example none or one L4 is a divalent 4- to 7-membered heterocyclyl ring. Typically, therefore, in formula (L’): L1 is selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -C(O)N(R’)-, - N(R’)C(O)-, -O-, -S(O2)N(R’)-, -N(R’)S(O2)-, and a divalent 4- to 7-membered heterocyclyl ring typically containing at least one N atom, for instance one or two N atoms; L3 is selected from a single bond, -N(R’)-, -C(O)N(R’)-, -O-, -N(R’)C(O)-, - S(O2)N(R’)-, -N(R’)S(O2)-, ethynyl and a divalent 4- to 7-membered heterocyclyl ring typically containing at least one N atom, for instance one or two N atoms; each L4 is independently selected from -CH2-, -CH2CH2O-, -OCH2CH2-, -CH2CH2S-, - SCH2CH2-, and a divalent 4- to 7-membered heterocyclyl ring, wherein when one or more L4 is a divalent 4- to 7-membered heterocyclyl ring, only one or two, e.g. one L4 is a divalent 4- to 7- membered heterocyclyl ring; m is selected from 1 to 10; each R’ is independently selected from H and methyl; and each R” is independently selected from H, fluro and chloro, for instance H and chloro. Preferably, in formula (L’): L1 is selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -C(O)N(H)-, - N(H)C(O)-, and a divalent moiety of piperidine or diazinane; L3 is selected from a single bond, -N(H)-, -C(O)N(H)-, -O-, -N(H)C(O)-, ethynyl and a divalent moiety of piperidine or diazinane; each L4 in formula (L) is -CH2-, each L4 in formula (L) is -CH2CH2O-, each L4 in formula (L) is -OCH2CH2-, each L4 in formula (L) is -CH2CH2S-, or each L4 in formula (L) is -SCH2CH2-, with each L4 preferably being -CH2-; m is selected from 1 to 10; each R’ is H; and each R” is H or chloro, for instance H. In a typical embodiment of formula (L’), L2 is -(C1-10alkylene)- or -(C1-10alkylene)-C(O)-, preferably -(C1-10alkylene)-. In this embodiment, L1 is preferably selected from a single bond, - C(O)N(H)-, -N(H)C(O)-, and a divalent moiety of piperidine or diazinane. In this embodiment, L3 is preferably selected from a single bond, -N(H)-, -C(O)N(H)-, -O-, -N(H)C(O)-, ethynyl and a divalent moiety of piperidine or diazinane. More preferably, L1 and L3 are selected from the following options: - L1 is a single bond and L3 is -N(H)-; - L1 is a divalent moiety of piperidine and L3 is -N(H)-; - L1 is -C(O)N(H)- or -N(H)C(O)-, and L3 is -C(O)N(H)- or -N(H)C(O)-; - L1 is a divalent moiety of piperidine and L3 is a divalent moiety of diazinane; - L1 is -C(O)N(H)- or -N(H)C(O)-, and L3 is a divalent moiety of diazinane; - L1 is a single bond and L3 is a divalent moiety of diazinane; - L1 is a single bond and L3 is a divalent moiety of piperidine; - L1 is a single bond and L3 is -O-; - L1 is a single bond and L3 is ethynyl; - L1 is a single bond and L3 is a single bond; and - L1 is -C(O)N(H)- or -N(H)C(O)-, and L3 is -O-. For the avoidance of doubt, the skilled person would readily appreciate that each of the definitions of moieties U, M and LINK provided herein may be taken together in any combination to arrive at a definition of the compound of the present invention. As examples that are in no way limiting, definitions of moieties U, M and LINK labelled “typically” may be combined to arrive at a definition of a typical compound of the present invention, and definitions of moieties U, M and LINK labelled “preferably” may be combined to arrive at a definition of a preferred compound of the present invention. However, the skilled person would appreciate that a definition labelled “typically” of one moiety may be combined with a definition labelled “preferably” of another moiety to arrive at a definition of a compound of the present invention. In preferred compounds of the present invention, M is of formula (III): wherein R1, R2, R3a, R3b, R3c, R3d, X, R4, R5, R6and R8are as defined herein. Typically, in such preferred compounds: R1is H or C1-4alkyl which is itself unsubstituted or substituted with C1-4alkoxy; R2is H or methyl; R3aand R3bare independently selected from H, C1-4alkyl, and C1-4alkoxy, or R3aand R3bform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, with the proviso that when X is O or -N(Me)-, then neither R3cnor R3dare halo; wherein at least two of R3a, R3b, R3cand R3dare H; X is a bond, -N(Me)-, O or -CH2-; R4is selected from H, CN, halo C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R5and R6are independently selected from H, halo C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R8is an 8- to 10-membered heteroaryl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two R9; each R9is independently selected from halo and C1-4alkoxy; and R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 6-membered heterocyclyl ring, and a phenyl ring, the group R10being unsubstituted or substituted by one or two substituents independently selected from C1-4alkyl, C1-4alkoxy, and halo; wherein M is bonded to LINK via a C or N atom within group R8or ring Hy (as described herein) such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK; and LINK is (a) a single bond, or (b) a chemical linker group represented by formula (L): wherein: LINK is attached to M via L1; LINK is attached to U via L3; L1 and L3 are each independently selected from a single bond, -N(R’)-, -C(O)N(R’)-, -O-, - N(R’)C(O)-, -C(O)-, -S(O2)N(R’)-, -N(R’)S(O2)-, -(C1-6alkylene)-, ethynylene, -(C2-6alkenylene)-, -C=C=C-, phenylene, a divalent 3- to 6-membered cycloalkyl ring and a divalent 4- to 7-membered heterocyclyl ring, the phenylene, cycloalkyl and heterocyclyl rings being unsubstituted or substituted by one or two C1-4alkyl; L2 is represented by the formula -(L4)m-; each L4 is independently a unit of formula: or each XLis independently selected from a single bond, -N(R’)-, -O-, -C(O)-, -S-, -SO-, -SO2-, - C(R”)=C(R”)- and -C≡C-; each YLis independently selected from a divalent 3- to 6-membered cycloalkyl ring, a divalent 4- to 7-membered heterocyclyl ring, or one of the following structures: the cycloalkyl and heterocyclyl rings being unsubstituted or substituted by one or two C1-4alkyl; n is selected from 0 to 4; n’ is selected from 0 or 1; n + n’ ≥ 1; m is selected from 1 to 10, preferably from 1 to 4 (for example 1, 2 or 3); each R’ is independently selected from H and C1-4alkyl; each R” is independently selected from H and halo;U is: (a) a CRBN E3 ubiquitin ligase binding moiety of formula (U1): wherein: RU1is H; Q is selected from -CH(RU6)-, -N(RU6)-, -O-, -C(O)-, -NH-CH(RU6)-, -N=C(RU6)-, or -N=N-; RU6is H or C1-4alkyl; RU2and RU5are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; RU3and RU4are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU2, RU3, RU4and RU5is a single bond to LINK; (b) a CRBN E3 ubiquitin ligase binding moiety of formula (U4): wherein: RU1’is H; Q’ is N and LUis a single bond, or Q’ is CH and LUis selected from a single bond or - C(O)N(H)-, wherein either (i) the C atom of LUis bonded to phenyl, and the N atom of LUis bonded to Q’; or (ii) the C atom of LUis bonded to Q’, and the N atom of LUis bonded to phenyl; RU12, RU13and RU14are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU12, RU13and RU14is a single bond to LINK; RU15and RU16are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN and CF3; (c) a CRBN E3 ubiquitin ligase binding moiety of formula (U5):

[0007] wherein: RU17is H; RU18, RU19, RU20and RU21are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU18, RU19, RU20and RU21is a single bond to LINK; or (d) a VHL E3 ubiquitin ligase binding moiety of formula (U2): wherein: RU7is a group selected from phenyl, a 5- to 6-membered heteroaryl ring, a 5- to 6-membered heterocyclyl ring, and a 5- to 6-membered cycloalkyl ring, the group RU7being unsubstituted or substituted by C1-4alkyl; RU11is H or C1-4 alkyl; RU8is selected from C1-4alkyl, phenyl and a 3- to 8-membered cycloalkyl ring; and RU9is a single bond to LINK. Alternatively, in such preferred compounds: R1is H or C1-4alkyl which is itself unsubstituted or substituted with C1-4alkoxy; R2is H or methyl; R3aand R3bare independently selected from H, C1-4alkyl, and C1-4alkoxy, or R3aand R3bform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, with the proviso that when X is O or -N(Me)-, then neither R3cnor R3dare halo; wherein at least two of R3a, R3b, R3cand R3dare H; X is a bond, -N(Me)-, O or -CH2-; R4is selected from H, CN, halo C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R5and R6are independently selected from H, halo C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R8is an 8- to 10-membered heteroaryl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4 alkyl which is itself unsubstituted or substituted by one or two R9; each R9is independently selected from halo and C1-4alkoxy; and R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 6-membered heterocyclyl ring, and a phenyl ring, the group R10being unsubstituted or substituted by one or two substituents independently selected from C1-4alkyl, C1-4alkoxy, and halo; wherein M is bonded to LINK via a C or N atom within group R8or ring Hy (as described herein) such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK; and LINK is (a) a single bond, or (b) a chemical linker group represented by formula (L’): wherein: LINK is attached to M via L1; LINK is attached to U via L3; L1 and L3 are each independently selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -N(R’)-, -C(O)N(R’)-, -O-, -N(R’)C(O)-, -C(O)-, -S(O2)N(R’)-, -N(R’)S(O2)-, -(C1-6alkylene)-, ethynyl, -(C2-6alkenylene)-, a divalent 3- to 6-membered cycloalkyl ring and a divalent 4- to 7-membered heterocyclyl ring; L2 is represented by the formula -(L4)m-; each L4 is independently selected from a divalent 3- to 6-membered cycloalkyl ring, a divalent4- to 7-membered heterocyclyl ring and a unit of formula: each XLis independently selected from a single bond, -N(R’)-, -O-, -C(O)-, -S-, -SO-, -SO2-, - C(R”)=C(R”)- and -C(H)≡C(H)-; n is selected from 1 to 4; m is selected from 1 to 30; each R’ is independently selected from H and C1-4alkyl; each R” is independently selected from H, fluoro and chloro; and U is: (a) a CRBN E3 ubiquitin ligase binding moiety of formula (U1): wherein: RU1is H; Q is selected from -CH(RU6)-, -N(RU6)-, -O-, -C(O)-, -NH-CH(RU6)-, -N=C(RU6)-, or -N=N-; RU6is H or C1-4alkyl; RU2and RU5are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; RU3and RU4are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU2, RU3, RU4and RU5is a single bond to LINK; (b) a CRBN E3 ubiquitin ligase binding moiety of formula (U4): wherein: RU1’is H; Q’ is N and LUis a single bond, or Q’ is CH and LUis selected from a single bond or - C(O)N(H)-, wherein either (i) the C atom of LUis bonded to phenyl, and the N atom of LUis bonded to Q’; or (ii) the C atom of LUis bonded to Q’, and the N atom of LUis bonded to phenyl; RU12, RU13and RU14are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU12, RU13and RU14is a single bond to LINK; RU15and RU16are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN and CF3; (c) a CRBN E3 ubiquitin ligase binding moiety of formula (U5):

[0008] wherein: RU17is H; RU18, RU19, RU20and RU21are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU18, RU19, RU20and RU21is a single bond to LINK; or (d) a VHL E3 ubiquitin ligase binding moiety of formula (U2): wherein: RU7is a group selected from phenyl, a 5- to 6-membered heteroaryl ring, a 5- to 6-membered heterocyclyl ring, and a 5- to 6-membered cycloalkyl ring, the group RU7being unsubstituted or substituted by C1-4alkyl; RU11is H or C1-4 alkyl; RU8is selected from C1-4alkyl, phenyl and a 3- to 8-membered cycloalkyl ring; and RU9is a single bond to LINK. In one preferred aspect of these embodiments, M is of formula (IV): wherein R8is as described herein, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo and C1-4alkyl; wherein M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK. In this embodiment, R8is preferably selected from one of the following structures: wherein: represents the point of attachment of R8to the rest of moiety M; represents the point of attachment of R8to LINK; and the group R8is further unsubstituted or substituted by one or two substituents independently selected from fluorine and methyl. For example, the group R8may be selected from one of the following structures: wherein: represents the point of attachment of R8to the rest of moiety M; and represents the point of attachment of R8to LINK. In this embodiment, L2 is preferably selected from -(CH2)m-, -(CH2CH2O)m-, -(OCH2CH2)m-, - (CH2CH2S)m-, -(SCH2CH2)m-, and a divalent 4- to 7-membered heterocyclyl ring. In this embodiment, preferably L1 and L3 are each independently selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -N(R’)-, -C(O)N(R’)-, -N(R’)C(O)-, -O-, ethynyl and a divalent 4- to 7-membered heterocyclyl ring. Preferably in this embodiment, R’ is H and the divalent 4- to 7-membered heterocyclyl ring is piperidine or diazinane. More preferably, L1 is a single bond, L2 is -(C1-10alkylene)- and L3 is ethynylene or a divalent moiety of piperidine (for instance ethynylene), preferably wherein L2 is -(C3-8alkylene)-, more preferably wherein L2 is -(C7alkylene)-. In this embodiment, U is preferably (i) of formula (U1) wherein preferably Q is selected from - CH2- and -C(O)-, RU6is H, one of RU2, RU3, RU4and RU5is a single bond to LINK, and the rest are H, for instance wherein RU2and RU3are H, one of RU4and RU5is a single bond to LINK, and the other of RU4and RU5is H, or (ii) of formula (U3) wherein preferably V is S, W is N, RU10is methyl, RU11is H, and RU8is t-butyl or phenyl, more preferably t-butyl. Most preferably, in formula (U1): Q is -CH2-; RU6is H; and RU2, RU3and RU4are H, and RU5is a single bond to LINK. Particularly preferred compounds of the invention may be selected from: 1-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; rac-1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}octyl)-3-methyl-N-[2- (1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl]indazole-6-carboxamide; 1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}octyl)-3-methyl-N-{2- [(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}octyl)-3-methyl-N-{2- [(2S)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 2-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)-3-methyl-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2H-indazole-6-carboxamide; 3-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindol-5-yl]piperazin-1- yl}methyl)piperidin-1-yl]-1-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2- c]pyridin-6-yl}indazole-5-carboxamide; 1-[1-(3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}propyl)piperidin-4-yl]-3- methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6- carboxamide; 1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]oxy}octyl)-3-methyl-N-{2-[(2R)- 1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-{8-[3-(2,4-dioxo-1,3-diazinan-1-yl)-2-methylphenoxy]octyl}-3-methyl-N-{2-[(2R)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-{6-[3-(2,4-dioxo-1,3-diazinan-1-yl)-2-methylphenoxy]hexyl}-3-methyl-N-{2-[(2R)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-{7-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-1,3-benzodiazol-4-yl]hept-6-yn-1-yl}-3- methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6- carboxamide; 1-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)octyl)-3-methyl-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)-3-methyl-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]amino}octyl)-3-methyl-N-{2- [(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]amino}octyl)-3-methyl-N-{2- [(2S)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]amino}octyl)-3-methyl-N-{2- [(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]amino}octyl)-3-methyl-N-{2- [(2S)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1-(8-((2-(2,6- dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)-3-methyl-1H-indazole-6- carboxamide; 1-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperazin-1-yl}butyl)-3-methyl- N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperazin-1-yl}butyl)-3-methyl- N-{2-[(2S)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)-3-methyl-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(6-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}hexyl)-3-methyl-N-{2- [(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-(5-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)pentyl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H- indazole-6-carboxamide; 1-(2-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)ethoxy)ethyl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)-1H-indazole-6-carboxamide; 1-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)ethyl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4yl)amino)ethoxy)ethyl)-3-methyl- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)propyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(3-(1-(4-((2,6-dioxopiperidin-3-yl)carbamoyl)-2-fluorophenyl)piperidin-4-yl)propyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(5-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)pentyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(7-(2-(2, 6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl) hept-6-yn-1-yl)-3-methyl-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(3-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)propyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-3-methyl-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(7-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)hept-6-yn-1-yl)-3-methyl-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(7-(3-((2,6-dioxopiperidin-3-yl)carbamoyl)-2-fluorophenyl)hept-6-yn-1-yl)-3-methyl-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(7-(3-((2,6-dioxopiperidin-3-yl)carbamoyl)-2-methylphenyl)hept-6-yn-1-yl)-3-methyl-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-5-carboxamide; 1-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)-N-(2-((S)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-5-carboxamide; 1-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2-c]pyridin-6-yl)-1H-indazole-5-carboxamide; 1-(9-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5- yl)non-8-yn-1-yl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)-1H-indazole-6-carboxamide; 1-((E)-9-chloro-9-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)non-8-en-1-yl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-((Z)-9-chloro-9-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)non-8-en-1-yl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-chloro-9-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)non-8-en-1-yl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(6-(((S)-2,6-dioxopiperidin-3-yl)carbamoyl)pyridin-3-yl)non-8-yn-1-yl)-3-methyl-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(6-(((S)-2,6-dioxopiperidin-3-yl)carbamoyl)pyridin-2-yl)non-8-yn-1-yl)-3-methyl-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(2-(((S)-2,6-dioxopiperidin-3-yl)carbamoyl)pyridin-4-yl)non-8-yn-1-yl)-3-methyl-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-N-(2-((R)-1- (methyl-d3)pyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(8-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oct-7-yn-1-yl)-3-methyl-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-3-methyl-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(5-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)pentyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-N-(2-((R)-1- ethylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-3-methyl-1H-indazole-6-carboxamide; 1-(5-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)pentyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(2-((6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)oxy)ethyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(9-(3-(((S)-2,6-dioxopiperidin-3-yl)carbamoyl)-2-fluorophenyl)non-8-yn-1-yl)-3-methyl-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(2-(2,6-dioxopiperidin-3-yl)-7-fluoro-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1-(9-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-1H-indazole-6- carboxamide; 1-(10-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl) dec-9-yn-1-yl)-3-methyl-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(2-(2, 6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl) non-8-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrol[3, 2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-N-(2-((R)-5- methyl-5-azaspiro[2.4]heptan-6-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-N-(3- methyl-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-5-fluoro-3-methyl-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 3-cyclopropyl-1-(9-(2-(2, 6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl) non-8-yn-1-yl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)non-8-yn-1-yl)-3-methyl-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(3-(2, 6-dioxopiperidin-3-yl)-2-fluorophenyl) non-8-yn-1-yl)-3-methyl-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(6-(2, 6-dioxopiperidin-3-yl) pyridin-2-yl) non-8-yn-1-yl)-3-methyl-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl)-1H-indazole-6-carboxamide; (R)-1-(9-(3-(2, 4-dioxotetrahydropyrimidin-1(2H)-yl)-2-fluorophenyl) non-8-yn-1-yl)-3- methyl-N-(2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl)-1H-indazole-6- carboxamide; (R)-1-(9-(6-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)pyridin-2-yl)non-8-yn-1-yl)-3-methyl-N- (2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; (R)-1-(9-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-5-fluoro-1-methyl-1H-indazol-6- yl)non-8-yn-1-yl)-3-methyl-N-(2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)- 1H-indazole-6-carboxamide; N-(3-cyano-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1-(9-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-1H-indazole-6- carboxamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1-(9-(2-(2,6- dioxopiperidin-3-yl)-7-fluoro-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-1H-indazole-6- carboxamide; 1-(1-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)piperidin-4-yl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidin-4- yl)methyl)piperidin-4-yl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4- yl)methyl)piperidin-4-yl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4- yl)methyl)piperidin-4-yl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)-3-methyl-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(6-(1-(6-(((S)-2,6-dioxopiperidin-3-yl)carbamoyl)pyridin-2-yl)piperidin-4-yl)hexyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(4-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl) pent-4-yn-1-yl) cyclohexyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c] pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(9-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1-(9-(2-((rel-S)- 2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-1H-indazole-6- carboxamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1-(9-(2-((rel-R)- 2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-1H-indazole-6- carboxamide; 1-(9-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-5-fluoro-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(9-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-5-fluoro-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl) methyl)-3-methyl- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c] pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(5-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)pentyl)-3-methyl-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)-3-methyl-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-((1-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-((1-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; and 1-(5-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)pentyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; and the pharmaceutically acceptable salts thereof. MLLT1 and / or MLLT3 inhibitors In a separate aspect of the present invention, compounds of formula (I’) are provided that are potent inhibitors of MLLT1 and / or MLLT3. Accordingly, the invention provides a compound which is a bicyclic compound of formula (I’) or a pharmaceutically acceptable salt thereof: wherein: one of Z1and Z3is -N(H)- and the other is N or -C(R4)-, Y1is N, Y2is N or -C(R6)-, and Y3is N or -C(R5)-; Hy is a 4- to 7-membered heterocyclic ring containing X and at least one N atom, wherein: ring Hy is linked to ring A via a C atom within ring Hy, said C atom also being linked to R2; a N atom within ring Hy is substituted by R1; X is a bond, -N(R11)-, O, S, -S(O)2-, -S(O)(NR11)-, or - C(R11)2-; and the rest of ring Hy is unsubstituted or substituted by one or two R3; L is –C(O)N(H)-, wherein the C atom of L is bonded to R8, and the N atom of L is bonded to ring B; R1is H, C1-4cycloalkyl, or C1-4alkyl which is itself unsubstituted or substituted with one C1-4alkoxy or one, two or three halo; R2is H or methyl; each R3is independently selected from C1-4alkyl, C1-4alkoxy, phenyl, a 5- to 6-membered heteroaryl ring and halo, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring; R4and R6are independently selected from H, halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R5is selected from H, halo, C1-4alkoxy, C3-5cycloalkyl and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; at least one of R4, R5and R6is not H; R8is an 8- to 10-membered heteroaryl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two R9; each R9is independently selected from halo and C1-4alkoxy; R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 6-membered heterocyclyl ring, and a phenyl ring, the group R10being unsubstituted or substituted by one or two substituents independently selected from C1-4alkyl, C1-4alkoxy, and halo; each R11is independently selected from H, C1-4alkyl, and C1-4cycloalkyl. Typically, in formula (I’), ring Hy is a 5- to 6- membered heterocyclyl ring containing X and at least one N atom, for instance one or two N atoms. X is typically a bond, -N(R11)-, O or -C(R11)2-. Preferably, X is a bond, -N(Me)-, O or -CH2-, most preferably X is a bond. In particular, when ring Hy is a 4- or 5-membered heterocyclyl ring, X is most preferably a bond. For example, ring Hy may be selected from a pyrrolidinyl, piperidinyl, morpholinyl or diazinanyl ring. Preferably, ring Hy is a 5-membered heterocyclyl ring containing X and at least one N atom, for instance one N atom. For example, ring Hy may be a pyrrolidinyl ring. Ring Hy is linked to ring A via a C atom within ring Hy, said C atom also being linked to R2. A N atom within ring Hy is substituted by R1. Typically, the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A. Typically, in formula (I’), R1is H, C1-4cycloalkyl, or C1-4alkyl which is itself unsubstituted or substituted with one C1-4alkoxy or one, two or three halo, preferably with one C1-4alkoxy, for example R1may be H or C1-2alkyl which is unsubstituted or substituted with one C1-2alkoxy or one, two or three halo, preferably with one C1-2alkoxy, or R1may be H or C1-2alkyl which is unsubstituted or substituted with one C1-2alkoxy. Preferably, R1is H, methyl, ethyl or methoxyethyl, more preferably methyl or ethyl. Most preferably, R1is methyl. In formula (I’), R2is H or methyl. Preferably, R2is H. Typically, in formula (I’), each R11is independently selected from H and methyl. When X is - N(R11)- or -S(O)(NR11)-, R11is preferably methyl. When X is -C(R11)2-, each R11is preferably H. Aside from groups R1and R2, ring Hy may further be unsubstituted or substituted by one or two R3. Typically, each R3is independently selected from C1-4alkyl, C1-4alkoxy and halo, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a C3-6cycloalkyl ring. More typically, each R3is independently selected from methyl, ethyl, t-butyl, methoxy and fluoro, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a cyclohexyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a cyclopropyl or cyclopentyl ring. Preferably, ring Hy is substituted by no R3groups. In another typical emobidment, each R3is independently selected from methyl, ethyl, t-butyl, methoxy and fluoro, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a cyclohexyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a cyclopropyl ring or a cyclopentyl ring. Preferably, ring Hy is substituted by two R3groups which are both C1-4alkyl, for instance both being methyl, or one R3group which is C1-4alkyl, for instance methyl, ethyl or t-butyl. Typically, therefore, in formula (I’), ring Hy is a 5- to 6- membered heterocyclyl ring containing X and at least one N atom, for example a pyrrolidinyl, piperidinyl, morpholinyl or diazinanyl ring; the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A; R1is H or C1-2alkyl which is unsubstituted or substituted with one C1-2 alkoxy or one, two or three halo, preferably with one C1-2alkoxy; R2is H or methyl; X is a bond, -N(R11)-, O or -C(R11)2-; R11is H or methyl; ring Hy is further unsubstituted or substituted by one or two R3; and each R3is independently selected from C1-4alkyl, C1-4alkoxy and halo, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a C3-6cycloalkyl ring. Preferably, in formula (I’), ring Hy is a pyrrolidinyl ring; the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A; R1is methyl or ethyl, more preferably methyl; R2is H; and ring Hy is substituted by no R3groups, i.e. ring Hy is not further substituted and carries substituent R1only. Alternatively, in formula (I), ring Hy is a pyrrolidinyl ring; the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A; R1is H, methyl, ethyl or methoxyethyl, more preferably methyl; R2is H; and ring Hy is further substituted by two R3groups which are both C1-4alkyl, for instance both being methyl, or one R3group which is C1-4alkyl, for instance methyl, ethyl or t-butyl. Typically, in formula (I’), no more than two of Y1, Y2and Y3are N. Preferably, no more than one of Y1, Y2and Y3are N. Most preferably, Y1is N, Y2is -C(R6)-, and Y3is -C(R5)-. Typically, Z1is -C(R4)-, Z3is -N(H)-, and Y1is N. Thus, the bicyclic structure formed by rings A and B has the structure: In one preferred embodiment, Z1is -C(R4)-, Z3is -N(H)-, Y1is N, Y2is -C(R6)-, and Y3is - C(R5)-, such that the bicyclic structure formed by rings A and B has the structure:

[0009] Typically, in formula (I’), one of R4, R5and R6is selected from halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo, and the rest are H, with the proviso that R5and R6arer not CN. Preferably, one of R4, R5and R6is selected from halo (e.g. fluoro or chloro), CN, methoxy, methyl and trifluoromethyl, and the rest are H, with the proviso that R5and R6are not CN. In one preferred embodiment, R5and R6are as defined herein and R4is selected from halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo. More preferably, R5and R6are as defined herein and R4is selected from halo, CN, C1-4alkyl and CF3. More preferably, R5and R6are as defined herein and R4is selected from halo, and CF3. Most preferably, R5and R6are as defined herein and R4is selected from F, Cl, and CF3. In one preferred embodiment, R5is selected from H, cyclopropyl, C1-4alkoxy, and C1-4alkyl, for example from H, C1-4 alkoxy, and C1-4 alkyl. More preferably, R5is selected from H, cyclopropyl, methoxy and methyl, for example H, methoxy and methyl. In one particularly preferred embodiment, R5is selected from cyclopropyl and C1-4alkyl, for example from C1-4alkyl. More preferably, R5is selected from cyclopropyl and methyl, for example methyl. In one preferred embodiment, R6is H. Typically, therefore, in formula (I’): - R4is selected from halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo, and R5and R6when present are H; or - R5is selected from cyclopropyl, C1-4alkoxy, and C1-4alkyl, typically from C1-4alkyl, and R4and R6when present are H. Preferably, in formula (I’): - R4is selected from F, Cl, and CF3, and R5and R6when present are H; - R5is selected from cyclopropyl and methyl, typically from methyl, and R4and R6when present are H. In formula (I’), L is -C(O)N(H)-, wherein the C atom of L is bonded to R8, and the N atom of L is bonded to ring B. Typically, in formula (I’), R8may be selected from indazolyl, thieno[2,3-c]pyrazolyl, imidazo[4,5-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, furo[2,3-c]pyridinyl, indolyl, benzoxazolyl, benzothiazolyl, [1,2,4]triazolo[4,3-a]pyridinyl, thieno[2,3-d]pyrimidinyl, 1,2,3-benzotriazolyl, imidazo[1,5-a]pyridinyl, imidazo[1,2-a]pyrazinyl, oxazolo[5,4-b]pyridinyl, quinolinyl, naphthyridinyl, isoquinolinyl, quinazolinyl, and quinoxalinyl. Preferably, R8is an 8- to 10- membered heteroaryl ring preferably containing one, two or three N atoms. More preferably, R8is an indazolyl group. In some preferred embodiments, R8is a group selected from the following structures. For the avoidance of doubt, the following structures may be unsubstituted or substituted by one, two or three substituents as defined herein. [see below]

[0010] In formula (I’), R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents. Typically, each substituent is independently selected from halo, C1-4alkoxy, R10, -(CH2)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo and C1-2alkoxy. More typically, each substituent is independently selected from fluoro, chloro, methoxy, R10, -(CH2)-R10, =O, -CN, and C1-2alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo (e.g. fluoro) and methoxy. Preferably, each substituent is independently selected from chloro, fluoro, R10and methyl. Most preferably, each substituent is independently selected from fluoro and methyl, for instance methyl. R10is as defined herein. Typically, in formula (I’), R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 5-membered heterocyclyl ring, and a phenyl ring. The cycloalkyl, heteroaryl and heterocyclyl rings are as defined herein. Preferably, R10is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, oxadiazolyl, oxetanyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, thiazinyl, thiazolyl and triazolyl, more preferably cyclopropyl and pyrazolyl. Typically, in formula (I’), R10is unsubstituted or substituted by one or two substituents independently selected from fluoro, methyl and methoxy. Preferably, R10is unsubstituted. Typically, therefore, in formula (I’), R8is an 8- to 10-membered heteroaryl ring; the group R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents, each independently selected from halo, C1-4alkoxy, R10, -(CH2)-R10, =O, -CN, and C1-4 alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo and C1-2alkoxy; wherein R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 5-membered heterocyclyl ring, and a phenyl ring; and R10is unsubstituted or substituted by one or two substituents independently selected from fluoro, methyl and methoxy. Preferably, in formula (I’), R8is an 8- to 10-membered heteroaryl ring containing one, two or three N atoms, for example an indazolyl group; the group R8is unsubstituted or substituted by one or two substituents, each independently selected from fluoro, R10and methyl; R10is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, oxadiazolyl, oxetanyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, thiazinyl, thiazolyl and triazolyl; and R10is unsubstituted. In a typical embodiment of formula (I’), the bicyclic structure formed by rings A and B has the structure:

[0011] and: ring Hy is a 5- to 6- membered heterocyclyl ring containing X and at least one N atom, for example a pyrrolidinyl, piperidinyl, morpholinyl or diazinanyl ring; wherein the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A; R1is H or C1-2 alkyl which is unsubstituted or substituted with one C1-2 alkoxy or one, two or three halo, preferably with one C1-2alkoxy; R2is H or methyl; X is a bond, -N(Me)-, O or -CH2-; ring Hy is further unsubstituted or substituted by one or two R3; wherein each R3is independently selected from C1-4alkyl, C1-4alkoxy and halo, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a C3-6cycloalkyl ring; R4is selected from CN, halo, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo, and R5and R6when present are H; the C atom of L is bonded to R8, and the N atom of L is bonded to ring B; R8is an 8- to 10-membered heteroaryl ring; wherein the group R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents, each independently selected from halo, C1-4alkoxy, R10, -(CH2)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two groups selected from halo and C1-2alkoxy; and R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 5-membered heterocyclyl ring, and a phenyl ring; wherein R10is unsubstituted or substituted by one or two substituents independently selected from fluoro, methyl and methoxy. In a preferred embodiment of formula (I’), the bicyclic structure formed by rings A and B has the structure:

[0012] and: ring Hy is a pyrrolidinyl ring; wherein the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A; R1is H, methyl, ethyl or methoxyethyl, more preferably methyl; R2is H; and ring Hy is substituted by no R3groups; R4is selected from CN, F, Cl, Me and CF3, and R5and R6when present are H; the C atom of L is bonded to R8, and the N atom of L is bonded to ring B; R8is an 8- to 10-membered heteroaryl ring containing one, two or three N atoms, for example an indazolyl group; the group R8is unsubstituted or substituted by one or two substituents, each independently selected from fluoro, R10and methyl; R10is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, oxadiazolyl, oxetanyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, thiazinyl, thiazolyl and triazolyl; and R10is unsubstituted. In a particular embodiment, the compound of the invention is a bicyclic compound of formula (II’) or a pharmaceutically acceptable salt thereof: wherein: Z1, Z3, Y1, Y2, Y3, R1, R2, R8, X and L are as defined in any one of the preceding claims; R3aand R3bare independently selected from H, C1-4alkyl, phenyl, a 5- to 6-membered heteroaryl ring and C1-4alkoxy, or R3aand R3bform, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring, R3cand R3dare independently selected from H, C1-4alkyl, halo, phenyl, a 5- to 6-membered heteroaryl ring and C1-4alkoxy, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring, or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, with the proviso that when X is -N(R11)-, O, S, -S(O)2- or -S(O)(NR11)-, then neither R3cnor R3dare halo; wherein at least two of R3a, R3b, R3cand R3dare H. Typically, in formula (II’): R3aand R3bare independently selected from H and methyl; R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, in particular from H, methyl, ethyl, fluoro, methoxy and t-butyl, or R3cand R3dform, together with the C atom to which they are attached, a C5-6cycloalkyl ring (in particular a cyclopentyl ring), with the proviso that when X is -N(R11)-, O, S, -S(O)2- or -S(O)(NR11)-, then neither R3cnor R3dare fluoro; or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring (in particular a cyclohexyl ring); wherein at least two of R3a, R3b, R3cand R3dare H. Preferably, in formula (II’), R3a, R3b, R3cand R3dare all H. In a typical embodiment of formula (II’), the bicyclic structure formed by rings A and B has the structure: and: R1is H or C1-2alkyl which is unsubstituted or substituted with one C1-2alkoxy or one, two or three halo, preferably with one C1-2alkoxy; R2is H or methyl; X is a bond, -N(Me)-, O or -CH2-; R3aand R3bare independently selected from H and methyl; R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, in particular from H, methyl, ethyl, fluoro, methoxy and t-butyl, or R3cand R3dform, together with the C atom to which they are attached, a C5-6cycloalkyl ring (in particular a cyclopentyl ring), with the proviso that when X is NR11or O, then neither R3cnor R3dare fluoro; or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring (in particular a cyclohexyl ring); wherein at least two of R3a, R3b, R3cand R3dare H; R4is selected from CN, halo, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo, and R5and R6when present are H; the C atom of L is bonded to R8, and the N atom of L is bonded to ring B; R8is an 8- to 10-membered heteroaryl ring; wherein the group R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents, each independently selected from halo, C1-4alkoxy, R10, -(CH2)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo and C1-2alkoxy; and R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 5-membered heterocyclyl ring, and a phenyl ring; wherein R10is unsubstituted or substituted by one or two substituents independently selected from fluoro, methyl and methoxy. In a preferred embodiment of formula (II’), the bicyclic structure formed by rings A and B has the structure: and: X is absent; R1is H, methyl, ethyl or methoxyethyl, more preferably methyl; R2is H; R3a, R3b, R3cand R3dare all H; R4is selected from CN, F, Cl, Me and CF3, and R5and R6when present are H; the C atom of L is bonded to R8, and the N atom of L is bonded to ring B; R8is an 8- to 10-membered heteroaryl ring containing one, two or three N atoms, for example an indazolyl group; the group R8is unsubstituted or substituted by one or two substituents, each independently selected from fluoro, R10and methyl; R10is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, oxadiazolyl, oxetanyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, thiazinyl, thiazolyl and triazolyl; and R10is unsubstituted. In a particularly preferred embodiment, the compound of the invention is a bicyclic compound of formula (III’) or a pharmaceutically acceptable salt thereof: wherein R1, R2, R3a, R3b, R3c, R3d, X, R4, R5, R6and R8are as defined herein. Typically, in the compounds of formula (III’): R1is H or C1-4alkyl which is itself unsubstituted or substituted with C1-4alkoxy; R2is H or methyl; R3aand R3bare independently selected from H, C1-4alkyl, and C1-4alkoxy, or R3aand R3bform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6 cycloalkyl ring, with the proviso that when X is O or -N(Me)-, then neither R3cnor R3dare halo; wherein at least two of R3a, R3b, R3cand R3dare H; X is a bond, -N(Me)-, O or -CH2-; R4is selected from CN, halo C1-4alkoxy, and C1-4alkyl, and R5and R6are H; R8is an 8- to 10-membered heteroaryl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two R9; each R9is independently selected from halo and C1-4alkoxy; and R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 6-membered heterocyclyl ring, and a phenyl ring, the group R10being unsubstituted or substituted by one or two substituents independently selected from C1-4alkyl, C1-4alkoxy, and halo. Typically, in formula (III’), R1is H, or C1-4alkyl which is itself unsubstituted or substituted with one C1-4alkoxy or one, two or three halo, preferably with one C1-4alkoxy, for example R1may be H or C1-2alkyl which is unsubstituted or substituted with one C1-2alkoxy or one, two or three halo, preferably with one C1-2alkoxy. Preferably, R1is H, methyl, ethyl or methoxyethyl. Most preferably, R1is methyl. In formula (III’), R2is H or methyl. Preferably, R2is H. Typically, in formula (III’), X is a bond, -N(R11)-, O or -C(R11)2-. Preferably, X is a bond, - N(Me)-, O or -CH2-, most preferably X is a bond. Typically, in formula (III’), each R11is independently selected from H and methyl. When X is - N(R11)- or -S(O)(NR11)-, R11is preferably methyl. When X is -C(R11)2-, each R11is preferably H. Typically, in formula (III’), R3aand R3bare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, in particular from H and methyl; R3cand R3dare independently selected from H, methyl, ethyl, fluoro, methoxy and t-butyl, or R3cand R3dform, together with the C atom to which they are attached, a C5-6cycloalkyl ring (in particular a cyclopentyl ring), with the proviso that when X is NR11, O, or S, then neither R3cnor R3dare fluoro; or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring (in particular a cyclohexyl ring); wherein at least two of R3a, R3b, R3cand R3dare H. Preferably, in formula (III’), R3a, R3b, R3cand R3dare all H. Typically, in formula (III’), R4is selected from halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo. Preferably, R4is selected from CN, F, Cl, Me and CF3. Typically, in formula (III’), R5is selected from H and C1-4alkyl. Preferably, R5is selected from H and methyl, more preferably H. Typically, in formula (III’), R6is H. Typically, therefore, in formula (III’): - R4is selected from halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo, and R5and R6are H; or - R5is selected from C1-4alkyl, and R4and R6when present are H. Preferably, in formula (III’): - R4is selected from selected from F, Cl, Me and CF3, and R5and R6are H; or - R5is selected from methyl, and R4and R6when present are H. In one preferred embodiment of formula (III’), R8is selected from indazolyl, thieno[2,3- c]pyrazolyl, imidazo[4,5-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, furo[2,3-c]pyridinyl, indolyl, benzoxazolyl, benzothiazolyl, [1,2,4]triazolo[4,3-a]pyridinyl, thieno[2,3-d]pyrimidinyl, 1,2,3- benzotriazolyl, imidazo[1,5-a]pyridinyl, imidazo[1,2-a]pyrazinyl, oxazolo[5,4-b]pyridinyl, quinolinyl, naphthyridinyl, isoquinolinyl, quinazolinyl, and quinoxalinyl. Preferably, R8is an 8- to 10-membered heteroaryl ring containing one, two or three N atoms. Most preferably, R8is an indazolyl group. Typically, in formula (III’), R8is a group selected from the following structures. For the avoidance of doubt, the following structures may be unsubstituted or substituted by one, two or three substituents as defined herein. [see below]

[0013] Preferably, R8is an indazolyl group. Typically, in formula (III’), R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents, independently selected from halo, C1-4alkoxy, R10, -(CH2)- R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo and C1-2alkoxy. More typically, each substituent is independently selected from fluoro, chloro, methoxy, R10, -(CH2)-R10, =O, -CN, and C1-2alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo (e.g. fluoro) and methoxy. Preferably, each substituent is independently selected from fluoro, R10and methyl. Most preferably, each substituent is independently selected from fluoro and methyl. R10is as defined herein. Typically, in formula (III’), R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 5-membered heterocyclyl ring, and a phenyl ring. The aryl, heteroaryl and heterocyclyl rings are as defined herein. Preferably, R10is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, oxadiazolyl, oxetanyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, thiazinyl, thiazolyl and triazolyl, more preferably pyrazolyl. Typically, in in formula (III’), R10is unsubstituted or substituted by one or two substituents independently selected from fluoro, methyl and methoxy. Preferably, R10is unsubstituted. In typical embodiments of formula (III’): R1is H or C1-2alkyl which is unsubstituted or substituted with one C1-2alkoxy or one, two or three halo, preferably with one C1-2alkoxy; R2is H or methyl; X is a bond, -N(Me)- O or -C(H)2-; R3aand R3bare independently selected from H and methyl; R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, in particular from H, methyl, ethyl, fluoro, methoxy and t-butyl, or R3cand R3dform, together with the C atom to which they are attached, a C5-6cycloalkyl ring (in particular a cyclopentyl ring), with the proviso that when X is NR11or O, then neither R3cnor R3dare fluoro; or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring (in particular a cyclohexyl ring); wherein at least two of R3a, R3b, R3cand R3dare H; one of the following options applies: R4is selected from halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo, and R5and R6are H; or R5is selected from C1-4alkyl, and R4and R6when present are H; the group R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents, each independently selected from halo, C1-4alkoxy, R10, -(CH2)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo and C1-2alkoxy; and R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 5-membered heterocyclyl ring, and a phenyl ring; wherein R10is unsubstituted or substituted by one or two substituents independently selected from fluoro, methyl and methoxy; and R8is a group selected from the following structures:

[0014] . In preferred embodiments of formula (III’), X is absent; R1is H, methyl, ethyl or methoxyethyl, more preferably methyl; R2is H; R3a, R3b, R3cand R3dare all H; R4is selected from F, Cl, Me and CF3; R8is an 8- to 10-membered heteroaryl ring containing one, two or three N atoms, for example an indazolyl group; the group R8is unsubstituted or substituted by one or two substituents, each independently selected from fluoro, R10and methyl; R10is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, oxadiazolyl, oxetanyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, thiazinyl, thiazolyl and triazolyl, preferably pyrazolyl; and R10is unsubstituted. In a most preferred embodiment, the compound of the invention is a bicyclic compound of formula (IV’) or a pharmaceutically acceptable salt thereof: wherein R8is an 8- to 10-membered heteroaryl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo and C1-4alkyl. Typically, in formula (IV’), R8may be selected from thiindazolyl, thieno[2,3-c]pyrazolyl, imidazo[4,5-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, furo[2,3-c]pyridinyl, indolyl, benzoxazolyl, benzothiazolyl, [1,2,4]triazolo[4,3-a]pyridinyl, thieno[2,3-d]pyrimidinyl, 1,2,3-benzotriazolyl, imidazo[1,5-a]pyridinyl, imidazo[1,2-a]pyrazinyl, oxazolo[5,4-b]pyridinyl, quinolinyl, naphthyridinyl, isoquinolinyl, quinazolinyl, and quinoxalinyl. More typically, in formula (IV’), R8is a group selected from the following structures. For the avoidance of doubt, the following structures may be unsubstituted or substituted by one, two or three substituents as defined herein. [see below]

[0015] Preferably, R8is an indazolyl group. Typically, in formula (IV’), R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents, independently selected from halo and C1-4alkyl. Preferably, each substituent is independently selected from fluoro and methyl. In a particularly preferred embodiment, in formula (IV’), R8is selected from one of the For the avoidance of doubt, R8may be selected from one of the two structures above in any of formulae (I’), (II’) and (III’). In one aspect, the following MLLT1 and / or MLLT3 inhibitors are provided: N-{3-chloro-2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}-1,3- dimethylindazole-6-carboxamide; N-{3-chloro-2-[(2S)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}-1,3- dimethylindazole-6-carboxamide; (R)-1,3-dimethyl-N-(2-(1-methylpyrrolidin-2-yl)-3-(trifluoromethyl)-1H-pyrrolo[3,2-c]pyridin- 6-yl)-1H-indazole-6-carboxamide; (S)-1,3-dimethyl-N-(2-(1-methylpyrrolidin-2-yl)-3-(trifluoromethyl)-1H-pyrrolo[3,2-c]pyridin- 6-yl)-1H-indazole-6-carboxamide; N-{3-fluoro-2-[(rel-2S)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}-1- methylindazole-5-carboxamide; N-{3-fluoro-2-[(rel-2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}-1- methylindazole-5-carboxamide; N-{3-fluoro-2-[(rel-2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}-1,3- dimethylindazole-6-carboxamide; N-{3-fluoro-2-[(rel-2S)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}-1,3- dimethylindazole-6-carboxamide; 1,3-dimethyl-N-{3-methyl-2-[(rel-2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6- yl}indazole-6-carboxamide; 1,3-dimethyl-N-{3-methyl-2-[(rel-2S)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6- yl}indazole-6-carboxamide; 1,3-dimethyl-N-{4-methyl-2-[(rel-2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6- yl}indazole-6-carboxamide; 1,3-dimethyl-N-{4-methyl-2-[(rel-2S)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6- yl}indazole-6-carboxamide; and (R)-N-(3-cyano-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1,3-dimethyl-1H- indazole-6-carboxamide; and the pharmaceutically acceptable salts thereof. Therapeutic Efficacy The compounds of the present invention are therapeutically useful. The present invention therefore provides compounds as described herein, for use in medicine. The present invention provides compounds as described herein, for use in treating the human or animal body. For the avoidance of doubt, the agent may comprise a compound of the invention in the form of a solvate. Also provided is a pharmaceutical composition comprising a compound of the invention together with a pharmaceutically acceptable carrier or diluent. Typically, the composition contains up to 85 wt% of a compound of the invention. More typically, it contains up to 50 wt% of a compound of the invention. Preferred pharmaceutical compositions are sterile and pyrogen free. Further, when the pharmaceutical compositions provided by the invention contain a compound of the invention which is optically active, the compound of the invention is typically a substantially pure optical isomer. The composition of the invention may be provided as a kit comprising instructions to enable the kit to be used in the methods described herein or details regarding which subjects the method may be used for. As explained above, the compounds of the invention are useful in treating or preventing various disorders. Disorders for treatment using the compounds of the invention may include cancer. In particular, the compounds of the invention are useful for inducing selective degradation of MLLT1 and / or MLLT3, or inhibiting MLLT1 and / or MLLT3. Cancer, e.g. acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, aids-related lymphoma, primary CNS lymphoma, anal cancer, astrocytomas, brain cancer, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer (e.g. ewing sarcoma, osteosarcoma and malignant fibrous histiocytoma), breast cancer, bronchial tumors, medulloblastoma and other CNS embryonal tumors, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative neoplasms, colorectal cancer, craniopharyngioma, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, ewing sarcoma, extragonadal germ cell tumor, intraocular melanoma, retinoblastoma, fallopian tube cancer, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumors (gist), germ cell tumors, extragonadal germ cell tumors, ovarian germ cell tumors, testicular cancer, gestational trophoblastic disease, hairy cell leukemia, hepatocellular cancer, histiocytosis, langerhans cell, hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumors, pancreatic neuroendocrine tumors, kaposi sarcoma, kidney (renal cell) cancer, langerhans cell histiocytosis, laryngeal cancer, leukemia, liver cancer, lung cancer (non-small cell, small cell, pleuropulmonary blastoma, and tracheobronchial tumor), lymphoma, malignant fibrous histiocytoma of bone and osteosarcoma, merkel cell carcinoma, mesothelioma, mouth cancer, multiple endocrine neoplasia syndromes, multiple myeloma / plasma cell neoplasms, mycosis fungoides, myelodysplastic syndromes, myelodysplastic / myeloproliferative neoplasms, myelogenous leukemia, neuroblastoma, non-hodgkin lymphoma, oropharyngeal cancer, osteosarcoma and undifferentiated pleomorphic sarcoma, pancreatic cancer, pancreatic neuroendocrine tumors (islet cell tumors), papillomatosis, paraganglioma, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pituitary tumor, prostate cancer, rectal cancer, retinoblastoma, rhabdomyosarcoma, t-cell lymphoma, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, tracheobronchial tumors and the like is particularly suitable to being treated with the compounds of the invention provided herein. Typically, the compounds of the invention are for use in treating cancers which are transcriptionally addicted cancers, such as breast cancer, acute leukemia, chronic leukemia, prostate cancer, bladder cancer, cholangiocarcinoma, colon adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, kidney chromophobe, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, pheochromocytoma and paraganglioma, rectum adenocarcinoma, stomach adenocarcinoma, uterine corpus endometrial carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, lung squamous cell carcinoma and sarcoma (Cell Rep, 2021, 16, 1087). Preferably, the compounds of the invention are for use in treating acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL), such as mixed-lineage leukaemia (MLL) rearranged acute leukemia (AML and ALL), NPM1 mutant acute leukemia, RUNX1-fusion acute leukemia, E2A-fusion acute leukemia, PML-fusion acute leukemia or NUP98-fusion acute leukemia. The compounds of the invention may be used as standalone therapeutic agents. Alternatively, they may be used in combination with other active agents such as chemotherapeutic agents, targeted precision medicines or immune oncology agents. For example, they may be used in combination with a menin inhibitor (for example revumenib, ziftomenib, bleximenib), Bcl2 targeted drug (for instance venetoclax), FLT3 inhibitor (for instance sorafenib, quizartinib or gilteritinib), IDH inhibitor (for instance enasideniob), EGFR inhibitor (for instance erlotinib, gefitinib, lapatinib or osimertinib), CDK4 / 6 inhibitor (for instance abemaciclib, palbociclib or ribociclib), a chemotherapy (for instance cytarabine, daunorubicin, azacitidine, cedazuridine, all trans retinoic acid, doxorubicin, gemcitabine, cisplatin or paclitaxel) or an immune checkpoint inhibitor (for instance pembrolizumab, nivolumab, durvalumab or cemiplimab). When used to treat a cancer, the compounds of the invention may be used in alleviating, ameliorating or preventing aggravation of the symptoms of the cancer. Typically, treating a cancer may comprise reducing progression of the cancer, e.g. increasing progression free survival (PFS) and / or increasing survival e.g. increasing overall survival (OS). Treating a cancer may comprise preventing or inhibiting growth of a tumour associated with the cancer. Treating a cancer may comprise preventing metastasis of the cancer. Preferably, treating a cancer may comprise reducing the size of a tumour associated with the cancer. As such, the treatment may cause tumour regression in the cancer. Treating a cancer may comprise reducing the number of tumours or lesions present in the patient. When the treatment reduces the size of a tumour associated with the cancer, the size of the tumour is typically reduced from base line by at least 10%. Base line is the size of the tumour at the date treatment with the compound is first started. The size of the tumour is typically as measured in accordance with version 1.1 of the RECIST criteria (for instance as described in Eisenhauer et al, European Journal of Cancer 45 (2009) 228-247). The response to the treatment with the compound may be complete response, partial response or stable disease, in accordance with version 1.1 of the RECIST criteria. Preferably, the response is partial response or complete response. The treatment may achieve progression free survival for at least 60 days, at least 120 days or at least 180 days. The reduction in tumour size may be greater 20%, greater than 30% or greater than 50% reduction relative to base line. The reduction in tumour size may be observed after 30 days of treatment or after 60 days of treatment. In haematological cancers, treating a cancer preferentially may lead to complete remission (CR) of the cancer or it may lead to complete remission with incomplete haematological recovery (CRh) or complete remission but with incomplete platelet recovery (CRp). Additionally, treatment may lead to an increase in duration of remission (DoR), an increase in minimal residual disease (MRD), or an increase in relapse free survival (RFS) (Blood 20071091815 and Leukemia Res 2018, 68, 32). As explained here, the compounds of the invention are useful in treating or preventing various disorders. The present invention therefore provides a compound of the invention for use in medicine. The invention also provides the use of a compound of the invention in the manufacture of a medicament. The invention also provides compositions and products comprising the compounds of the invention. Such compositions and products are also useful in treating or preventing disorders. The present invention therefore provides a composition or product as defined herein for use in medicine. The invention also provides the use of a composition or product of the invention in the manufacture of a medicament. Also provided is a method of treating a subject in need of such treatment, said method comprising administering to the subject a compound of the invention. In some embodiments the subject suffers from or is at risk of suffering from one of the disorders disclosed herein. In one aspect, the subject is a mammal, in particular a human. However, it may be non-human. Preferred non-human animals include, but are not limited to, primates, such as marmosets or monkeys, commercially farmed animals, such as horses, cows, sheep or pigs, and pets, such as dogs, cats, mice, rats, guinea pigs, ferrets, gerbils or hamsters. The subject can be any animal that is capable of being infected by a bacterium. A subject is typically a human patient. The patient may be male or female. The age of the patient is typically at least 18 years, for instance from 30 to 70 years or from 40 to 60 years. Alternatively, the patient may be a child, for instance the patient may be under 18 years of age, or under 12 years of age. In one embodiment, the patient is a child under ten years of age or an infant under two years of age. In one embodiment the invention provides a compound as defined herein for use in treating cancer in paediatric patients. A compound or composition of the invention can be administered to the subject in order to treat one or more symptoms of the disorder. In this embodiment, the subject is typically symptomatic. A therapeutically effective amount of the agent or formulation is administered to such a subject. A therapeutically effective amount is an amount effective to ameliorate one or more symptoms of the disorder. The compound or composition of the invention may be administered in a variety of dosage forms. Thus, it can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. The compound or composition of the invention may also be administered parenterally, whether subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. The compound or composition may also be administered as a suppository. Preferably, the compound, composition or combination may be administered orally. The compound or composition of the invention is typically formulated for administration with a pharmaceutically acceptable carrier or diluent. For example, solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and / or polyethylene glycols; binding agents; e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar coating, or film coating processes. Liquid dispersions for oral administration may be syrups, emulsions and suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and / or mannitol and / or sorbitol. Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspension or solutions for intramuscular injections or inhalation may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride. Solutions for inhalation, injection or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions. Pharmaceutical compositions suitable for delivery by needleless injection, for example, transdermally, may also be used. A therapeutically effective amount of the compound or composition of the invention is administered to a subject. The dose may be determined according to various parameters, especially according to the compound used; the age, weight and condition of the subject to be treated; the route of administration; and the required regimen. Again, a physician will be able to determine the required route of administration and dosage for any particular subject. A typical daily dose is from about 0.01 to 100 mg per kg, preferably from about 0.1 mg / kg to 50 mg / kg, e.g. from about 1 to 10 mg / kg of body weight, according to the activity of the specific compound, the age, weight and conditions of the subject to be treated, the type and severity of the disease and the frequency and route of administration. Preferably, daily dosage levels are from 5 mg to 2 g. When the compound or composition of the invention is administered to a subject in combination with another active agent, the dose of the other active agent can be determined as described above. The dose may be determined according to various parameters, especially according to the agent used; the age, weight and condition of the subject to be treated; the route of administration; and the required regimen. Again, a physician will be able to determine the required route of administration and dosage for any particular subject. A typical daily dose is from about 0.01 to 100 mg per kg, preferably from about 0.1 mg / kg to 50 mg / kg, e.g. from about 1 to 10 mg / kg of body weight, according to the activity of the specific agent, the age, weight and conditions of the subject to be treated, the type and severity of the disease and the frequency and route of administration. Preferably, daily dosage levels are from 5 mg to 2 g. Synthesis Compounds of the invention can be prepared by the synthetic methods described in the Examples that follow, or by analogy with such methods using appropriate starting materials and methodologies familiar to the skilled chemist. The following examples illustrate the invention. They do not however limit the invention in any way. In this regard, it is important to understand that the particular assay used in the Examples section is designed only to provide an indication of biological activity. There are many assays available to determine biological activity, and a negative result in any one particular assay is therefore not determinative. The invention is defined according to the claims. Examples In the examples which follow below, compounds may be produced in racemic form. Compounds in racemic form are indicated by use of the term rac- in advance of the IUPAC name. In some instances, as indicated, enantiomers and / or diastereomers are separated. In general, the enantiomers and / or diastereomers of the invention can be separated using chiral chromatography. The separated enantiomers and / or diastereomers may be identified in the order in which they elute, for example the first, second, third or fourth eluting isomer respectively, as obtained by separation using chiral chromatography. The isomers may alternatively or additionally be identified using IUPAC naming conventions. Thus, where enantiomers and / or diastereomers have been assigned an absolute stereochemistry, this is indicated as R or S stereochemistry, as appropriate, and by use of a wedge-shaped bond (e.g. the chemical formula. Where enantiomers have been separated but have undefined absolute stereochemistry the term “rel-R” or “rel-S” has been used. In these examples it is understood that the absolute configuration is unknown and the “rel-R” and “rel-S” labels are used merely to distinguish the two enantiomers from one another. The absolute stereochemistry of an enantiomer labelled as “rel-R” may be either R or S. In either case, the corresponding “rel-S” enantiomer has the opposite configuration to the “rel-R” enantiomer. In these examples the use of a rectangular bond (e.g. ) has been used to define the “rel” configuration. This labelling convention also applies where diastereomers have been separated and the absolute configuration of a first chiral centre is known but the absolute configuration of a second chiral centre is unknown. In these examples, the known absolute configuration of the first chiral centre is indicated as R or S stereochemistry, as appropriate, and by use of a wedge-shaped bond (e.g. in the chemical formula, while the unknown absolute configuration of the second chiral centre is indicated as “rel-R” or “rel-S”, and by use of a rectangular bond (e.g. ) in the chemical formula. Alternatively, where diastereomers have been separated and the absolute configuration of both chiral centres is unknown they may be assigned a relative stereochemistry, which denotes the stereochemistry of a first chiral centre with respect to a second chiral centre. Where a relative stereochemistry has been assigned, this is indicated by the term “rel” in the IUPAC name, and by use of a rectangular-shaped bond (e.g. ). Where diastereomers have been separated and the relative and absolute configuration is unknown, the compounds have been labelled by the order in which they elute, for example the first, second, third or fourth eluting isomer respectively, as obtained by separation using chiral chromatography. The moieties U of formulae (U1), (U4) when Q’ is CH and (U5) typically contain at least one chiral centre at the carbon atoms marked with an asterisk as depicted below: . Specifically in relation to the examples that follow, unless otherwise stated, it is understood that the moiety U is typically in the form of a 1:1 mixture of the R- and S-enantiomers at said carbon atom, indicated specifically in the examples that follow by the use of a simple line-shaped bond (e.g. In certain examples, the enantiomers or diastereomers have been separated such that the compounds are in enantiomerically or diastereomerically pure form. In these examples, when the stereochemistry at the chiral carbon atom in moiety U is known, the known absolute configuration is indicated as R or S stereochemistry, as appropriate, and by use of a wedge- shaped bond (e.g. ). When the stereochemistry at the chiral carbon atom in moiety U is unknown, the unknown absolute configuration is indicated as “rel-R” or “rel-S”, and by use of a rectangular bond (e.g. ). Temperatures are given in degrees Celsius (°C). The reactants used in the examples below may be obtained from commercial sources or they may be prepared from commercially available starting materials as described herein or by methods known in the art. All the compounds of the invention are synthesized according to the Examples described herein. The progress of the reactions described herein were followed as appropriate by e.g. LC, GC or TLC, and as the skilled person will readily realize, reaction times and temperatures may be adjusted accordingly. NMR spectroscopy: Solids / oils were solubilized in DMSO-d6or MeOH-d4, vortexed vigorously until the solution was clear and transferred to an NMR tube for data acquisition. Liquid-state NMR experiments were recorded using: - 600 MHz (14.1 Tesla) Bruker Avance III NMR spectrometer (600 MHz for1H, 151 MHz for13C) using a triple-resonance1H,15N,13C CP-TCI 5 mm cryoprobe (Bruker Biospin, Germany) - 500 MHz (11.75 Tesla) Bruker Avance I NMR spectrometer (500 MHz for1H, 125 MHz for13C) using a Dual Resonance BBI 5 mm probe (Bruker Biospin, Germany) - 400 MHz (9.4 Tesla) Bruker Avance NEO NMR spectrometer (400 MHz for1H, 100 MHz for13C) using a SEI 5 mm probe (Bruker Biospin, Germany) - 400 MHz (9.4 Tesla) Bruker Avance NEO NMR spectrometer using a PI HR- BBO400S1-BBF / H / D-5.0-Z SP probe (Bruker Biospin, Germany) - 300 MHz Bruker AVANCE III HD NMR spectrometer using a PA BBO 300S1 BBF- H-D-05 Z probe (Bruker Biospin, Germany) - 300 MHz Bruker Avance NEO NMR spectrometer using a PA BBO BBF-H-D-05 Z (Bruker Biospin, Germany) All the experiments used for the resonance assignment procedure and the elucidation of the products structure (1D1H, 2D1H-1H-COSY, 2D1H-1H-ROESY, 2D1H-13C-HSQC, 2D1H-13C- HMBC) were recorded at 300 K.1H chemical shifts are reported in δ ppm as s (singlet), d (doublet), t (triplet), q (quartet), dd (double doublet), m (multiplet) or br s (broad singlet). UPLC-MS chromatography: UPLC-MS chromatography analysis were recorded using the following apparatus using: - Waters UPLC: Acquity, UV: Acquity PDA, MS: Qda, ELSD - Waters UPLC: Acquity, UV: Acquity TUV, MS: Qda - Waters UPLC: Acquity, UV: Acquity PDA, MS: Qda The apparatus was tested using a CSH C18 Waters column (50 x 2.1 mm), 1.7 µm. It used a combination of the following eluents: H2O + 0.05% TFA (v / v) (solvent A) and MeCN + 0.035% TFA (v / v) (solvent B) and a positive electrospray ES+ as ionization mode. The UV detection was set at 220 and 254 nm. The methods used were the following: - Polar method (1.7 min run): gradient t=02% B, t=0.5 min 2% B, t=1.5 min 98% B, t=1.52 min 2% B, t=1.7 min 2% B - Polar method (3.5 min run): gradient t=02% B, t=1.0 min 2% B, t=2.4 min 98% B, t=3.00 min 98% B, t=3.03 min 2% B, t=3.5 min 2% B - Normal method (1.7 min run): gradient t=02% B, t=1.0 min 98% B, t=1.5 min 98% B, t=1.52 min 2% B, t=1.7 min 2% B - Normal method (3.5 min run): gradient t=02% B, t=2.4 min 98% B, t=3.0 min 98% B, t=3.03 min 2% B, t=3.5 min 2% B Where it is observed mass spectra analysis is reported as [M+H]+for the molecular ion; Someone skilled in the art will also appreciate that isotope patterns may be reported where evident, for example [M+H+2]+represents the higher mass isotopic peak of Br if it is present in the molecule; Additionally, some fragmentation ions may be included in the analysis, for example [M+H-tBu]+, [M+H-100]+, [M+H-Boc]+and [M-Cl+MeOH]+. Preparative HPLC Where Example purification has been performed by preparative HPLC (chiral or achiral) the conditions are included in the reaction Step where the purification was performed or one of the general Methods below was used: Method A: Gilson system used for preparative HPLC purification purposes. The system is equipped with a 333 pump A and a 334 pump B, Gilson Verity 1741 detector and GX-271 liquid handler fraction collector. The reverse phase purification was carried out by using a preparative column X-BRIDGE C18 (250 x 30 mm), 5 µM. Gradient elution was done using 10 mmol ammonium bicarbonate in water (as Phase A) and 100% Acetonitrile (as Phase B) with a gradient Program (B%): 10% B at 0 min hold until 3 min, 35% B at 10.0 min, 65% B at 35 min, 99% B at 35.1 min hold till 40.0 min, 10% B at 40.1 min hold until 45 min. Flow rate: 25 mL / min. Method B: Gilson system used for preparative HPLC purification purposes. The system is equipped with a 333 pump A and a 334 pump B, Gilson Verity 1741 detector and GX-271 liquid handler Fraction collector. The reverse phase purification is carried out by using preparative column YMC-ACTUS C18 (250*20mm) 5 µM. Gradient elution is done with 0.1% Formic acid in water (as Phase A) and 100% Acetonitrile (Phase B) with a gradient Program (B%): 5% B at 0 min hold till 5min,15%B at 200.0 min, 35% B at 35 min, 99% B at 35.1min hold till 40.0 min, 5% B at 40.1min hold till 45 min. Flow rate: 18 mL / min. Abbreviations: In addition to the definitions above, the following abbreviations are used in the Example experimental procedures below. If an abbreviation used herein is not defined, it has its generally accepted meaning: Ac Acetyl AcOH Acetic acid AIBN 2,2′-Azobis(2-methylpropionitrile) Boc tert-butyloxycarbonyl Boc2O Di-tertbutyl decarbonate BrettPhos 2-(Dicyclohexylphosphino)3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′- biphenyl BrettPhos Pd G3 [(2-Di-cyclohexylphosphino-3,6-dimethoxy-2′,4′,6′- triisopropyl-1,1′- biphenyl)-2-(2′-amino-1,1′ -biphenyl)]palladium(II) methanesulfonate methanesulfonate CBr4tetrabromomethane Cs2CO3Cesium carbonate CuI Copper (I) iodide DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene DCM Dichloromethane DHP 3,4-Dihydro-2H-pyran DIAD Diisopropyl azodicarboxylate DIPEA N,N-Diisopropylethylamine Dioxane 1,4-dioxane DMAP 4-Dimethylaminopyridine DMEDA N,N’-dimethylethylenediamine DMF Dimethylformamide DMSO Dimethylsulfoxide DMSO-d6Hexadeuterodimethylsulfoxide ee Enantiomeric excess Et Ethyl EtOAc Ethyl acetate Et3N Triethylamine EtOH Ethanol Et2O Diethylether EPhos Pd G4 Methanesulfonato{Dicyclohexyl[3-(1-methylethoxy)-2',4',6'-tris(1- methylethyl)[1,1'-biphenyl]-2-yl]phosphine}(2'-methylamino-1,1'- biphenyl-2-yl)palladium(II) FeCl3Iron(III) chloride GC Gas chromatography GPhos (3-(tert-Butoxy)-2′,6′-diisopropyl-6-methoxy-[1,1′-biphenyl]-2- yl)dicyclohexylphosphane Gphos Pd G6TES GPhos OAc precatalyst TES h hour H2O water HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate HCl Hydrochloric acid Het Heteroaromatic HPLC High performance liquid chromatography IPA Isopropyl amine K2CO3Potassium carbonate KI Potassium iodide LC Liquid chromatography LDA Lithium diisopropylamide LiBH4Lithium borohydride LiHMDS Lithium bis(trimethylsilyl)amide LiOH Lithium hydroxide min Minutes Me Methyl MeCN Acetonitrile MeOH Methanol MeTHF 2-Methyltetrahydrofuran MgSO4Magnesium sulfate MS Mass spectrometry MsCl Methanesulfonyl chloride MsOH Methanesulfonic acid MTBE Methyl tert-butyl ether MW Microwave N2Nitrogen NaH Sodium hydride NaOCN Sodium cyanate NaOH Sodium hydroxide Na2SO4Sodium sulfate NaBH3CN Sodium cyanoborohydride NBS N-bromosuccinimide NCS N-chlorosuccinimide NH4Cl Ammonium chloride NIS N-iodosuccinimide NMP N-methyl-2-pyrrolidone Pd / C palladium on carbon Pd(dppf)Cl2[1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) Pd(PPh3)2Cl2Bis(triphenylphosphine)palladium(II) dichloride PE Petroleum ether PPh3Triphenylphosphine PMB-Cl 4-methoxybenzyl chloride rt room temperature (18 to 22 °C) Selectfluor 1-(Chloromethyl)-4-fluoro-1,4-diazabicyclo[2.2.2]octane-1,4-diium ditetrafluoroborate SEM-Cl 2-(Trimethylsilyl)ethoxymethyl chloride TBS-Cl tert-Butyldimethylsilyl chloride tBuOK Potassium tert-butoxide TFA Trifluoroacetic acid TfOH Trifluoromethanesulfonic acid TLC Thin layer chromatography THF Tetrahydrofuran TsCl p-Toluenesulfonyl chloride TsOH p-Toluenesulfonic acid monohydrate UPLC Ultra Performance Liquid Chromatography Xantphos 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene Example 1 was synthesised following Scheme 1

[0016] Scheme 1 Step 1 Intermediate 3: tert-butyl-6-(1-(9-(2-(2,6-dioxo-1-((2- (trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3- methyl-1H-indazole-6-carboxamido)-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridine-1-carboxylate To a solution of 1-(9-(2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1- oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-1H-indazole-6-carboxamide (Intermediate 2, 0.8 g, 1 mmol) in 1,4-dioxane (20 mL) was added tert-butyl-(R)-6-bromo-2-(1-methylpyrrolidin-2- yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 1, 1.00 g, 2.63 mmol) followed by cesium carbonate (2.5 g, 7.7 mmol). The reaction mixture was purged with argon for 15 min, then Pd2(dba)3(0.15 g, 0.16 mmol) and Xantphos (0.3 g, 0.5 mmol) were added. The reaction mixture was further purged with argon for 10 min and then heated at 100°C for 2h. The reaction mixture was filtered through celite and washed with ethyl acetate (50 mL). The filtrate was concentrated in vacuo and the resultant crude material was purified by combi-flash column chromatography, by eluting with 100% ethyl acetate in heptane, to afford tert-butyl 6-(1-(9-(2- (2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn- 1-yl)-3-methyl-1H-indazole-6-carboxamido)-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridine-1-carboxylate (Intermediate 3, 1.00 g, 39%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm -0.05 (s, 9H), 0.76-0.84 (m, 2H), 1.25-1.45 (m, 7H), 1.59-1.66 (m, 2H), 1.70 (s, 9H), 1.73-1.80 (m, 2H), 1.82-1.92 (m, 3H), 2.04 (s, 3H), 2.31-2.34 (m, 1H), 2.36 (s, 3H), 2.42-2.47 (m, 3H), 2.72-2.81 (m, 2H), 2.98-3.17 (m, 3H), 3.46-3.55 (m, 1H), 3.88-3.96 (m, 1H), 4.21-4.26 (m, 1H), 4.35-4.47 (m, 3H), 4.99-5.10 (m, 2H), 5.24-5.28 (m, 1H), 6.76 (s, 1H), 7.47- 7.52 (m, 1H), 7.58-7.62 (m, 1H), 7.68-7.73 (m, 2H), 7.76-7.81 (m, 1H), 8.42 (s, 1H), 8.60 (s, 1H), 8.97 (s, 1H), 10.74 (s, 1H). Mass spec: m / z: 969.2 [M+H]+. Step 2 Example 1: 1-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide To a solution of tert-butyl-6-(1-(9-(2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin- 3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-1H-indazole-6-carboxamido)-2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 3, 5.00 g, 5.16 mmol) in acetonitrile (50 mL) was added methanesulfonic acid (3.35 mL, 51.59 mmol) and the reaction mixture was then heated at 50°C for 2h. After cooling to room temperature, N,N’- dimethylethylenediamine (2.78 mL, 25.79 mmol) followed by triethylamine (14.4 mL, 103.2 mmol) were added and the reaction was stirred at room temperature for 3h. The reaction mixture was quenched with water (20 mL), the resultant precipitate was collected by filtration and dried in vacuo to afford the crude compound. The crude material was purified by preparative HPLC (Method A) to afford 1-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide (Example 1, 2.00 g , 52%) as an off-white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.22-1.46 (m, 7H), 1.50-1.59 (m, 2H), 1.76-1.94 (m, 5H), 1.96-2.03 (m, 1H), 2.12-2.15 (m, 1H), 2.17 (s, 3H), 2.24-2.30 (m, 1H), 2.41-2.44 (m, 1H), 2.45 (s, 3H), 2.53-2.62 (m, 2H), 2.85- 2.95 (m, 1H), 3.13-3.17 (m, 1H), 3.34-3.36 (m, 1H), 4.24-4.33 (m, 1H), 4.37-4.47 (m, 3H), 5.10-5.15 (m, 1H), 6.40 (s, 1H), 7.45-7.52 (m, 1H), 7.58-7.60 (m, 1H), 7.67-7.80 (m, 3H), 8.25 (s, 1H), 8.43 (s, 1H), 8.52 (s, 1H), 10.52 (s, 1H), 11.00 (s, 1H), 11.38 (s, 1H). Mass spec: m / z: 739.3 [M+H]+. Intermediate 1 was synthesised following Scheme 2

[0017] Scheme 2 Step 1 Intermediate 4: 2-bromo-5-iodopyridin-4-amine To solution of 2-bromopyridin-4-amine (CAS No: 7598-35-8, 200 g, 1156.0 mmol) in acetonitrile (1 L) was added N-iodosuccinimide (297.23 g, 1294.7 mmol) and the reaction mixture was heated at 80°C for 16h. The reaction mixture was then cooled to room temperature and concentrated in vacuo. The obtained residue was diluted with aqueous saturated sodium thiosulphate solution (2 L) and extracted with ethyl acetate (3 × 2 L). The combined organic layers were dried over anhydrous Na2SO4and concentrated in vacuo to obtain the crude compound. The crude material was purified by combi-flash chromatography, by eluting with 5% ethyl acetate in heptane, to afford 2-bromo-5-iodo-pyridin-4-amine (Intermediate 4, 115 g, 33%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 6.48 (br s, 2H), 6.77 (s, 1H), 8.16 (s, 1H). Mass spec: m / z: 300.8 [M+H]+. Step 2 Intermediate 5: N-(2-bromo-5-iodopyridin-4-yl)-N-(methylsulfonyl)methanesulfonamide To a cooled (0°C) solution of 2-bromo-5-iodo-pyridin-4-amine (Intermediate 4, 100 g, 334.55 mmol) in dichloromethane (2.50 g, 29 mmol) was added triethylamine (234 mL, 1673 mmol) followed by methanesulfonyl chloride (106 mL, 1338.2 mmol) in dichloromethane (300 mL). After the addition was complete, the reaction mixture was stirred at room temperature for 3h. The reaction mixture was quenched with aqueous saturated NaHCO3solution (2 L) and extracted with dichloromethane (2 × 2 L). The combined organic layers were dried over anhydrous Na2SO4and concentrated in vacuo to afford N-(2-bromo-5-iodopyridin-4-yl)-N- (methylsulfonyl)methanesulfonamide (Intermediate 5, 150 g, 98%) as a yellow liquid, which was used for next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 3.65 (s, 6H), 8.10 (s, 1H), 8.92 (s, 1H). Mass spec: m / z: 456 [M+H]+. Step 3 Intermediate 6: N-(2-bromo-5-iodopyridin-4-yl)methanesulfonamide To a solution of N-(2-bromo-5-iodopyridin-4-yl)-N-(methylsulfonyl)methanesulfonamide (Intermediate 5, 150 g, 329.6 mmol) in tetrahydrofuran (2 L) and water (2 L) was added sodium hydroxide (79.9 g, 1978 mmol) and the reaction mixture was stirred at room temperature for 3h. The reaction mixture was poured into water (500 mL), extracted with ethyl acetate (3 × 1000 mL) and acidified with citric acid solution (1 L) to pH ~ 4. The resultant precipitate was collected by filtration, washed with water (100 mL) and dried in vacuo to afford N-(2-bromo-5-iodopyridin-4-yl) methanesulfonamide (Intermediate 6, 75 g, 60%) as a yellow solid, which was used for next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 3.28(s, 3H), 7.54 (s, 1H), 8.64 (s, 1H), 9.51 (s, 1H). Mass spec: m / z: 378.7 [M+H]+. Step 4 Intermediate 8: tert-butyl (R)-2-(6-bromo-1-(methylsulfonyl)-1H-pyrrolo[3,2-c]pyridin-2- yl)pyrrolidine-1-carboxylate To a solution of N-(2-bromo-5-iodopyridin-4-yl)methanesulfonamide (Intermediate 6, 50.0 g, 132.63 mmol) and tert-butyl (R)-2-ethynylpyrrolidine-1-carboxylate (Intermediate 7, 25.89 g, 132.63 mmol) in THF (500 mL) was added DIPEA (138 g, 1061.0 mmol). The reaction mixture was purged with argon gas for 15 min then PdCl2(PPh3)2(9.60 g, 13.263 mmol) and copper(I) iodide (2.55 g, 13.26 mmol) were added. The reaction mixture was further purged with argon gas for 10 min and then heated at 60°C for 3h. The reaction mixture was diluted with water (500 mL) and extracted with ethyl acetate (3 × 300 mL). The combined organic layers were dried over anhydrous Na2SO4and concentrated in vacuo to obtain crude compound. The crude material was purified by combi-flash chromatography, by eluting with 30% ethyl acetate in heptane, to afford tert-butyl (R)-2-(6-bromo-1-(methylsulfonyl)-1H-pyrrolo[3,2-c]pyridin-2- yl)pyrrolidine-1-carboxylate (Intermediate 8, 38.0 g, 62%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.40 (s, 9H), 1.85-1.91 (m, 4H), 3.18-3.21 (m, 1H), 3.37-3.41 (m, 1H), 3.62 (s, 3H), 5.23-5.31 (m, 1H), 6.72 (s, 1H), 7.97 (s, 1H), 8.69 (s, 1H). Mass spec: m / z: 445.9 [M+H]+. Step 5 Intermediate 9: (R)-6-bromo-1-(methylsulfonyl)-2-(pyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridine hydrochloride To a cooled (0°C) solution of tert-butyl-(R)-2-(6-bromo-1-(methylsulfonyl)-1H-pyrrolo[3,2- c]pyridin-2-yl)pyrrolidine-1-carboxylate (Intermediate 8, 200 g, 450.1 mmol) in 1,4-dioxane (1 L) was added 4M HCl in 1,4-dioxane (2 L) and the reaction mixture was stirred at room temperature for 6h. The reaction mixture was concentrated in vacuo to afford (R)-6-bromo-1- (methylsulfonyl)-2-(pyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine hydrochloride (Intermediate 9, 160 g) as a yellow solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.87-2.20 (m, 2H), 2.33-2.46 (m, 2H), 3.15-3.34 (m, 2H), 3.75 (s, 3H), 5.12-5.17 (m, 1H), 7.38 (s, 1H), 7.98 (s, 1H), 8.78 (s, 1H), 9.45 (s, 2H). Mass spec: m / z: 345.8 [M+H]+. Step 6 Intermediate 10: (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1-(methylsulfonyl)-1H-pyrrolo [3,2-c]pyridine To a cooled (0°C) solution of (R)-6-bromo-1-(methylsulfonyl)-2-(pyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridine hydrochloride (Intermediate 9, 90.0 g, 236.4 mmol) in methanol (900 mL) was added triethylamine (192 g, 1891 mmol) followed by formaldehyde (60.83 g, 709.2 mmol). The reaction mixture was stirred for 5 min and then sodium cyanoborohydride (34.96 g, 472.8 mmol) was added at 0°C. The reaction mixture was then heated at 60°C for 16h. The reaction mixture was diluted with water (500 mL) and extracted with dichloromethane (3 × 500 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated in vacuo to the obtain crude compound. The crude material was purified by combi-flash chromatography by eluting with 60% ethyl acetate in heptane, to afford (R)-6-bromo-2-(1- methylpyrrolidin-2-yl)-1-(methylsulfonyl)-1H-pyrrolo[3,2-c]pyridine (Intermediate 10, 60.0 g, 71%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.70-1.78 (m, 3H), 2.33 (s, 3H), 2.36-2.40 (m, 2H), 3.01-3.22 (m, 1H), 3.56 (s, 3H), 3.76-3.81 (m, 1H), 6.89 (s, 1H), 7.97 (s, 1H), 8.68 (s, 1H). Mass spec: m / z: 359.8 [M+H]+. Step 7 Intermediate 11: (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2-c]pyridine To a solution of (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1-(methylsulfonyl)-1H-pyrrolo[3,2- c]pyridine (Intermediate 10, 110 g, 307.1 mmol) in methanol (600 mL) was added tetrahydrofuran (600 mL) and the mixture cooled to 0°C. Cesium carbonate (200 g, 614.2 mmol) was added and the reaction mixture was stirred at room temperature for 4h. The reaction mixture was quenched with water (2 L) and extracted with ethyl acetate (2 × 1 L). The combined organic layers were dried over anhydrous Na2SO4and concentrated in vacuo to afford (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine (Intermediate 11, 60.0 g, 70%) as a yellow solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.75-1.91 (m, 3H), 2.14 (s, 3H), 2.21-2.29 (m, 1H), 3.10-3.15 (m, 1H), 3.33-3.36 (m, 2H), 6.45 (s, 1H), 7.43 (s, 1H), 8.48 (s, 1H), 11.57 (br s, 1H). Mass spec: m / z: 279.9 [M+H]+. Step 8: Intermediate 1: tert-butyl (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridine-1-carboxylate To a solution of (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2-c]pyridine (Intermediate 11, 60.0 g, 214.16 mmol) in dichloromethane (600 mL) was added triethylamine (65.3 g, 642.49 mmol) followed by di-tert-butyldicarbonate (94.42 g, 428.33 mmol) and 4- (dimethylamino)pyridine (5.28 g, 42.833 mmol) and the reaction mixture was stirred at room temperature for 3h. The reaction mixture was diluted with water (500 mL) and extracted with diethyl ether (3 × 500 mL). The combined organic layers were dried over anhydrous Na2SO4and concentrated in vacuo to obtain the crude compound. The crude material was purified by combi-flash chromatography, by eluting with 45% ethyl acetate in heptane, followed by SFC purification (Waters SFC Prep 150 Mgm equipped with 2489 PDA detector; Column: Chiralpak IC (30 x 250 mm, 5 µM); Solvent A) CO270 g / min; B) 0.1% Isopropyl amine in IPA and MeCN (50:50) 25 mL / min) to afford tert-butyl-(R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 1, 43 g, 53%) as an off white solid. Enantiomeric excess (ee) 98.4%.1H NMR (400 MHz, DMSO-d6) δ ppm 1.65 (s, 9H), 1.71-1.75 (m, 3H), 2.30-2.33 (m, 1H), 2.34 (s, 3H), 2.37-2.40 (m, 1H), 3.11-3.14 (m, 1H), 3.87-3.91 (m, 1H), 6.80 (s, 1H), 8.05 (s, 1H), 8.61 (s, 1H). Mass spec: m / z: 379.9 [M+H]+. Intermediate 1 can also be synthesized following Scheme 3

[0018] Scheme 3 Step 1 Intermediate 12: rac-tert-butyl 2-[2-(4-amino-6-bromopyridin-3-yl)ethynyl]pyrrolidine-1- carboxylate A solution of 2-bromo-5-iodopyridin-4-amine (Intermediate 4: 17 g, 54.2 mmol), rac-tert-butyl 2-ethynylpyrrolidine-1-carboxylate (CAS: 316141-37-4, 13.4 g, 65.04 mmol), Pd(PPh3)2Cl2(3.81 g, 5.42 mmol), CuI (1.03 g, 5.42 mmol) and Et3N (16.4 g, 162.6 mmol) in DMF (400 mL) was stirred for 2h at rt under nitrogen atmosphere. The reaction mixture was quenched with water and the resulting solution was extracted three times with EtOAc. The organic layers were combined, washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography on silica gel using petroleum ether / EtOAc (7 / 3) as eluent to afford rac-tert-butyl 2-[2-(4-amino-6-bromopyridin-3- yl)ethynyl]pyrrolidine-1-carboxylate (Intermediate 12: 18 g, 83%) as a yellow oil. Mass spec: m / z 366 [M+H]+. Step 2 Intermediate 13: rac-tert-butyl 2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}pyrrolidine-1- carboxylate To a solution of rac-tert-butyl 2-[2-(4-amino-6-bromopyridin-3-yl)ethynyl]pyrrolidine-1- carboxylate (Intermediate 12: 8 g, 20.8 mmol) in NMP (40 mL) was added a solution of tBuOK (65.53 mL, 65.53 mmol, 1M in THF). The reaction mixture was stirred for 4h at 80°C. The reaction mixture was quenched with water and the resulting solution was extracted three times with EtOAc. The organic layers were combined, washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography on silica gel using DCM / MeOH (95 / 5) as eluent to afford rac-tert-butyl 2- {6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}pyrrolidine-1-carboxylate (Intermediate 13: 6 g, 71%) as a yellow oil. Mass spec: m / z 366 [M+H]+. Step 3 Intermediate 14: rac-2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}pyrrolidine trifluoroacetate To a solution of rac-tert-butyl 2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}pyrrolidine-1- carboxylate (Intermediate 13: 16 g, 41.5 mmol) in DCM (300 mL) was added TFA (30 mL). The reaction mixture was stirred for 2h at rt. The solution was concentrated under reduced pressure to afford rac-2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}pyrrolidine trifluoroacetate (Intermediate 14: 10 g, 77%) as a yellow oil which was used in Step 5 without further purification. Mass spec: m / z 266 [M+H]+. Step 4 Intermediate 15: rac-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine To a solution of rac-6-bromo-2-(pyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine trifluoroacetate (Intermediate 14: 10 g, 35.8 mmol) in MeOH (300 mL) were added Et3N (10.9 g, 108 mmol) and paraformaldehyde (5.37 g, 179 mmol). The reaction mixture was stirred for 1h at rt. NaBH3CN (6.77 g, 107.4 mmol) was added and the reaction mixture was stirred overnight at 60°C. The reaction mixture was quenched with water and the resulting solution was extracted three times with EtOAc. The organic layers were combined, washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was chromatographed by reverse-phase flash chromatography (C18 aq) using MeCN / H2O (45 / 55) as eluent to afford rac-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine (Intermediate 15: 8 g, 69%) as a yellow oil. Mass spec: m / z 280 [M+H]+. Step 5 Intermediate 16: rac-tert-butyl 6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridine-1-carboxylate To a solution of rac-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine (Intermediate 15: 88 g, 25.8 mmol) in DCM (200 mL) were added Boc2O (8.44 g, 38.7 mmol), Et3N (7.82 g, 77.4 mmol) and DMAP (310 mg, 2.58 mmol). The reaction mixture was stirred overnight at rt and then quenched with water. The resulting solution was extracted three times with EtOAc and the organic layers were combined, washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography on silica gel using EtOAc / petroleum ether (3 / 2) as eluent to afford rac-tert-butyl 6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1- carboxylate (Intermediate 16: 8.1 g, 71%) as a yellow oil. Mass spec: m / z 380 [M+H]+. Step 6 Intermediate 17: (2R)-2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}-1-methylpyrrolidine and Intermediate 18: (2S)-2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}-1-methylpyrrolidine rac-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine (Intermediate 15, 9.00 g, 30.5 mmol) was separated by SFC (Column: CHIRALPAK IH 3*25 cm, 5 μm; Mobile Phase A: CO2, Mobile Phase B: MeOH (+1%-2M NH3in MeOH); Flow rate: 85 mL / min; Gradient: isocratic 20% B) to afford (2R)-2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}-1- methylpyrrolidine (Intermediate 17, 1st eluting peak, 3.5 g, 37%) as a white solid and (2S)-2- {6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}-1-methylpyrrolidine (Intermediate 18, 2nd eluting peak, 4.0 g, 40%) as a white solid. Intermediate 17: (2R)-2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}-1-methylpyrrolidine 1steluting peak from SFC purification. Retention time: 4.35 mins. Enantiomeric excess (ee) 99.8%.1H NMR (400 MHz, DMSO-d6) δ ppm 11.56 (s, 1H), 8.49 (s, 1H), 7.43 (s, 1H), 6.45 (s, 1H), 3.34 (t, J = 9.0 Hz, 1H), 3.13 (t, J = 7.8 Hz, 1H), 2.24 - 2.30 (m, 1H), 2.15 (s, 4H), 1.87 - 1.90 (m, 1H), 1.75 - 1.84 (m, 2H). Intermediate 18: (2S)-2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}-1-methylpyrrolidine 2nd eluting peak from SFC purification. Retention time: 4.87 mins. Enantiomeric excess (ee) 99.8%.1H NMR (400 MHz, DMSO-d6) δ ppm 11.56 (s, 1H), 8.49 (s, 1H), 7.43 (s, 1H), 6.45 (s, 1H), 3.35 (t, J = 11.4 Hz, 1H), 3.14 (t, J = 8.0 Hz, 1H), 2.26 (t, J = 8.6 Hz, 1H), 2.15 (s, 4H), 1.88 (d, J = 8.0 Hz, 1H), 1.80 (d, J = 8.0 Hz, 2H). Step 7 Intermediate 1: tert-butyl (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridine-1-carboxylate A 500 mL round-bottom flask was charged with (2R)-2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2- yl}-1-methylpyrrolidine (Intermediate 17, 500 mg, 1.68 mmol), DCM (10 mL), Et3N (541 mg, 5.35 mmol), DMAP (21.8 mg, 0.178 mmol), (Boc)2O (778 mg, 3.57 mmol) and the reaction was stirred overnight at room temperature. The reaction was quenched with water (200 mL). The resulting solution was extracted with ethyl acetate (3 x 200 mL) and the organic layers were combined, washed with brine (2 x 300 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was chromatographed on a silica gel column, eluting with EtOAc / Petroleum ether (35 / 65) to afford tert-butyl (R)-6-bromo-2-(1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 1, 600 mg, 92%) as an off-white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.65 (s, 9H), 1.71-1.75 (m, 3H), 2.30-2.33 (m, 1H), 2.34 (s, 3H), 2.37-2.40 (m, 1H), 3.11-3.14 (m, 1H), 3.87-3.91 (m, 1H), 6.80 (s, 1H), 8.05 (s, 1H), 8.61 (s, 1H). Mass spec: m / z: 379.9 [M+H]+. Mass spec: m / z: 380.0 [M+H]+. Step 8 Intermediate 19: tert-butyl (S)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridine-1-carboxylate Intermediate 19 was prepared in an analogous manner to Intermediate 1 using (2S)-2-{6- bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}-1-methylpyrrolidine (Intermediate 18) and exhibited the following data:1H NMR (400 MHz, DMSO-d6) δ ppm 1.65 (s, 9H), 1.71-1.75 (m, 3H), 2.30-2.33 (m, 1H), 2.34 (s, 3H), 2.37-2.40 (m, 1H), 3.11-3.14 (m, 1H), 3.87-3.91 (m, 1H), 6.80 (s, 1H), 8.05 (s, 1H), 8.61 (s, 1H). Mass spec: m / z: 379.9 [M+H]+. Mass spec: m / z: 380.0 [M+H]+. Intermediate 7: tert-butyl (R)-2-ethynylpyrrolidine-1-carboxylate To a cooled (-30°C) solution of tert-butyl-(R)-2-formylpyrrolidine-1-carboxylate (CAS No: 73365-02-3, 50.0 g, 250.94 mmol) in methanol (500 mL) was added potassium carbonate (51.94 g, 376.41 mmol). Dimethyl(1-diazo-2-oxopropyl)phosphonate (CAS No: 90965-06-3, 57.85 g, 301.13 mmol) was then added dropwise over 20 min and the reaction mixture was stirred at - 30°C for 3h. The reaction mixture was diluted with water (1000 mL) and extracted with diethyl ether (3 × 500 mL). The combined organic layers were dried over anhydrous Na2SO4and concentrated in vacuo to obtain the crude compound. The crude material was purified by combi- flash chromatography, by eluting with 10% ethyl acetate in heptane, to afford tert-butyl (R)-2- ethynylpyrrolidine-1-carboxylate (Intermediate 7, 35.0 g, 71%) as a yellow liquid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.40 (s, 9H), 1.81-1.89 (m, 3H), 1.99-2.12 (m, 1H), 3.08-3.25 (m, 2H), 3.26-3.35 (m, 1H), 4.32-4.38 (m, 1H). Intermediate 2 was synthesized following Scheme 4 Scheme 4 Step 1 Intermediate 20: non-8-yn-1-yl 4-methylbenzenesulfonate To a cooled (0°C) solution of non-8-yn-1-ol (CAS No: 10160-28-8, 25.0 g, 178.29 mmol) in dichloromethane (250 mL) was added trimethylamine (74.6 mL, 534.87 mmol) followed by 4- dimethylaminopyridine (2.30 g, 17.83 mmol), then p-toluene sulfonyl chloride (1.50 g, 7.9 mmol) and the reaction mixture was stirred at room temperature for 16h. The reaction mixture was then diluted with water (250 mL) and extracted with dichloromethane (3 × 250 mL). The combined organic layers were dried over anhydrous Na2SO4,and concentrated in vacuo. The crude material was purified by combi-flash chromatography, by eluting with 55% ethyl acetate in heptane, to afford non-8-yn-1-yl 4-methylbenzenesulfonate (Intermediate 20, 34 g, 65%) as a colorless oil.1H NMR (400 MHz, DMSO-d6) δ ppm 1.12-1.30 (m, 6H), 1.32-1.41 (m, 2H), 1.50-1.57 (m, 2H), 2.08-2.13 (m, 2H), 2.42 (s, 3H), 2.71 (s, 1H), 3.98-4.02 (m, 2H), 7.48 (d, J=7.88 Hz, 2H), 7.78 (d, J=8.29 Hz, 2H). Step 2 Intermediate 22: methyl 3-methyl-1-(non-8-yn-1-yl)-1H-indazole-6-carboxylate To a solution of non-8-yn-1-yl 4-methylbenzenesulfonate (Intermediate 20, 17.03 g, 57.83 mmol) in dimethylformamide (100 mL) was added cesium carbonate (51.4 g, 157.73 mmol) and methyl 3-methyl-1H-indazole-6-carboxylate (Intermediate 21, 10.0 g, 52.57 mmol) at room temperature. The reaction mixture was heated at 80°C for 2h then diluted with water (500 mL) and extracted with ethyl acetate (3 × 200 mL). The combined organic layers were washed with brine solution (2 × 200 mL), dried over Na2SO4,and concentrated in vacuo. The crude material was purified by combi-flash chromatography, by eluting with 30% ethyl acetate in heptane, to afford methyl 3-methyl-1-(non-8-yn-1-yl)-1H-indazole-6-carboxylate (Intermediate 22, 12 g, 67%) as an off-white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.18-1.32 (m, 6H), 1.34-1.43 (m, 2H), 1.76-1.83 (m, 2H), 2.09-2.13 (m, 2H), 2.51 (s, 3H), 2.70 (s, 1H), 3.90 (s, 3H), 4.40 (t, J=7.02 Hz, 2H), 7.65 (d, J=7.89 Hz, 1H), 7.81 (d, J=8.33 Hz, 1H), 8.23 (s, 1H). Mass spec: m / z 313.0 [M+H]+. Step 3 Intermediate 23: 3-methyl-1-(non-8-yn-1-yl)-1H-indazole-6-carboxylic acid To a solution of methyl 3-methyl-1-(non-8-yn-1-yl)-1H-indazole-6-carboxylate (Intermediate 22, 21 g, 50.3 mmol) in methanol (100 mL) and tetrahydrofuran (100 mL) and was added lithium hydroxide (4 g, 200 mmol) in water (50 mL) and the reaction mixture was stirred at room temperature for 16h. The reaction mixture was then concentrated in vacuo. The crude residue was taken up in water (30 mL) and acidified with 0.5 N HCl solution to pH~4. The resultant precipitate was collected by filtration and dried in vacuo to afford 3-methyl-1-(non-8- yn-1-yl)-1H-indazole-6-carboxylic acid (Intermediate 23, 19.0 g, 94%) as a white solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.26-1.38 (m, 8H), 1.75-1.78 (m, 2H), 2.08-2.11 (m, 2H), 2.52 (s, 3H), 2.70 (s, 1H), 4.33-4.37 (m, 2H), 7.63-7.72 (m, 2H), 8.13 (s, 1H). Mass spec m / z 299 [M+H]+. Step 4 Intermediate 24: 3-methyl-1-(non-8-yn-1-yl)-1H-indazole-6-carboxamide To a solution of 3-methyl-1-(non-8-yn-1-yl)-1H-indazole-6-carboxylic acid (Intermediate 23, 18.0 g, 60.32 mmol) in dimethylformamide (180 mL) was added HATU (35.47 g, 90.48 mmol) and DIPEA (31.6 mL, 181.0 mmol) at room temperature. After stirring for 10 min, ammonium chloride (16.2 g, 301.6 mmol) was added and the reaction mixture was stirred at room temperature for a further 16h. The reaction mixture was then poured into ice cold water (200 mL), the resultant precipitate was collected by filtration and dried in vacuo to afford 3-methyl- 1-(non-8-yn-1-yl)-1H-indazole-6-carboxamide (Intermediate 24, 17.0 g, 95%) as a white solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.19-1.33 (m, 6H), 1.35-1.44 (m, 2H), 1.75-1.87 (m, 2H), 2.09-2.13 (m, 2H), 2.51 (s, 3H), 2.71 (s, 1H), 4.31-4.35 (m, 2H), 7.42 (br s, 1H), 7.59 (d, J=8.29 Hz, 1H), 7.73 (d, J=8.29 Hz, 1H), 8.04 (br s, 1H), 8.12 (s, 1H). Mass spec m / z 296.0 [M-H]-. Step 5 Intermediate 2: 1-(9-(2-(2, 6-dioxo-1-((2-(trimethylsilyl) ethoxy) methyl) piperidin-3-yl)-1- oxoisoindolin-4-yl) non-8-yn-1-yl)-3-methyl-1H-indazole-6-carboxamide To solution of 3-methyl-1-(non-8-yn-1-yl)-1H-indazole-6-carboxamide (Intermediate 24, 10.0 g, 33.62 mmol) and 3-(4-iodo-1-oxoisoindolin-2-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione (Intermediate 25, 16.83 g, 33.62 mmol) in dimethylformamide (100 mL) was added triethylamine (170 mL, 1210 mmol). The reaction mixture was purged with argon gas for 15 min then PdCl2(PPh3)2(2.38 g, 3.36 mmol) and copper (I) iodide (0.65 g, 3.36 mmol) were added. The reaction mixture was purged with argon gas for another 10 min and then stirred at room temperature for 2h. The reaction mixture was concentrated in vacuo to obtain the crude compound which was purified by combi-flash chromatography, by eluting with 80% ethyl acetate in heptane, to afford 1-(9-(2-(2,6-dioxo-1- ((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3- methyl-1H-indazole-6-carboxamide (Intermediate 2, 16.0 g, 71%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm -0.04 (s, 9H), 0.79-0.86 (m, 2H), 1.24-1.41 (m, 6H), 1.49-1.56 (m, 2H), 1.78-1.85 (m, 2H), 2.01-2.09 (m, 1H), 2.42-2.45 (m, 3H), 2.50 (s, 3H), 2.73-2.76 (m, 2H), 3.01-3.11 (m, 1H), 3.48-3.55 (m, 2H), 4.23-4.27 (m, 1H), 4.30-4.37 (m, 2H), 4.43-4.47 (m, 1H), 5.00-5.08 (m, 2H), 7.41 (br s, 1H), 7.49-7.54 (m, 1H), 7.58-7.63 (m, 2H), 7.69-7.75 (m, 2H), 8.02 (br s, 1H), 8.12 (s, 1H). Mass spec m / z 670.1 [M+H]+. Intermediate 25 was synthesised following Scheme 5 Scheme 5 Step 1 Intermediate 26: 3-(4-iodo-1-oxoisoindolin-2-yl)piperidine-2,6-dione To a solution of 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione (CAS No 191732-72-6, 25.0 g, 96.41 mmol) in acetonitrile (300 mL) was added copper(I) iodide (28.10 g, 144.6 mmol). The reaction mixture was purged with argon gas for 20 min then tert-butyl nitrite (16.57 g, 144.6 mmol) was added and the reaction mixture was heated at 60°C for 12h. The reaction mixture was poured then into water (300 mL), a solid precipitate formed, which was filtered and dried under vacuum to afford 3-(4-iodo-1-oxoisoindolin-2-yl) piperidine-2, 6-dione (Intermediate 26, 45.2 g) as an off white solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.98-2.04 (m, 2H), 2.82-2.98 (m, 2H), 4.11-4.32 (m, 2H), 5.13 (m, 1H), 7.31-7.42 (m, 1H), 7.71-7.80 (m, 1H), 7.98-8.06 (m, 1H), 10.99 (br s, 1H). Mass spec: m / z [M+H]+371.0. Step 2 Intermediate 25: 3-(4-iodo-1-oxoisoindolin-2-yl)-1-((2-(trimethylsilyl) ethoxy)methyl) piperidine-2,6-dione To solution of 3-(4-iodo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Intermediate 24, 30.0 g, 81.06 mmol) in dimethylformamide (250 mL) was added DBU (44.07 g, 283.7 mmol) at 0°C, then 2-(trimethylsilyl)ethoxymethyl chloride (52 mL, 283.7 mmol) was added and the reaction mixture was stirred at room temperature for 16h under a nitrogen atmosphere. The reaction mixture was quenched with water (700 mL), diluted with ethyl acetate (500 mL) and filtered through a celite bed. The organic layer was separated, washed with water (500 mL), dried over anhydrous Na2SO4and concentrated in vacuo. The crude material was purified by combi-flash chromatography, eluting with 50% ethyl acetate in heptane to afford 3-(4-iodo-1-oxoisoindolin- 2-yl)-1-((2-(trimethylsilyl) ethoxy) methyl) piperidine-2,6-dione (Intermediate 25, 8.56 g, 21%) as an off-white solid.1H NMR (400 MHz, DMSO-d6) δ ppm -0.02 (s, 9H), 0.78-0.90 (m, 2H), 2.03-2.11 (m, 1H), 2.76-2.82 (m, 1H), 3.02-3.12 (m, 1H), 3.48-3.60 (m, 3H), 4.08-4.13 (m, 1H), 4.28-4.33 (m, 1H), 5.02-5.10 (m, 2H), 5.26-5.31 (m, 1H), 7.31-7.37 (m, 1H), 7.79 (d, J=7.46 Hz, 1H), 8.05 (d, J=7.46 Hz, 1H). Mass spec: m / z [M-H]- 498.8. Intermediate 21 was synthesized following Scheme 6 Scheme 6 Step 1 Intermediate 27: 6-bromo-3-methyl-1H-indazole To a solution of 1-(4-bromo-2-fluorophenyl)ethan-1-one (CAS No: 625446-22-2, 25.0 g, 115.19 mmol) in ethylene glycol (160.0 mL, 2850 mmol) was added hydrazine hydrate solution (9.18 mL, 287.97 mmol) at room temperature and the reaction mixture was heated at 165°C for 16h. The reaction mixture was quenched with water (250 mL) resulting in a precipitate which was filtered, washed with water (3 × 150 mL) and pentane (3 × 60 mL) and dried under vacuum to afford 6-bromo-3-methyl-1H-indazole (Intermediate 27, 22 g, 90%) as an off-white solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 2.47 (s, 3H), 7.19 (d, J=8.80 Hz, 1H), 7.62-7.68 (m, 2H), 12.73 (br s, 1H). Mass spec: m / z: 213.0 [M+H+2]+. Step 2 Intermediate 21: methyl 3-methyl-1H-indazole-6-carboxylate To a solution of 6-bromo-3-methyl-1H-indazole (Intermediate 27, 15.00 g, 71.07 mmol) in methanol (200 mL) was added triethylamine (29.9 mL, 213.2 mmol) followed by [1,1'- bis(diphenylphosphino)ferrocene] dichloropalladium(II) (5.25 g, 7.11 mmol) at room temperature and the reaction mixture was heated at 90°C for 16h under a CO atmosphere (100 psi). The reaction mixture was filtered through celite and concentrated in vacuo to obtain crude compound. The crude material was purified by combi-flash column chromatography by eluting with 25% EtOAc in heptane to afford methyl 3-methyl-1H-indazole-6-carboxylate (Intermediate 21, 10.5 g, 78%) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 2.52 (s, 3H), 3.88 (s, 3H), 7.64 (d, J=8.32 Hz, 1H), 7.81 (d, J=8.32 Hz, 1H), 8.08 (s, 1H), 13.00 (br s, 1H). Mass spec: m / z: 190.8 [M+H]+. Example 2 was synthesized following Scheme 7 Scheme 7 Step 1 Intermediate 28: methyl 1-{8-[(tert-butoxycarbonyl)amino]octyl}-3-methylindazole-6- carboxylate and Intermediate 29: methyl 2-(8-((tert-butoxycarbonyl)amino)octyl)-3- methyl-2H-indazole-6-carboxylate To a solution of methyl 3-methyl-1H-indazole-6-carboxylate (Intermediate 21, 12.0 g, 56.8 mmol) in DMF (150 mL) was added tert-butyl (8-bromooctyl)carbamate (21.0 g, 68.2 mmol) and Cs2CO3(55.5 g, 170 mmol). and the mixture was stirred at 60°C overnight. Water (200 mL) was added and the resulting solution was extracted with ethyl acetate (3 x 400 mL) and the organic layers were combined, washed with brine (1000 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was chromatographed on a silica gel column, eluting with ethyl acetate / petroleum ether (65 / 35), to afford methyl 1-(8- ((tert-butoxycarbonyl)amino)octyl)-3-methyl-1H-indazole-6-carboxylate (Intermediate 28, 20.0 g, 76%) as a yellow oil and methyl 2-(8-((tert-butoxycarbonyl)amino)octyl)-3-methyl-2H- indazole-6-carboxylate (Intermediate 29, 7.0 g, 27%) as a yellow oil. Intermediate 28 exhibited:1H NMR (400 MHz, DMSO-d6) δ ppm 8.20 (s, 1H), 7.78 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 6.72 (br, 1H), 4.37 (t, J = 6.8 Hz, 2H), 3.90 (s, 3H), 2.85 - 2.87 (m, 2H), 1.78 -1.79 (m, 2H), 1.30 - 1.35 (m, 13H), 1.17 - 1.22 (m, 9H). Mass spec: m / z: 418.0 [M+H]+. Intermediate 29 exhibited:1H NMR (400 MHz, DMSO-d6) δ ppm 8.21 (s, 1H), 7.78 (d, J = 8.8 Hz, 1H), 7.49 (d, J = 8.8 Hz, 1H), 6.74 (t, J = 5.2 Hz, 1H), 4.38 (t, J = 7.2 Hz, 2H), 3.87 (s, 3H), 2.87 - 2.88 (m, 2H), 2.65 (s, 3H), 1.86 (br, 2H), 1.32 - 1.36 (m, 10H), 1.22 - 1.28 (m, 9H). Mass spec: m / z: 418.0 [M+H]+. Step 2 Intermediate 30: 1-{8-[(tert-butoxycarbonyl)amino]octyl}-3-methylindazole-6-carboxylic acid To a solution of methyl 1-{8-[(tert-butoxycarbonyl)amino]octyl}-3-methylindazole-6- carboxylate (Intermediate 28: 500 mg, 1.08 mmol) in H2O (30 mL) / THF (30 mL) was added NaOH (3.00 g, 75.0 mmol). The reaction mixture was stirred at rt for 2h, followed by addition of water. The solution was adjusted to pH = 6 with a solution of HCl (12N in H2O). The mixture was extracted three times with EtOAc and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford 1-{8- [(tert-butoxycarbonyl)amino]octyl}-3-methylindazole-6-carboxylic acid (Intermediate 30: 451 mg, 91%) which was used in Step 3 without further purification. Mass spec: m / z: 404 [M+H]+. Step 3 Intermediate 31: tert-butyl N-[8-(6-carbamoyl-3-methylindazol-1-yl)octyl]carbamate To a solution of 1-{8-[(tert-butoxycarbonyl)amino]octyl}-3-methylindazole-6-carboxylic acid (Intermediate 30: 451 mg, 1.13 mmol) in DMF (15 mL) were added NH4Cl (265 mg, 5.00 mmol), DIPEA (961 mg, 7.43 mmol) and HATU (612 mg, 1.61mmol). The reaction mixture was stirred at rt overnight and quenched with water. The mixture was extracted three times with EtOAc and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford tert-butyl N-[8-(6-carbamoyl-3- methylindazol-1-yl)octyl]carbamate (Intermediate 31: 265 mg, 65%) as a yellow solid which was used in Step 4 without further purification. Mass spec: m / z: 403 [M+H]+. Step 4 Intermediate 32: rac-tert-butyl N-[8-(3-methyl-6-{[2-(1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl]carbamoyl}indazol-1-yl)octyl]carbamate To a solution of tert-butyl N-[8-(6-carbamoyl-3-methylindazol-1-yl)octyl]carbamate (Intermediate 31: 230 mg, 0.496 mmol) in 1,4-dioxane (8 mL) were added rac-2-{6-bromo- 1H-pyrrolo[3,2-c]pyridin-2-yl}-1-methylpyrrolidine (Intermediate 15: 160 mg, 0.513 mmol), Cs2CO3(558 mg, 1.71 mmol), GPhos Pd G6 TES (54.0 mg, 0.0570 mmol) and GPhos (30.7 mg, 0.0570 mmol). The reaction mixture was stirred at 100°C for 3h under nitrogen atmosphere and then quenched with water. The mixture was extracted three times with EtOAc, the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography on silica gel using DCM / MeOH (85 / 15) as eluent to afford rac-tert-butyl N-[8-(3-methyl-6-{[2-(1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl]carbamoyl}indazol-1-yl)octyl]carbamate (Intermediate 32: 230 mg, 77%) as a yellow solid. Mass spec: m / z: 602 [M+H]+. Step 5 Intermediate 33: rac-1-(8-aminooctyl)-3-methyl-N-[2-(1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl]indazole-6-carboxamide dihydrochloride To a solution of rac-tert-butyl N-[8-(3-methyl-6-{[2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl]carbamoyl}indazol-1-yl)octyl]carbamate (Intermediate 32: 160 mg, 0.256 mmol) in 1,4-dioxane (2 mL) was added a solution of HCl (1 mL, 12N in H2O). The reaction mixture was stirred at rt for 2h and concentrated under reduced pressure to afford rac-1-(8- aminooctyl)-3-methyl-N-[2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl]indazole- 6-carboxamide dihydrochloride (Intermediate 33: 130 mg, 96%) as a yellow solid. Mass spec: m / z: 502 [M+H]+. Step 6 Example 2: rac-1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}octyl)-3- methyl-N-[2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl]indazole-6- carboxamide To a solution of rac-1-(8-aminooctyl)-3-methyl-N-[2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl]indazole-6-carboxamide hydrochloride (Intermediate 33: 130 mg, 0.247 mmol) in DMF (5 mL) were added 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione (CAS: 835616-60-9, 71.6 mg, 0.260 mmol) and K2CO3(143 mg, 1.04 mmol). The reaction mixture was stirred at 90°C overnight and then quenched with water. The mixture was extracted three times with EtOAc, the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography on silica gel using DCM / MeOH (95 / 5) as eluent, followed by a second purification using preparative HPLC (column: Kinetex EVO C1821.2 x 250 mm, 5.0 um; Eluent: H2O (10 mmol / L NH4HCO3) / MeCN from 49 / 51 to 19 / 81; Flow rate: 25 mL / min) to afford rac-1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}octyl)-3-methyl-N- [2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl]indazole-6-carboxamide (Example 2: 9.6 mg, 5%) as a yellow solid. Mass spec: m / z: 758 [M+H]+;1H NMR (300 MHz, MeOH-d4) δ ppm 8.52 (s, 1H), 8.20 (d, J = 6.6 Hz, 2H), 7.81 - 7.84 (m, 1H), 7.70 - 7.74 (m, 1H), 7.44 - 7.49 (m, 1H), 6.93 - 6.98 (m, 2H), 6.51 (s, 1H), 4.40 - 4.44 (m, 1H), 3.20 - 3.64 (m, 5H), 2.70 - 2.85 (m, 3H), 2.58 (s, 3H), 2.35 - 2.38 (m, 1H), 2.29 (s, 3H), 1.89 - 2.09 (m, 6H), 1.55 - 1.57 (m, 2H), 1.28 - 1.32 (m, 9H). Example 3 was synthesised following Scheme 8

[0019] Scheme 8 Step 1 Intermediate 34: tert-butyl 6-(1-{8-[(tert-butoxycarbonyl)amino]octyl}-3-methylindazole- 6-amido)-2-[(2R)-1-methylpyrrolidin-2-yl]pyrrolo[3,2-c]pyridine-1-carboxylate To a solution of tert-butyl N-[8-(6-carbamoyl-3-methylindazol-1-yl)octyl]carbamate (Intermediate 31: 200 mg, 0.621 mmol) in 1,4-dioxane (6.00 ml) were added tert-butyl 6- bromo-2-[(2R)-1-methylpyrrolidin-2-yl]pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 1: 212 mg, 0.559 mmol), Cs2CO3(1.01 g, 3.11 mmol) followed by Gphos (31.9 mg, 0.106 mmol) and Gphos Pd G6 TES (43.3 mg, 0.154 mmol). The reaction mixture was stirred at 100℃ for 3h under nitrogen atmosphere and quenched with water. The mixture was extracted three times with EtOAc, the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography on silica gel using DCM / MeOH (95 / 5) as eluent to afford tert-butyl 6-(1- {8-[(tert-butoxycarbonyl)amino]octyl}-3-methylindazole-6-amido)-2-[(2R)-1-methylpyrrolidin- 2-yl]pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 34: 250 mg, 75%) as an off-white solid. Mass spec: m / z: 602 [M+H-Boc]+. Step 2 Intermediate 35: 1-(8-aminooctyl)-3-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H- pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide dihydrochloride To a solution of tert-butyl 6-(1-{8-[(tert-butoxycarbonyl)amino]octyl}-3-methylindazole-6- amido)-2-[(2R)-1-methylpyrrolidin-2-yl]pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 34: 250 mg, 0.299 mmol) in 1,4-dioxane (3 mL) was added a solution of HCl (1.5 mL, 12N in H2O). The reaction mixture was stirred at rt for 2h and concentrated under reduced pressure to afford 1-(8-aminooctyl)-3-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2- c]pyridin-6-yl}indazole-6-carboxamide dihydrochloride (Intermediate 35: 170 mg, 95%) as an off-white solid. Mass spec: m / z: 502 [M+H]+. Step 4 Example 3: 1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}octyl)-3- methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6- carboxamide To a solution of 1-(8-aminooctyl)-3-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H- pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide dihydrochloride (Intermediate 35: 150 mg, 0.299 mmol) in DMSO (1 mL) were added 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3- dione (CAS: 835616-60-9, 165 mg, 0.598 mmol) and DIPEA (231 mg, 1.79 mmol). The reaction mixture was stirred at 90°C overnight and concentrated under reduced pressure. The crude material was purified by preparative HPLC (Column: XBridge OBD, 30 x 150 mm, 5μm; Eluent: H2O (10 mmol / L NH4HCO3) / MeCN from 1 / 1 to 20 / 80; Flow rate: 60 mL / min) to afford 1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}octyl)-3-methyl-N-{2-[(2R)- 1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide (Example 3: 45.1 mg, 20%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 11.43 (s, 1H), 11.01 - 11.09 (m, 1H), 10.61 (s, 1H), 8.51 (s, 1H), 8.47 (s, 1H), 8.28 (s, 1H), 7.73 - 7.82 (m, 2H), 7.53 - 7.59 (m, 1H), 6.92 - 7.06 (m, 2H), 6.53 - 6.59 (m, 1H), 6.41 (s, 1H), 5.02 - 5.09 (m, 1H), 4.36 - 4.58 (m, 2H), 3.32 (s, 3H), 3.13-3.17 (m, 1H), 2.84 - 2.88 (m, 1H), 2.67 -2.72 (m, 4H), 2.24 - 2.28 (m, 1H), 2.14 -2.17 (m, 4H), 1.99 - 2.03 (m, 1H), 1.74 - 1.90 (m, 5H), 1.53 - 1.62 (m, 2H), 1.21 - 1.36 (m, 9H). Mass spec: m / z: 758 [M+H]+. Example 4: 1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}octyl)-3- methyl-N-{2-[(2S)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6- carboxamide Following an analogous procedure to Scheme 8, Step 3, using 1-(8-aminooctyl)-3-methyl-N- {2-[(2S)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide dihydrochloride (Intermediate 36: 50 mg, 0.119 mmol), after purification by reverse-phase flash chromatography (C18) using MeCN / H2O (80 / 20) as eluent, afforded 1-(8-{[2-(2,6- dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}octyl)-3-methyl-N-{2-[(2S)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide (Example 4: 26.4 mg, 35%) as a yellow solid. Mass spec: m / z: 758 [M+H]+;1H NMR (400 MHz, DMSO-d6) δ ppm 11.41 (s, 1H), 11.09 (s, 1H), 10.56 (s, 1H), 8.53 (s, 1H), 8.44 (s, 1H), 8.26 (s, 1H), 7.72 - 7.79 (m, 2H), 7.54 -7.58 (m, 1H), 6.99 - 7.05 (m, 2H), 6.43 - 6.53 (m, 2H), 5.02 - 5.06 (m, 1H), 4.38 - 4.41 (m, 2H), 3.17 (s, 3H), 2.84 - 2.87 (m, 1H), 2.51 -2.60 (m, 5H), 2.01 - 2.31 (m, 6H), 1.89 - 2.02 (m, 5H), 1.57 - 1.61 (m, 2H), 1.87 - 1.91 (m, 9H). Intermediate 36: 1-(8-aminooctyl)-3-methyl-N-{2-[(2S)-1-methylpyrrolidin-2-yl]-1H- pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide dihydrochloride Following an analogous procedure to Scheme 8, Step 2, using tert-butyl 6-(1-{8-[(tert- butoxycarbonyl)amino]octyl}-3-methylindazole-6-amido)-2-[(2S)-1-methylpyrrolidin-2- yl]pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 37, 120 mg, 0.141 mmol), afforded 1-(8- aminooctyl)-3-methyl-N-{2-[(2S)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6- yl}indazole-6-carboxamide dihydrochloride (Intermediate 36: 50 mg, 90%) as an off-white solid. Mass spec: m / z: 502 [M+H]+. Intermediate 37: tert-butyl 6-(1-{8-[(tert-butoxycarbonyl)amino]octyl}-3-methylindazole- 6-amido)-2-[( 2S)-1-methylpyrrolidin-2-yl]pyrrolo[3,2-c]pyridine-1-carboxylate Following an analogous procedure to Scheme 8, Step 1, using tert-butyl N-[8-(6-carbamoyl-3- methylindazol-1-yl)octyl]carbamate (Intermediate 31: 190 mg, 0.472 mmol) and tert-butyl 6- bromo-2-[(2S)-1-methylpyrrolidin-2-yl]pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 19: 162 mg, 0.424 mmol), afforded tert-butyl 6-(1-{8-[(tert-butoxycarbonyl)amino]octyl}-3- methylindazole-6-amido)-2-[(2S)-1-methylpyrrolidin-2-yl]pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 37: 120 mg, 25%) as an off-white solid. Mass spec: m / z: 602 [M+H-Boc]+. Example 5 was synthesised following Scheme 9 Scheme 9 Step 1 Intermediate 38: 2-(8-((tert-butoxycarbonyl)amino)octyl)-3-methyl-2H-indazole-6- carboxylic acid To a solution of methyl 2-(8-((tert-butoxycarbonyl)amino)octyl)-3-methyl-2H-indazole-6- carboxylate (Intermediate 29, 500 mg, 1.14 mmol, 95%) in MeOH (10 mL) was added NaOH (800 mg, 21.1 mmol) in H2O (10 mL) and the mixture was stirred at room temperature for 3h. The pH of the mixture was adjusted to 6 by the addition of HCl (1M). The resulting solution was extracted with ethyl acetate (3 x 50 mL) and the organic layers were combined, washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford 2-(8-((tert-butoxycarbonyl)amino)octyl)-3-methyl-2H-indazole-6- carboxylic acid (Intermediate 38, 480 mg, 99%) as a yellow solid, which was used in the next step without further purification. Mass spec: m / z 404.3 [M+H]+. Step 2 Intermediate 39: tert-butyl (8-(6-carbamoyl-3-methyl-2H-indazol-2-yl)octyl)carbamate To a solution of 2-(8-((tert-butoxycarbonyl)amino)octyl)-3-methyl-2H-indazole-6-carboxylic acid (Intermediate 38, 250 mg, 0.589 mmol) in DMF (5 mL) was added NH4Cl (126 mg, 2.36 mmol), HATU (336 mg, 0.883 mmol) and DIPEA (456 mg, 3.53 mmol) and the mixture was stirred at room temperature for 3h. Water (10 mL) was added and the resulting solution was extracted with ethyl acetate (3 x 20 mL). The organic layers were combined, washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was chromatographed on a silica gel column, eluting with methanol / dichloromethane (5 / 95), to afford tert-butyl (8-(6-carbamoyl-3-methyl-2H-indazol-2- yl)octyl)carbamate (Intermediate 39, 240 mg, 98%) as yellow oil. Mass spec: m / z 403.2 [M+H]+. Step 3 Intermediate 40: tert-butyl (R)-(8-(3-methyl-6-((2-(1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)carbamoyl)-2H-indazol-2-yl)octyl)carbamate To a solution of tert-butyl (8-(6-carbamoyl-3-methyl-2H-indazol-2-yl)octyl)carbamate (Intermediate 39, 200 mg, 0.482 mmol) in toluene (10 mL) was added tert-butyl 6-bromo-2- [(2R)-1-methylpyrrolidin-2-yl]pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 1, 183 mg, 0.482 mmol), Brettphos (155 mg, 0.289 mmol), Brettphos Pd G3(131 mg, 0.145 mmol) and Cs2CO3(314 mg, 0.964 mmol) and the mixture was stirred at 120°C for overnight under nitrogen. The reaction was then concentrated under reduced pressure and the resulting residue was chromatographed on a silica gel column, eluting with MeOH / DCM (4 / 96), to afford tert- butyl (R)-(8-(3-methyl-6-((2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)carbamoyl)-2H-indazol-2-yl)octyl)carbamate (Intermediate 40, 150 mg, 41%) as yellow oil. Mass spec: m / z: 702.4 [M+H]+. Step 4 Intermediate 41: (R)-2-(8-aminooctyl)-3-methyl-N-(2-(1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)-2H-indazole-6-carboxamide ditrifluoroacetate To a solution of tert-butyl (R)-(8-(3-methyl-6-((2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)carbamoyl)-2H-indazol-2-yl)octyl)carbamate (Intermediate 40, 150 mg, 0.197 mmol) in DCM (2 mL) was added TFA (1 mL) and the mixture was stirred at room temperature for 1h. The volatiles were removed under reduced pressure to afford (R)-2-(8-aminooctyl)-3- methyl-N-(2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2H-indazole-6- carboxamide ditrifluoroacetate (Intermediate 41, 100 mg, 97%) as yellow oil, which was used in the next step without further purification. Mass spec: m / z: 502.3 [M+H]+. Step 5 Example 5: 2-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2H-indazole-6- carboxamide To a solution of (R)-2-(8-aminooctyl)-3-methyl-N-(2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)-2H-indazole-6-carboxamide ditrifluoroacetate (Intermediate 41, 100 mg, 0.191 mmol) in DMSO (4 mL) was added 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione (CAS No: 835616-60-9, 79.3 mg, 0.286 mmol) and DIPEA (148 mg, 1.15 mmol) and the reaction mixture was stirred at 120°C for overnight. Water (5 mL) was added the resulting crude was purified by preparative HPLC (Column: WelFlash C18, Regular C1820-40 μm, 120g; Mobile Phase A: Water (with 10 mmol / L NH4HCO3+ 0.05% NH3.H2O), Mobile Phase B: MeCN; Flow rate: 60 mL / min; Gradient: 35% B to 65% B in 30 min) to afford 2-(8-((2-(2,6- dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)-3-methyl-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2H-indazole-6-carboxamide (Example 5, 15.2 mg, 10%) as a yellow solid.1H NMR (400 MH, DMSO-d6) δ ppm 11.37 (s, 1H), 11.10 (s, 1H), 10.43 (s, 1H), 8.51 (s, 1H), 8.29 (s, 1H), 8.20 (s, 1H), 7.75 (d, J = 8.8Hz, 1H), 7.58 (t, J = 8.0Hz, 2H), 7.09 (d, J = 8.8Hz, 1H), 7.02 (d, J = 6.8Hz, 1H), 6.52 (t, J = 5.2Hz, 1H), 6.40 (s, 1H), 5.03 - 5.07 (m, 1H), 4.39 (t, J = 7.2Hz, 2H), 3.24 - 3.32 (m, 2H), 3.15 (t, J = 7.6Hz, 1H), 2.87 - 2.93 (m, 1H), 2.83 - 2.84 (m, 3H), 2.57 - 2.65 (m, 1H), 2.26 - 2.34 (m, 1H), 2.12 - 2.17 (m, 4H), 1.99 - 2.11 (m, 2H), 1.78 - 1.97 (m, 6H), 1.51 - 1.59 (m, 2H), 1.29 - 1.39 (m, 8H). Mass spec: m / z: 758.5 [M+H]+. Example 6 were synthesized following Scheme 10 Scheme 10 Step 1 Intermediate 42: methyl 3-iodo-1-methylindazole-5-carboxylate To a solution of methyl 1-methylindazole-5-carboxylate (CAS: 1092351-82-0, 5.00 g, 25.5 mmol) in DMF (80 mL) was added NIS (13.2 g, 58.6 mmol). The reaction mixture was stirred at 120°C overnight and then quenched with water. The mixture was extracted three times with EtOAc, the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography on silica gel using petroleum ether / EtOAc (8 / 2) as eluent to afford methyl 3- iodo-1-methylindazole-5-carboxylate (Intermediate 42, 5 g, 25%) as a yellow solid. Mass spec: m / z: 317 [M+H]+. Step 2 Intermediate 43: methyl 3-(4-{[4-(tert-butoxycarbonyl)piperazin-1-yl]methyl}piperidin-1- yl)-1-methylindazole-5-carboxylate To a solution of methyl 3-iodo-1-methylindazole-5-carboxylate (Intermediate 42, 5.00g, 6.33 mmol) and tert-butyl 4-(piperidin-4-ylmethyl)piperazine-1-carboxylate (CAS: 1211568-27-2, 1.80 g, 6.33 mmol) in 1,4-dioxane (80 mL) were added Xantphos (0.730 g, 1.26 mmol), Cs2CO3 (6.18 g, 19.0 mmol) and Pd2dba3(0.580 g, 0.633 mmol). The reaction mixture was stirred at 100°C overnight under nitrogen atmosphere. The reaction mixture was quenched with water and extracted three times with EtOAc. The combined organic extracts were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The crude material was purified by flash chromatography on silica gel using petroleum ether / EtOAc (1 / 2) as eluent to afford methyl 3-(4-{[4-(tert-butoxycarbonyl)piperazin-1-yl]methyl}piperidin-1-yl)-1- methylindazole-5-carboxylate (Intermediate 43, 1.70 g, 44%) as a yellow solid. Mass spec: m / z: 472 [M+H]+. Step 3 Intermediate 44: 3-(4-{[4-(tert-butoxycarbonyl)piperazin-1-yl]methyl}piperidin-1-yl)-1- methylindazole-5-carboxylic acid To a solution of methyl 3-(4-{[4-(tert-butoxycarbonyl)piperazin-1-yl]methyl}piperidin-1-yl)-1- methylindazole-5-carboxylate (Intermediate 43, 1.70 g, 2.81 mmol) in THF (30 mL) / MeOH (10 mL) / H2O (8 mL) was added LiOH (0.67 g, 28.1 mmol). The reaction mixture was stirred at 50°C for 3h. The reaction mixture was acidified to pH = 5 with an aqueous solution HCl 4M, then concentrated under reduced pressure. The crude material was chromatographed by reverse- phase flash chromatography (C18) using MeCN / H2O (72 / 28) as eluent to afford 3-(4-{[4-(tert- butoxycarbonyl)piperazin-1-yl]methyl}piperidin-1-yl)-1-methylindazole-5-carboxylic acid (Intermediate 44, 1.10 g, 77%) as a yellow solid. Mass spec: m / z: 458 [M+H]+. Step 4 Intermediate 45: tert-butyl 4-{[1-(5-carbamoyl-1-methylindazol-3-yl)piperidin-4- yl]methyl}piperazine-1-carboxylate A solution of 3-(4-{[4-(tert-butoxycarbonyl)piperazin-1-yl]methyl}piperidin-1-yl)-1- methylindazole-5-carboxylic acid (Intermediate 44, 1.00 g, 1.97 mmol), DIPEA (1.27 g, 9.83 mmol) and HATU (0.820 g, 2.16 mmol) in DMF (15 mL) was stirred at rt for 1h. Then a solution of NH4Cl (0.320 g, 5.90 mmol) in H2O (1 mL) was added dropwise and the mixture was stirred for another 1h. The reaction mixture was quenched with water and concentrated under reduced pressure. The crude material was chromatographed by reverse-phase flash chromatography (C18) using MeCN / H2O (75 / 25) as eluent to afford tert-butyl 4-{[1-(5- carbamoyl-1-methylindazol-3-yl)piperidin-4-yl]methyl}piperazine-1-carboxylate (Intermediate 45, 900 mg, 98%) as a yellow solid. Mass spec: m / z: 457 [M+H]+. Step 5 Intermediate 46: tert-butyl 4-({1-[1-methyl-5-({2-[(2R)-1-methylpyrrolidin-2-yl]-1H- pyrrolo[3,2-c]pyridin-6-yl}carbamoyl)indazol-3-yl]piperidin-4-yl}methyl)piperazine-1- carboxylate To a solution of tert-butyl 4-{[1-(5-carbamoyl-1-methylindazol-3-yl)piperidin-4- yl]methyl}piperazine-1-carboxylate (Intermediate 45, 200 mg, 0.430 mmol) and tert-butyl 6- bromo-2-[(2R)-1-methylpyrrolidin-2-yl]pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 1, 212 mg, 0.558 mmol) in 1,4-dioxane (6 mL) were added Cs2CO3(420 mg, 1.29 mmol), Xantphos (99.3 mg, 0.172 mmol) and Pd2dba3(39.3 mg, 0.043 mmol). The reaction mixture was stirred at 100°C overnight under nitrogen atmosphere, then concentrated under reduced pressure. The residue was chromatographed by reverse-phase flash chromatography (C18) using MeCN / H2O (28 / 72) as eluent to afford tert-butyl 4-({1-[1-methyl-5-({2-[(2R)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}carbamoyl)indazol-3-yl]piperidin-4- yl}methyl)piperazine-1-carboxylate (Intermediate 46: 180 mg, 56%) as a yellow solid. Mass spec: m / z: 656 [M+H]+. Step 6 Intermediate 47: 1-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin- 6-yl}-3-[4-(piperazin-1-ylmethyl)piperidin-1-yl]indazole-5-carboxamide dihydrochloride To a stirred solution of tert-butyl 4-{[1-(5-{[1-(tert-butoxycarbonyl)-2-[(2R)-1- methylpyrrolidin-2-yl]pyrrolo[3,2-c]pyridin-6-yl]carbamoyl}-1-methylindazol-3-yl)piperidin-4- yl]methyl}piperazine-1-carboxylate (Intermediate 46, 180 mg, 0.207 mmol) in 1,4-dioxane (5 mL) was added a solution of HCl (2 mL, 12N in H2O). The reaction mixture was stirred at rt for 2h, then concentrated under reduced pressure to afford 1-methyl-N-{2-[(2R)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}-3-[4-(piperazin-1-ylmethyl)piperidin-1- yl]indazole-5-carboxamide dihydrochloride (120 mg, 95%) as a yellow solid. Mass spec: m / z: 556 [M+H]+. Step 7 Example 6: 3-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindol-5-yl]piperazin- 1-yl}methyl)piperidin-1-yl]-1-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2- c]pyridin-6-yl}indazole-5-carboxamide A solution of 1-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}-3- [4-(piperazin-1-ylmethyl)piperidin-1-yl]indazole-5-carboxamide dihydrochloride (Intermediate 47, 80.0 mg, 0.131 mmol) in DMSO (3 mL) were added 2-(2,6-dioxopiperidin-3-yl)-5,6- difluoroisoindole-1,3-dione (CAS: 1496997-41-1, 46.2 mg, 0.157 mmol) and DIPEA (169 mg, 1.31 mmol). The reaction mixture was stirred at 130°C for 2h, quenched with water and concentrated under reduced pressure. The residue was purified by preparative HPLC (Column: XBridge OBD, 30 x 150 mm, 5μm; Eluent: Water (10mmol / L NH4HCO3+ 0.05% NH3H2O) / MeCN from 72 / 28 to 42 / 58; Flow rate: 60 mL / min) to afford 3-[4-({4-[2-(2,6- dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindol-5-yl]piperazin-1-yl}methyl)piperidin-1-yl]-1- methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-5- carboxamide (Example 6, 20.5 mg, 18%) as a yellow solid. Mass spec: m / z: 830 [M+H]+;1H NMR (400 MHz, DMSO-d6) δ ppm 11.36 (s, 1H), 11.10 (s, 1H), 10.59 (s, 1H), 8.52 (d, J = 6.0 Hz, 2H), 8.20 (s, 1H), 8.02 (d, J = 9.6 Hz, 1H), 7.72 - 7.75 (m, 1H), 7.45 - 7.52 (m, 2H), 6.39 (s, 1H), 5.08 - 5.13 (m, 1H), 4.00 - 4.03 (m, 2H), 3.87 (s, 3H), 3.27 - 3.31 (m, 5H), 3.14 - 3.16 (m, 1H), 2.84 - 2.87 (m, 3H), 2.67 (s, 1H), 2.50 - 2.57 (m, 5H), 2.30 - 2.32 (m, 3H), 2.14 - 2.28 (m, 4H), 2.02 - 2.04 (m, 1H), 1.90 – 2.04 (m, 4H), 1.81 – 1.88 (m, 2H), 1.32 - 1.46 (m, 2H). Example 7 was synthesized following Scheme 11 Scheme 11 Step 1 Intermediate 48: methyl-1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-3-methyl-1H-indazole- 6-carboxylate To a cooled (0°C) solution of methyl 3-methyl-1H-indazole-6-carboxylate (Intermediate 21, 400 mg, 2.10 mmol), PPh3(1.10 g, 4.21 mmol) and tert-butyl 4-hydroxypiperidine-1- carboxylate (CAS No: 109384-19-2, 846 mg, 4.21 mmol) in tetrahydrofuran (10 mL) was added DIAD (850 mg, 4.21 mmol) dropwise and the resulting mixture was stirred overnight at 60°C. Water (300 mL) was then added and the mixture extracted with ethyl acetate (3 × 300 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude material was purified by combi-flash column chromatography, by eluting with 14% ethyl acetate in heptane, then further purified by reverse-phase C18 combi- flash column chromatography, by eluting with 78% acetonitrile in water, to afford methyl 1-(1- (tert-butoxycarbonyl)piperidin-4-yl)-3-methyl-1H-indazole-6-carboxylate (Intermediate 48, 290 mg, 35%) as a colorless oil. Mass spec: m / z: 374.0 [M+H]+. Step 2 Intermediate 49: methyl-3-methyl-1-(piperidin-4-yl)-1H-indazole-6-carboxylate hydrochloride A solution of methyl-1-[1-(tert-butoxycarbonyl)piperidin-4-yl]-3-methylindazole-6-carboxylate (Intermediate 48, 290 mg, 0.787 mmol) in HCl (4M in 1,4-dioxane) was stirred at room temperature for 2h. The resulting mixture was concentrated in vacuo to afford methyl 3-methyl- 1-(piperidin-4-yl)-1H-indazole-6-carboxylate hydrochloride (Intermediate 49, 200 mg) as a colorless oil, which was used in the next step without further purification. Mass spec: m / z: 274.0 [M+H]+. Step 3 Intermediate 50: methyl-1-(1-{3-[(tert-butoxycarbonyl)amino]propyl}piperidin-4-yl)-3- methylindazole-6-carboxylate To a solution of methyl-3-methyl-1-(piperidin-4-yl)indazole-6-carboxylate hydrochloride (Intermediate 49, 200 mg, 0.732 mmol) and tert-butyl N-(3-bromopropyl)carbamate (CAS No: 83948-53-2, 261 mg, 1.10 mmol) in dimethylformamide (6 mL) was added potassium carbonate (303 mg, 2.19 mmol) and potassium iodide (24.3 mg, 0.146 mmol) and the reaction mixture was stirred at 80 °C for 2h. Water (200 mL) was added and the aqueous phase extracted with ethyl acetate (3 × 200 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by combi-flash column chromatography, by eluting with 4% methanol in dichloromethane, to afford methyl-1-(1-{3-[(tert-butoxycarbonyl)amino]propyl}piperidin-4-yl)-3-methylindazole-6- carboxylate (Intermediate 50, 170 mg, 48%) as a colorless oil. Mass spec: m / z: 431.0 [M+H]+. Step 4 Intermediate 51: 1-(1-(3-((tert-butoxycarbonyl)amino)propyl)piperidin-4-yl)-3-methyl-1H- indazole-6-carboxylic acid To a solution of methyl-1-(1-{3-[(tert-butoxycarbonyl)amino]propyl}piperidin-4-yl)-3- methylindazole-6-carboxylate (Intermediate 50, 170 mg, 0.395 mmol) in THF (4 mL) and H2O (1 mL) was added LiOH (47.4 mg, 1.97 mmol) and the reaction mixture was stirred at 60°C for 2h. The pH of the solution was adjusted to pH 5 by the dropwise addition of dilute aqueous HCl (1M) and the resulting mixture was extracted with CH3Cl / i-PrOH (3:1, 3 × 200 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo to afford 1-(1-(3-((tert-butoxycarbonyl)amino)propyl)piperidin-4-yl)-3- methyl-1H-indazole-6-carboxylic acid (Intermediate 51, 150 mg, 88%) as a brown solid, which was used in the next step without further purification. Mass spec: m / z: 417.0 [M+H]+. Step 5 Intermediate 52: tert-butyl-(3-(4-(6-carbamoyl-3-methyl-1H-indazol-1-yl)piperidin-1- yl)propyl)carbamate To a solution of 1-(1-{3-[(tert-butoxycarbonyl)amino]propyl}piperidin-4-yl)-3-methylindazole- 6-carboxylic acid (Intermediate 51, 150 mg, 0.360 mmol) in DMF (4 mL) was added NH4Cl (57.8 mg, 1.08 mmol), HATU (205 mg, 0.540 mmol) and DIPEA (233 mg, 1.80 mmol) and the reaction mixture was stirred at room temperature for 2h. The reaction mixture was purified directly by reverse-phase C18 combi-flash column chromatography, by eluting with 70% acetonitrile in water, to afford tert-butyl-(3-(4-(6-carbamoyl-3-methyl-1H-indazol-1- yl)piperidin-1-yl)propyl)carbamate (Intermediate 52, 80 mg, 52%) as a brown oil. Mass spec: m / z: 416.0 [M+H]+. Step 6 Intermediate 53: tert-butyl-(R)-6-(1-(1-(3-((tert-butoxycarbonyl)amino)propyl)piperidin-4- yl)-3-methyl-1H-indazole-6-carboxamido)-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridine-1-carboxylate To a solution of tert-butyl-N-{3-[4-(6-carbamoyl-3-methylindazol-1-yl)piperidin-1- yl]propyl}carbamate (Intermediate 52, 80 mg, 0.193 mmol) and tert-butyl-6-bromo-2-[(2R)-1- methylpyrrolidin-2-yl]pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 1, 73.2 mg, 0.193 mmol) in 1,4-dioxane (3 mL) was added BrettPhos Pd G3 (52.4 mg, 0.058 mmol), BrettPhos (62.0 mg, 0.116 mmol) and Cs2CO3(125 mg, 0.386 mmol) and the reaction mixture was stirred at 100°C for 4h. The reaction mixture was concentrated in vacuo and the resulting residue was purified by preparative TLC, by eluting with 10% methanol in dichloromethane, to afford tert- butyl-(R)-6-(1-(1-(3-((tert-butoxycarbonyl)amino)propyl)piperidin-4-yl)-3-methyl-1H-indazole- 6-carboxamido)-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 53, 80 mg, 57%) as a yellow oil. Mass spec: m / z: 715.0 [M+H]+. Step 7 Intermediate 54: 1-[1-(3-aminopropyl)piperidin-4-yl]-3-methyl-N-{2-[(2R)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide ditrifluoroacetate To a solution of tert-butyl 6-[1-(1-{3-[(tert-butoxycarbonyl)amino]propyl}piperidin-4-yl)-3- methylindazole-6-amido]-2-[(2R)-1-methylpyrrolidin-2-yl]pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 53, 75 mg, 0.105 mmol) in dichloromethane (5 mL) was added TFA (1 mL) and the reaction mixture was stirred at room temperature for 2h. The resulting mixture was concentrated in vacuo to afford 1-[1-(3-aminopropyl)piperidin-4-yl]-3-methyl-N-{2-[(2R)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide ditrifluoroacetate (Intermediate 54, 55 mg, 67%) as a brown oil, which was used in the next step without further purification. Mass spec: m / z: 515.0 [M+H]+. Step 8 Example 7: 1-[1-(3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4- yl]amino}propyl)piperidin-4-yl]-3-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H- pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide To a solution of 1-[1-(3-aminopropyl)piperidin-4-yl]-3-methyl-N-{2-[(2R)-1-methylpyrrolidin- 2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide ditrifluoroacetate (Intermediate 54, 55 mg, 0.107 mmol) and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione (CAS No: 835616-60-9, 44.3 mg, 0.161 mmol) in DMSO (3 mL) was added DIPEA (82.9 mg, 0.642 mmol) and the reaction mixture was stirred at 120°C for 2h. The reaction mixture was then purified directly by preparative HPLC (Column: XBridge Prep OBD C18 Column, 30*150 mm, 5μm; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: MeCN; Flow rate: 60 mL / min; Gradient: 35% B to 65 % B in 10 min), to afford 1-[1-(3-{[2-(2,6-dioxopiperidin-3- yl)-1,3-dioxoisoindol-4-yl]amino}propyl)piperidin-4-yl]-3-methyl-N-{2-[(2R)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide (Example 7, 11.7 mg, 14%) as a yellow solid.1H NMR (400 MHz, MeOH-d4) δ ppm 8.54 (s, 1H), 8.24 - 8.28 (m, 2H), 7.84 (d, J = 8.4 Hz, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.59 (t, J = 8.4 Hz, 1H), 7.14 (d, J = 8.8 Hz, 1H), 7.06 (d, J = 7.2 Hz, 1H), 6.54 (s, 1H), 5.05 - 5.09 (m, 1H), 4.60 - 4.79 (m, 4H), 3.47 - 3.49 (m, 3H), 3.17 - 3.25 (m, 3H), 2.85 - 2.87 (m, 1H), 2.76 - 2.77 (m, 2H), 2.74 - 2.75 (m, 1H), 2.68 - 2.72 (m, 5H), 2.32 - 2.60 (m, 9H), 2.05 - 2.21 (m, 5H), 1.89 - 1.99 (m, 3H). Mass spec: m / z: 771.5 [M+H]+. Example 8 was synthesized following Scheme 12

[0020] Scheme 12 Step 1 Intermediate 55: 2-[(8-bromooctyl)oxy]oxane To a solution of 8-bromooctan-1-ol (CAS No: 50816-19-8, 4.00 g, 19.1 mmol) and DHP (4.83 g, 57.3 mmol) in DCM (30.0 mL) was added TsOH (99.6 mg, 1.92 mmol) at 0oC. The reaction was stirred at room temperature overnight and quenched with water (300 ml). The resulting solution was extracted with EtOAc (3 x 100 mL) and the organic layers were combined, washed with brine (3 x 50 mL),dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford 2-[(8-bromooctyl)oxy]oxane (Intermediate 55, 4.70 g, 80%) as a yellow oil.1H NMR (400 MHz, DMSO-d6) δ ppm 4.53 - 4.54 (m, 1H), 3.70 - 3.76 (m, 1H), 3.58 - 3.63 (m, 1H), 3.51 - 3.54 (m, 2H), 3.40 - 3.44 (m, 1H), 3.24 - 3.30 (m, 1H), 1.76 - 1.81 (m, 2H), 1.70 - 1.73 (m, 1H), 1.57 - 1.68 (m, 3H), 1.32 - 1.47 (m, 7H), 1.29 (br, 5H). Step 2 Intermediate 56: methyl 3-methyl-1-[8-(oxan-2-yloxy)octyl]indazole-6-carboxylate To a solution of methyl 3-methyl-1H-indazole-6-carboxylate (Intermediate 21, 1.00 g, 5.26 mmol) in DCM (10.0 mL) was added 2-[(8-bromooctyl)oxy]oxane (Intermediate 55, 4.63 g, 15.8 mmol) and Cs2CO3(3.43 g, 10.5 mmol) and the reaction stirred at 60℃ overnight. Water (200 mL) was added and the resulting solution was extracted with EtOAc (3 x 300 mL) and the organic layers were combined, washed with brine (3 x 300 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was chromatographed on a silica gel column, eluting with EtOAc / petroleum ether (11 / 89) to afford methyl 3-methyl-1-[8- (oxan-2-yloxy)octyl]indazole-6-carboxylate (Intermediate 56, 1.80 g, 54.4%) as an oil. Mass spec: m / z: 403.0 [M+H]+. Step 3 Intermediate 57: 3-methyl-1-[8-(oxan-2-yloxy)octyl]indazole-6-carboxylic acid To a solution of methyl 3-methyl-1-[8-(oxan-2-yloxy)octyl]indazole-6-carboxylate (Intermediate 56, 800 mg, 1.99 mmol) in THF (10.0 mL) was added 2M NaOH solution (5 mL, 10 mmol) and the reaction was stirred at room temperature for 2h. The pH was adjusted to 6 by the addition of aqueous HCl (12M). The resulting mixture was extracted with EtOAc (3 x 100 mL) and the organic layers were combined, washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford 3-methyl- 1-[8-(oxan-2-yloxy)octyl]indazole-6-carboxylic acid (Intermediate 57, 400 mg, 81.2%) as a yellow oil, which was used in the next step without further purification. Mass spec: m / z: 389.0 [M+H]+. Step 4 Intermediate 58: 3-methyl-1-[8-(oxan-2-yloxy)octyl]indazole-6-carboxamide To a solution of 3-methyl-1-[8-(oxan-2-yloxy)octyl]indazole-6-carboxylic acid (Intermediate 57, 400 mg, 1.03 mmol) in DMF (10.0mL) was added DIPEA (798 mg, 6.18 mmol), HATU (391 mg, 1.03 mmol) and NH4Cl (220 mg, 4.12 mmol) and the reaction was stirred overnight at room temperature. Water (10 mL) was added and the mixture was extracted with EtOAc (3 x 100 mL) and the organic layers were combined, washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was chromatographed on a silica gel column, eluting with ethyl acetate / petroleum ether (60 / 40), to afford 3-methyl-1-[8-(oxan-2-yloxy)octyl]indazole-6-carboxamide (Intermediate 58, 340 mg, 85%) as a white solid. m / z: 388.0 [M+H]+. Step 5 Intermediate 59: tert-butyl-6-(3-methyl-1-(8-((tetrahydro-2H-pyran-2-yl)oxy)octyl)-1H- indazole-6-carboxamido)-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1- carboxylate To a solution of 3-methyl-1-[8-(oxan-2-yloxy)octyl]indazole-6-carboxamide (Intermediate 58, 200 mg, 0.516 mmol) and tert-butyl-6-bromo-2-[(2R)-1-methylpyrrolidin-2-yl]pyrrolo[3,2- c]pyridine-1-carboxylate (Intermediate 1, 177 mg, 0.464 mmol) in 1,4-dioxane (10.0 mL) was added Brettphos (166 mg, 0.310 mmol), Brettphos Pd G3 (173 mg, 0.323 mmol) and Cs2CO3(336 mg, 1.03 mmol) and the reaction was stirred overnight at 100°C under nitrogen. Water (50 mL) was added, the mixture was extracted with EtOAc (3 x 100 mL) and the organic layers were combined, washed with brine (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was chromatographed on a silica gel column, eluting with EtOAc / petroleum ether (30 / 70), to afford tert-butyl 6-(3-methyl-1-(8- ((tetrahydro-2H-pyran-2-yl)oxy)octyl)-1H-indazole-6-carboxamido)-2-((R)-1-methylpyrrolidin- 2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 59, 270 mg, 49%) as an off-white solid. Mass spec: m / z: 687.0 [M+H]+. Step 6 Intermediate 60: 1-(8-hydroxyoctyl)-3-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H- pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide hydrochloride To a solution of tert-butyl 6-{3-methyl-1-[8-(oxan-2-yloxy)octyl]indazole-6-amido}-2-[(2R)-1- methylpyrrolidin-2-yl]pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 59, 270 mg, 0.393 mmol) in 1,4-dioxane (10.0 mL) was added conc. aqueous HCl (12M, 2.00 mL) and the reaction was stirred at room temperature for 2h. The reaction was concentrated under reduced pressure to afford 1-(8-hydroxyoctyl)-3-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H- pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide hydrochloride (Intermediate 60, 120 mg) as an off-white solid, which was used in the next step without further purification. Mass spec: m / z: 503.0 [M+H]+. Step 7 Intermediate 61: 8-[3-methyl-6-({2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2- c]pyridin-6-yl}carbamoyl)indazol-1-yl]octyl methanesulfonate To a solution of 1-(8-hydroxyoctyl)-3-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H- pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide hydrochloride (Intermediate 60, 120 mg, 0.398 mmol) and Et3N (313 mg, 1.91 mmol) in THF (10.0 mL) was added MsCl (82 mg, 0.716 mmol) at 0℃ and the reaction was stirred at room temperature for 2h. Water (20 mL) was added and the resulting mixture was extracted with EtOAc (3 x 100 mL) and the organic layers were combined, washed with brine (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford 8-[3-methyl-6-({2-[(2R)-1-methylpyrrolidin-2- yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}carbamoyl)indazol-1-yl]octyl methanesulfonate (Intermediate 61, 110 mg, 53%) as an off-white solid, which was used in the next step without further purification. Mass spec: m / z: 581.0 [M+H]+. Step 8 Example 8: 1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]oxy}octyl)-3-methyl- N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6- carboxamide To a solution of 8-[3-methyl-6-({2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6- yl}carbamoyl)indazol-1-yl]octyl methanesulfonate (Intermediate 61, 60.0 mg, 0.103 mmol) in DMF (3 mL) was added NaHCO3(17.4 mg, 0.206 mmol), KI (17.2 mg, 0.103 mmol) and 2- (2,6-dioxopiperidin-3-yl)-5-hydroxyisoindole-1,3-dione (CAS No: 64567-60-8, 28.3 mg, 0.103 mmol) and the reaction was stirred at 80℃ overnight. The crude reaction was then purified by preparative HPLC (Column: XBridge Prep OBD C18 Column, 30 * 150 mm, 5 μm; Mobile Phase A: Water (with 10 mmol / L NH4HCO3), Mobile Phase B: MeCN; Flow rate: 60 mL / min; Gradient: 46% B to76 % B in 10 min) to afford 1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindol-5-yl]oxy}octyl)-3-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide (Example 8, 4.3 mg, 8.5%) as a white solid. 1H NMR(400 MHz, DMSO-d6) δ ppm 11.40 (s, 1H), 11.10 (s, 1H), 10.56 (s, 1H), 8.52 (s, 1H), 8.45 (s, 1H), 8.25 (s, 1H), 7.73 - 7.80 (m, 3H), 7.39 (s, 1H), 7.30 (d, J= 8.4 Hz, 1H), 6.41 (s, 1H), 5.11 (t, J=12.8 Hz, 1H), 4.41 (s, 2H), 4.12 (s, 2H), 3.15 - 3.35 (m, 2H), 2.86 - 2.89 (m, 2H), 2.51 – 2.62 (m, 2H), 2.26 - 2.28 (m, 1H), 2.17 (s, 4H), 2.06 – 2.09 (m, 1H), 1.72 – 1.87 (m, 8H), 1.18 - 1.49 (m, 9H). Mass spec: m / z: 759.5 [M+H]+. Example 9 was synthesized following Scheme 13 Scheme 13 Step 1 Intermediate 62: 3-[(2-carboxyethyl)(3-hydroxy-2-methylphenyl)amino]propanoic acid To a solution of 3-amino-2-methylphenol (CAS No: 53222-92-7, 2.00 g, 16.2 mmol) in H2O (20.0 mL) was added acrylic acid (3.51 g, 48.7 mmol) and the reaction was stirred overnight at 100℃. The mixture was then chromatographed directly on a C18 silica column, eluting with water, to afford 3-[(2-carboxyethyl)(3-hydroxy-2-methylphenyl)amino]propanoic acid (Intermediate 62, 3.00 g, 58%) as a yellow oil. Mass spec: m / z: 268.0 [M+H]+. Step 2 Intermediate 63: 1-(3-hydroxy-2-methylphenyl)-1,3-diazinane-2,4-dione To a solution of 3-[(2-carboxyethyl)(3-hydroxy-2-methylphenyl)amino]propanoic acid (Intermediate 62, 1.70 g, 6.36 mmol) in acetic acid (12.8 mL) was added urea (573 mg, 9.54 mmol) and the reaction was stirred overnight at 130 ℃. The mixture was allowed to cool to room temperature, water (50 mL) was added, resulting in a formation of a precipitate. The precipitate was filtered, washed with 0.1% aqueous HCl (3 x 100 mL) and dried under vacuum to afford 1-(3-hydroxy-2-methylphenyl)-1,3-diazinane-2,4-dione (Intermediate 63, 500 mg, 42%) as an off-white solid. Mass spec: m / z: 221.0 [M+H]+Step 3 Example 9: 1-{8-[3-(2,4-dioxo-1,3-diazinan-1-yl)-2-methylphenoxy]octyl}-3-methyl-N-{2- [(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide To a solution of 1-(3-hydroxy-2-methylphenyl)-1,3-diazinane-2,4-dione (Intermediate 63, 27.7 mg, 0.125 mmol) and 1-(8-iodooctyl)-3-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H- pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide (Intermediate 64, 70.0 mg, 0.114 mmol) in DMF (3.50 mL) was added K2CO3(63.2 mg, 0.456 mmol) and the reaction was stirred at 80℃ for 2h. The resulting solution was purified directly by preparative HPLC (Column: XBridge Prep Phenyl OBD C18 Column, 30*150 mm, 5μm; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: MeCN; Flow rate: 60 mL / min; Gradient: 40% B to70 % B in 10 min) to afford 1-{8-[3-(2,4-dioxo-1,3-diazinan-1-yl)-2-methylphenoxy]octyl}-3-methyl-N-{2- [(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide (Example 9, 1.7 mg, 2%) as a white solid.1H NMR δ ppm 11.42 (s, 1H), 10.54 (s, 1H), 10.32 (s, 1H), 8.52 (s, 1H), 8.44 (s, 1H), 8.25 (s, 1H), 7.72 - 7.80 (m, 2H), 7.14 (t, J = 8.8 Hz, 1H), 6.82 - 6.87 (m, 2H), 6.41 (s, 1H), 4.41 - 4.45 (m, 3H), 3.93 (t, J = 6.4 Hz, 2H), 3.70 - 3.76 (m, 2H), 3.15 - 3.16 (m, 2H), 2.18 - 2.33 (m, 4H), 1.96 (s, 4H), 1.82 - 1.88 (m, 5H), 1.71 - 1.72 (m, 3H), 1.32 - 1.36 (m, 3H), 1.24 - 1.26 (m, 7H), 1.19 - 1.21 (m, 1H). Mass spec: m / z: 705.5 [M+H]+. Example 10 was synthesized following Scheme 14 Scheme 14 Step 1 Intermediate 65: methyl 3-methyl-1-[6-(oxan-2-yloxy)hexyl]indazole-6-carboxylate To a solution of methyl 3-methyl-1H-indazole-6-carboxylate (Intermediate 21, 1.00 g, 5.26 mmol) in DMF (20.0 mL) was added 2-(6-Bromohexyloxy)tetrahydro-2H-pyran (CAS No: 53963-10-3, 2.09 g, 7.89 mmol) and Cs2CO3(3.43 g, 10.5 mmol) and the reaction was stirred at 60 ℃ for 2h. Water (50 mL) was added and the aqueous phase was extracted with EtOAc (3 x 200 mL). The combined organic phases were washed with brine (3 x 200 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The resulting residue was chromatographed on a silica gel column, eluting with EtOAc / petroleum ether (20 / 80), to afford methyl 3-methyl-1-[6-(oxan-2-yloxy)hexyl]indazole-6-carboxylate (Intermediate 65, 1.30 g, 61%) as a yellow oil. Mass spec: m / z: 375.0 [M+H]+. Step 2 Intermediate 66: 3-methyl-1-[6-(oxan-2-yloxy)hexyl]indazole-6-carboxylic acid To a solution of methyl 3-methyl-1-[6-(oxan-2-yloxy)hexyl]indazole-6-carboxylate (Intermediate 65, 1.30 g, 3.47 mmol) in MeOH (25 mL) was added NaOH (4M in H2O, 5 mL) and the reaction was stirred at room temperature for 2h. Water (50 mL) was added and the pH the solution was adjusted to pH 6 by dropwise addition of concentrated aqueous HCl. The mixture was then extracted with EtOAc (3 x 200 mL), washed with brine (3 x 200 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford 3-methyl-1- [6-(oxan-2-yloxy)hexyl]indazole-6-carboxylic acid (Intermediate 66, 1.10 g, 87%) as a colourless oil. Mass spec: m / z: 361.0 [M+H]+. Step 3 Intermediate 67: 3-methyl-1-[6-(oxan-2-yloxy)hexyl]indazole-6-carboxamide To a solution of 3-methyl-1-[6-(oxan-2-yloxy)hexyl]indazole-6-carboxylic acid (Intermediate 66, 800 mg, 2.22 mmol) in DMF (10 mL) was added DIPEA (1.72 g, 13.3 mmol), HATU (844 mg, 2.22 mmol) and NH4Cl (475 mg, 8.88 mmol) and the reaction was stirred at room temperature for 4h. Water (20 mL) was added and the aqueous phase extracted with EtOAc (3 x 100 mL). The combined organic phases were washed with brine (3 x 100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The resulting residue was chromatographed on a silica gel column, eluting with EtOAc / petroleum ether (65 / 35) to afford 3-methyl-1-[6-(oxan-2-yloxy)hexyl]indazole-6-carboxamide (Intermediate 67, 700 mg, 99%) as a colorless oil. Mass spec: m / z: 360.0 [M+H]+. Step 4 Intermediate 68: tert-butyl 6-{3-methyl-1-[6-(oxan-2-yloxy)hexyl]indazole-6-amido}-2- [(2R)-1-methylpyrrolidin-2-yl]pyrrolo[3,2-c]pyridine-1-carboxylate To a solution of 3-methyl-1-[6-(oxan-2-yloxy)hexyl]indazole-6-carboxamide (Intermediate 67, 700 mg, 1.95 mmol) in 1,4-dioxane (10.0 ml) was added tert-butyl 6-bromo-2-[(2R)-1- methylpyrrolidin-2-yl]pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 1, 0.665 g, 1.75 mmol), Brettphos (0.630 g, 1.168 mmol), Brettphos Pd G3 (0.532 g, 0.585 mmol) and Cs2CO3(1.27 g, 3.89 mmol) and the reaction mixture was stirred at 100 ℃ for 4h , under N2. The volatiles were then removed under reduced pressure and the resulting residue was purified on a C18 silica column, eluting with MeCN, to afford tert-butyl 6-{3-methyl-1-[6-(oxan-2- yloxy)hexyl]indazole-6-amido}-2-[(2R)-1-methylpyrrolidin-2-yl]pyrrolo[3,2-c]pyridine-1- carboxylate (Intermediate 68, 500 mg, 37%) as a yellow solid. Mass spec: m / z: 659.0 [M+H]+. Step 5 Intermediate 69: 1-(6-hydroxyhexyl)-3-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H- pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide hydrochloride To a solution of tert-butyl 6-{3-methyl-1-[6-(oxan-2-yloxy)hexyl]indazole-6-amido}-2-[(2R)-1- methylpyrrolidin-2-yl]pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 68, 500 mg, 0.759 mmol) in 1,4-dioxane (16.6 mL) was added concentrated aqueous HCl (8.3 mL) and the reaction was stirred at room temperature for 2h. The volatiles were then removed under reduced pressure to afford 1-(6-hydroxyhexyl)-3-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H- pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide hydrochloride (Intermediate 69, 330 mg, 97%) as a yellow oil. Mass spec: m / z: 475.0 [M+H]+. Step 6 Intermediate 70: 6-[3-methyl-6-({2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2- c]pyridin-6-yl}carbamoyl)indazol-1-yl]hexyl methanesulfonate To a solution of 1-(6-hydroxyhexyl)-3-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H- pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide hydrochloride (Intermediate 69, 150 mg, 0.316 mmol) and Et3N (320 mg, 3.16 mmol) in THF (4.50 mL) was added MsCl (109 mg, 0.948 mmol), at 0℃, and the reaction was stirred at room temperature for 2h. Water (10 mL) was added and the resulting aqueous phase was extracted with EtOAc (3 x 50 mL). The organic layers were combined, washed with brine (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford 6-[3-methyl-6-({2-[(2R)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}carbamoyl)indazol-1-yl]hexyl methanesulfonate (Intermediate 70, 170 mg, 81%) as an off-white solid, which was used in the next step without further purification. Mass spec: m / z: 553.0 [M+H]+. Step 7 Example 10: 1-{6-[3-(2,4-dioxo-1,3-diazinan-1-yl)-2-methylphenoxy]hexyl}-3-methyl-N-{2- [(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide To a solution of 1-(6-hydroxyhexyl)-3-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H- pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide (Intermediate 70, 100 mg, 0.211 mmol) in DMF (5.00 mL) was added 1-(3-hydroxy-2-methylphenyl)-1,3-diazinane-2,4-dione (Intermediate 63, 51.0 mg, 0.232 mmol) and K2CO3(116 mg, 0.844 mmol) and the reaction was stirred at 80 ℃ for 2h. The resulting mixture was purified directly by preparative HPLC (Column: Xselect CSH Prep C18 Column, 30*150 mm, 5μm; Mobile Phase A: Water (with 0.1% formic acid), Mobile Phase B: MeCN; Flow rate: 60 mL / min; Gradient: 5% B to35 % B in 10 min) to afford 1-{6-[3-(2,4-dioxo-1,3-diazinan-1-yl)-2-methylphenoxy]hexyl}-3-methyl-N- {2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide (Example 10, 4.5 mg, 4.3%) as a white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 11.43 (s, 1H), 10.54 (s, 1H), 10.31 (s, 1H), 8.53 (s, 1H), 8.45 (s, 1H), 8.25 (s, 1H), 7.73 - 7.80 (m, 2H), 7.15 (t, J = 8.0 Hz, 1H), 6.83 - 6.89 (m, 2H), 6.41(s, 1H), 4.43 (t, J = 6.8 Hz, 2H), 3.95 (t, J = 6.0 Hz, 2H), 3.68 - 3.71 (m, 3H), 3.13 - 3.16 (m, 2H), 2.71 -2.75 (m, 3H), 2.27 - 2.34 (m, 2H), 2.15 - 2.18 (m, 3H), 1.93 (s, 3H), 1.72 - 1.91 (m, 7H), 1.49 - 1.52 (m, 2H), 1.37 - 1.41 (m, 2H), 0.94 - 0.96 (m, 1H). Mass spec: m / z: 677.50 [M+H]+. Example 11 was synthesized following Scheme 15 Scheme 15 Step 1 Intermediate 71: 3-(4-bromo-3-methyl-2-oxo-1,3-benzodiazol-1-yl)piperidine-2,6-dione To a solution of 7-bromo-1-methyl-3H-1,3-benzodiazol-2-one (CAS No: 913297-44-6, 2.00 g, 8.72 mmol) in THF (20 mL) was added LiHMDS (26.2 mL, 26.2 mmol, 1M in THF) dropwise at 0 °C under N2. After 15 min, 3-bromopiperidine-2,6-dione (CAS No: 62595-74-8, 2.51 g, 13.1 mmol) in THF (5 mL) was added dropwise at 0 °C and the reaction was stirred at 70 °C for 4h under N2. The reaction mixture was then cooled to 0 °C and pH of the mixture was adjusted to pH 2-3 with dilute aqueous HCl (1M) resulting in a precipitate. The precipitate was collected by filtration to afford 3-(4-bromo-3-methyl-2-oxo-1,3-benzodiazol-1-yl)piperidine-2,6-dione (Intermediate 71, 2.00 g, 34%) as an off white solid. Mass spec: m / z: 338.0 [M+H]+. Step 2 Intermediate 72: 3-(4-bromo-3-methyl-2-oxo-1,3-benzodiazol-1-yl)-1-{[2- (trimethylsilyl)ethoxy]methyl}piperidine-2,6-dione To a stirred solution of 3-(4-bromo-3-methyl-2-oxo-1,3-benzodiazol-1-yl)piperidine-2,6-dione (Intermediate 71, 1.9 g, 2.81 mmol) and DBU (0.86 g, 5.62 mmol) in DMF (40 mL) was added SEM-Cl (0.94 g, 5.62 mmol) at 0° C. The resulting mixture was allowed to warm to room temperature and stirred overnight. The mixture was quenched with water (100 mL) and extracted with EtOAc (3 x 200 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO,filtered and concentrated under reduced pressure. The residue was chromatographed on a silica gel column, eluting with EtOAc / petroleum ether (35 / 65), to afford 3-(4-bromo-3-methyl-2-oxo-1,3-benzodiazol-1-yl)-1-{[2- (trimethylsilyl)ethoxy]methyl}piperidine-2,6-dione (Intermediate 72, 1.5 g, 91%) as a an oil. Mass spec: m / z :468.1 [M+H]+. Step 3 Intermediate 74: 3-(4-{7-[(tert-butyldimethylsilyl)oxy]hept-1-yn-1-yl}-3-methyl-2-oxo-1,3- benzodiazol-1-yl)-1-{[2-(trimethylsilyl)ethoxy]methyl}piperidine-2,6-dione To a stirred solution of hept-6-yn-1-ol (CAS No: 63478-76-2, 500 mg, 4.413 mmol) in DCM (10 mL) was added imidazole (360 mg, 5.296 mmol) and TBS-Cl (798 mg, 5.296 mmol) and the reaction mixture was stirred overnight at room temperature. The resulting mixture was filtered and concentrated under reduced pressure to afford tert-butyl(hept-6-yn-1- yloxy)dimethylsilane (Intermediate 73, 1.00 g, 91%) as a colorless liquid, which was used in the stage without further purification. A 50 mL round-bottom flask was charged with 3-(4- bromo-3-methyl-2-oxo-1,3-benzodiazol-1-yl)-1-{[2-(trimethylsilyl)ethoxy]methyl}piperidine- 2,6-dione (Intermediate 72, 700 mg, 1.196 mmol), tert-butyl(hept-6-yn-1-yloxy)dimethylsilane (541 mg, 2.39 mmol), Pd(PPh3)2Cl2(134 mg, 0.191 mmol), CuI (45.5 mg, 0.239 mmol), triethylamine (3 mL, 21.58 mmol) in DMF (10 mL) under N2and the reaction was stirred overnight at 100°C. The mixture was quenched with water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was chromatographed on a silica gel column, eluting with petroleum ether / EtOAc (38 / 72) to afford 3-(4-{7-[(tert- butyldimethylsilyl)oxy]hept-1-yn-1-yl}-3-methyl-2-oxo-1,3-benzodiazol-1-yl)-1-{[2- (trimethylsilyl)ethoxy]methyl}piperidine-2,6-dione (Intermediate 74, 900 mg, 86%) as a yellow oil. Mass spec: m / z :614.0 [M+H]+. Step 4 Intermediate 75: 3-[4-(7-hydroxyhept-1-yn-1-yl)-3-methyl-2-oxo-1,3-benzodiazol-1-yl]-1- {[2-(trimethylsilyl)ethoxy]methyl}piperidine-2,6-dione To a stirred solution of 3-(4-{7-[(tert-butyldimethylsilyl)oxy]hept-1-yn-1-yl}-3-methyl-2-oxo- 1,3-benzodiazol-1-yl)-1-{[2-(trimethylsilyl)ethoxy]methyl}piperidine-2,6-dione (Intermediate 74, 870 mg, 0.992 mmol) in THF (15 mL) was added HCl (4M in 1,4-dioxane, 3 mL) at room temperature and the reaction stirred for 0.5h. The mixture was quenched with water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was chromatographed on a silica gel column, eluting with DCM / MeOH (96 / 4), to afford 3-[4- (7-hydroxyhept-1-yn-1-yl)-3-methyl-2-oxo-1,3-benzodiazol-1-yl]-1-{[2- (trimethylsilyl)ethoxy]methyl}piperidine-2,6-dione (Intermediate 75, 450 mg, 73%) as a yellow oil. Mass spec: m / z: 500.0 [M+H]+. Step 5 Intermediate 76: 7-[1-(2,6-dioxo-1-{[2-(trimethylsilyl)ethoxy]methyl}piperidin-3-yl)-3- methyl-2-oxo-1,3-benzodiazol-4-yl]hept-6-yn-1-yl methanesulfonate To a solution of 3-[4-(7-hydroxyhept-1-yn-1-yl)-3-methyl-2-oxo-1,3-benzodiazol-1-yl]-1-{[2- (trimethylsilyl)ethoxy]methyl}piperidine-2,6-dione (Intermediate 75, 450 mg, 0.720 mmol) in DCM (6 mL) was added triethylamine (365 mg, 3.60 mmol) and MsCl (165 mg, 1.44 mmol) and the reaction mixture was stirred at room temperature for 1h. MeOH (10 mL) was added and the volatiles were removed under reduced pressure. The residue was then chromatographed on a silica gel column, eluting with EtOAc / petroleum ether (60 / 40), to afford 7-[1-(2,6-dioxo-1-{[2- (trimethylsilyl)ethoxy]methyl}piperidin-3-yl)-3-methyl-2-oxo-1,3-benzodiazol-4-yl]hept-6-yn- 1-yl methanesulfonate (Intermediate 76, 390 mg, 84%) as a yellow oil. Mass spec: m / z :578.0 [M+H]+. Step 6 Intermediate 77: 1-{7-[1-(2,6-dioxo-1-{[2-(trimethylsilyl)ethoxy]methyl}piperidin-3-yl)-3- methyl-2-oxo-1,3-benzodiazol-4-yl]hept-6-yn-1-yl}-3-methylindazole-6-carboxamide A 10 mL round-bottom flask was charged with 7-[1-(2,6-dioxo-1-{[2- (trimethylsilyl)ethoxy]methyl}piperidin-3-yl)-3-methyl-2-oxo-1,3-benzodiazol-4-yl]hept-6-yn- 1-yl methanesulfonate (Intermediate 76, 370 mg, 0.576 mmol), 3-methyl-1H-indazole-6- carboxamide (Intermediate 144, 121 mg, 0.691 mmol,), K2CO3(159 mg, 1.152 mmol), KI (95.6 mg, 0.576 mmol) in DMF (4 mL) and the reaction mixture was stirred at 60°C for 4h, under N2. The crude reaction mixture was purified on a C18 silica column, eluting with MeCN / H2O (1-2 drops formic acid) (45 / 55), to afford 1-{7-[1-(2,6-dioxo-1-{[2- (trimethylsilyl)ethoxy]methyl}piperidin-3-yl)-3-methyl-2-oxo-1,3-benzodiazol-4-yl]hept-6-yn- 1-yl}-3-methylindazole-6-carboxamide (Intermediate 77, 80 mg, 17%d) as a yellow solid. Mass spec: m / z 657.0 [M+H]+. Step 7 Intermediate 78: tert-butyl 6-(1-{7-[1-(2,6-dioxo-1-{[2- (trimethylsilyl)ethoxy]methyl}piperidin-3-yl)-3-methyl-2-oxo-1,3-benzodiazol-4-yl]hept-6- yn-1-yl}-3-methylindazole-6-amido)-2-[(2R)-1-methylpyrrolidin-2-yl]pyrrolo[3,2- c]pyridine-1-carboxylate A 5 mL round-bottom flask was charged with 1-{7-[1-(2,6-dioxo-1-{[2- (trimethylsilyl)ethoxy]methyl}piperidin-3-yl)-3-methyl-2-oxo-1,3-benzodiazol-4-yl]hept-6-yn- 1-yl}-3-methylindazole-6-carboxamide (Intermediate 77, 80.0 mg, 0.097 mmol), tert-butyl 6- bromo-2-[(2R)-1-methylpyrrolidin-2-yl]pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 1, 40.7 mg, 0.107 mmol), Pd2(dba)3(8.92 mg, 0.010 mmol), Xantphos (11.3 mg, 0.019 mmol), Cs2CO3(63.5 mg, 0.194 mmol) in 1,4-dioxane (3 mL), under N2and the mixture was stirred at 60°C for 3h. The volatiles were removed under reduced pressure and the residue was purified by preparative TLC, eluting with DCM / MeOH (95 / 5), to afford tert-butyl 6-(1-{7-[1-(2,6- dioxo-1-{[2-(trimethylsilyl)ethoxy]methyl}piperidin-3-yl)-3-methyl-2-oxo-1,3-benzodiazol-4- yl]hept-6-yn-1-yl}-3-methylindazole-6-amido)-2-[(2R)-1-methylpyrrolidin-2-yl]pyrrolo[3,2- c]pyridine-1-carboxylate (Intermediate 78, 38 mg, 34%) as a yellow solid. Mass spec: m / z 956.0 [M+H]+. Step 8 Example 11: 1-{7-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-1,3-benzodiazol-4-yl]hept-6- yn-1-yl}-3-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6- yl}indazole-6-carboxamide To a solution of tert-butyl 6-(1-{7-[1-(2,6-dioxo-1-{[2-(trimethylsilyl)ethoxy]methyl}piperidin- 3-yl)-3-methyl-2-oxo-1,3-benzodiazol-4-yl]hept-6-yn-1-yl}-3-methylindazole-6-amido)-2- [(2R)-1-methylpyrrolidin-2-yl]pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 78, 38 mg, 0.033 mmol) in DCM (1 mL) was added MsOH (41.7 mg, 0.429 mmol) and the reaction mixture was stirred at room temperature for 2h. Triethylamine (39.5 mg, 0.390 mmol) and N,N’- dimethylethylenediamine (5.89 mg, 0.066 mmol) was then added and the reaction stirred for a further 2h at room temperature. The reaction mixture was then purified by preparative TLC, eluting with DCM / MeOH (90 / 10), to afford crude product. The crude product was further purified by preparative HPLC (Column: XBridge Prep Shield RP C18 Column, 19*250 mm, 5μm; Mobile Phase A: Water (0.1%FA), Mobile Phase B: MeOH; Flow rate: 25 mL / min ; Gradient: 25% B to 55% B in 10 min), to afford 1-{7-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2- oxo-1,3-benzodiazol-4-yl]hept-6-yn-1-yl}-3-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H- pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide (Example 11, 2.1 mg, 8.2%) as a white solid.1H NMR (400 MHz, MeOH-d4) δ ppm 8.63 (s, 1H), 8.28 (s, 1H), 8.19 (s, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.04 (d, J = 7.6 Hz, 1H), 6.92 - 6.94 (m, 2H), 6.75 (s, 1H), 5.36 - 5.40 (m, 1H), 4.47 - 4.87 (m, 2H), 4.09 - 4.12 (m, 1H), 3.50 - 3.56 (m, 1H), 3.35 – 3.36 (m, 3H), 3.31 - 3.32 (m, 3H), 2.91 - 2.94 (m, 2H), 2.79 - 2.82 (m, 2H), 2.62 (s, 3H).2.48 - 2.52 (m, 1H), 2.43- 2.46 (m, 2H), 2.29 - 2.35 (m, 1H), 2.16 - 2.19 (m, 3H), 2.00 - 2.02 (m, 2H), 1.61 - 1.66 (m, 2H), 1.42 - 1.48 (m, 2H). Mass spec: m / z 726.4 [M+H]+. Example 12 was synthesis following Scheme 16 Scheme 16 Step 1 Intermediate 79: methyl 3-methyl-1-(8-((tetrahydro-2H-pyran-2-yl)oxy)octyl)-1H- indazole-6-carboxylate To a solution of methyl 3-methyl-1H-indazole-6-carboxylate (Intermediate 21, 2.00 g, 9.46 mmol) in DMF (20 mL) was added 2-((8-bromooctyl)oxy)tetrahydro-2H-pyran (CAS No: 50816-20-1, 8.33 g, 28.4 mmol) and Cs2CO3(6.17 g, 18.9 mmol) and the mixture was stirred at 60 °C for 2h. Water (20 mL) was added and the aqueous phase was extracted with EtOAc (3 x 50 mL). The organic layers were combined, washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was chromatographed on a silica gel column, eluting with EtOAc / petroleum ether (1 / 9), to afford methyl 3-methyl-1-(8-((tetrahydro-2H-pyran-2-yl)oxy)octyl)-1H-indazole-6-carboxylate (Intermediate 79, 3.50 g 83%) as a yellow oil. Mass spec: m / z 403.0 [M+H]+. Step 2 Intermediate 80: 3-methyl-1-(8-((tetrahydro-2H-pyran-2-yl)oxy)octyl)-1H-indazole-6- carboxylic acid To a solution of methyl 3-methyl-1-(8-((tetrahydro-2H-pyran-2-yl)oxy)octyl)-1H-indazole-6- carboxylate (Intermediate 79, 3.50 g, 7.83 mmol) in MeOH (40 mL) and H2O (27 mL), was added NaOH (12.5 g, 313 mmol) and the mixture was stirred at room temperature for 2h. The pH value of the mixture was adjusted to pH 6 by the dropwise addition of dilute aqueous HCl (1M). The mixture was then extracted with CHCl3 / iPrOH (3 / 1, 3 x 100 mL) and the organic layers were combined, washed with brine (300 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford 3-methyl-1-(8-((tetrahydro-2H-pyran- 2-yl)oxy)octyl)-1H-indazole-6-carboxylic acid (Intermediate 80, 3.00 g 84%) as a yellow oil, which was used in the next step without further purification. Mass spec: m / z 389.0 [M+H]+. Step 3 Intermediate 81: 3-methyl-1-(8-((tetrahydro-2H-pyran-2-yl)oxy)octyl)-1H-indazole-6- carboxamide To a solution of 3-methyl-1-(8-((tetrahydro-2H-pyran-2-yl)oxy)octyl)-1H-indazole-6-carboxylic acid (Intermediate 80, 3.00 g, 6.56 mmol) in DMF (40 mL) was added HATU (3.74 g, 9.85 mmol), DIPEA (5.09 g, 39.4 mmol) and NH4Cl (1.40 g, 26.3 mmol) and the reaction mixture was stirred at room temperature for 4h. Water (50 mL) was added and the mixture was extracted with EtOAc (3 x 100 mL) and the organic layers were combined, washed with brine (300 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was chromatographed on a silica gel column, eluting with MeOH / DCM (5 / 95) to afford 3-methyl-1-(8-((tetrahydro-2H-pyran-2-yl)oxy)octyl)-1H-indazole-6-carboxamide (Intermediate 81, 3.00 g 94%) as a yellow oil. Mass spec: m / z 388.0 [M+H]+. Step 4 Intermediate 82: tert-butyl 6-(3-methyl-1-(8-((tetrahydro-2H-pyran-2-yl)oxy)octyl)-1H- indazole-6-carboxamido)-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1- carboxylate To a solution of 3-methyl-1-(8-((tetrahydro-2H-pyran-2-yl)oxy)octyl)-1H-indazole-6- carboxamide (Intermediate 81, 1.00 g, 2.32 mmol) in 1,4-dioxane (50 mL) was added tert- butyl (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 1, 1.28 g, 3.02 mmol), Brettphos (748 mg, 1.39 mmol), Brettphos Pd G3(632 mg, 0.697 mmol) and Cs2CO3(1.51 g, 4.64 mmol) an the reaction was stirred at 100 °C for 2 days. The resulting crude was then chromatographed on a silica gel column, eluting with MeOH / DCM (5 / 95), to afford tert-butyl 6-(3-methyl-1-(8-((tetrahydro-2H-pyran-2- yl)oxy)octyl)-1H-indazole-6-carboxamido)-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridine-1-carboxylate (Intermediate 82, 900 mg 50.77%) as a yellow oil. Mass spec: m / z 687.0 [M+H]+. Step 5 Intermediate 83: (R)-1-(8-hydroxyoctyl)-3-methyl-N-(2-(1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide hydrochloride To a solution of tert-butyl 6-(3-methyl-1-(8-((tetrahydro-2H-pyran-2-yl)oxy)octyl)-1H- indazole-6-carboxamido)-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1- carboxylate (Intermediate 82, 850 mg, 1.11 mmol) in 1,4-dioxane (15 mL) was added concentrated HCl (2 mL) and the mixture was stirred at room temperature for 2h. The volatiles were then removed under reduced pressure to afford (R)-1-(8-hydroxyoctyl)-3-methyl-N-(2-(1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide hydrochloride (Intermediate 83, 550 mg) as a yellow solid, which was used in the next step without further purification. Mass spec: m / z: 503.0 [M+H]+. Step 6 Intermediate 64: (R)-1-(8-iodooctyl)-3-methyl-N-(2-(1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide To a solution of (R)-1-(8-hydroxyoctyl)-3-methyl-N-(2-(1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide hydrochloride (Intermediate 83, 450 mg, 0.806 mmol) in DCM (10 mL) was added PPh3(634 mg, 2.42 mmol) and imidazole (494 mg, 7.25 mmol), under N2. I2(675 mg, 2.66 mmol) was then added and the mixture was stirred at room temperature for 3h. Water (10 mL) was added and the mixture was extracted with EtOAc (3 x 20 mL). The organic layers were combined, washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was chromatographed on a silica gel column, eluting with EtOAc / petroleum ether (3 / 7), to afford (R)-1-(8-iodooctyl)-3-methyl-N-(2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)- 1H-indazole-6-carboxamide (Intermediate 64, 280 mg 51.06%) as a yellow solid. Mass spec: m / z 613.0 [M+H]+. Step 7 Example 12: 1-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)octyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide To a solution of (R)-1-(8-iodooctyl)-3-methyl-N-(2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)-1H-indazole-6-carboxamide (Intermediate 64, 80.0 mg, 0.118 mmol) in DMSO (2 mL) was added 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione (CAS No: 5054- 59-1, 32.2 mg, 0.118 mmol), NaHCO3(29.6 mg, 0.354 mmol) and KI (19.5 mg, 0.118 mmol) and the reaction was stirred overnight at 100°C. The resulting crude was chromatographed on a C18 silica column, eluting with water / MeCN (5 / 5) to afford crude product (40 mg). This was further purified by preparative HPLC (Column: YMC-Actus Triart C18 ExRs, 30*150 mm, 5μm; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: MeCN; Flow rate: 60 mL / min; Gradient: 38% B to 68% B in 7 min, 68% B to 81% B in 10 min) to afford 1-(8-((2- (2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)octyl)-3-methyl-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide (Example 12, 7.00 mg 7.8%) as a white solid.1H NMR (400 MHz, DMSO-d6) δ ppm as 11.38 (s, 1H), 11.10 (s, 1H), 10.54 (s, 1H), 8.52 (s, 1H), 8.44 (s, 1H), 8.25 (s, 1H), 7.72 - 7.80 (m, 3H), 7.41 - 7.48 (m, 2H), 6.41 - 6.53 (m, 1H), 5.05 - 5.09 (m, 1H), 4.41 (t, J = 6.8Hz, 2H), 4.16 (t, J = 6.4Hz, 2H), 3.16 - 3.17 (m, 1H), 2.85 - 2.95 (m, 1H), 2.55 - 2.65 (m, 2H), 2.45 - 2.55 (m, 2H), 2.20 - 2.25 (m, 1H), 2.15 - 2.20 (m, 4H), 1.65 - 2.01(m, 10H) 1.40 - 1.55 (m, 2H), 1.25 - 1.30 (m, 6H). Mass spec: m / z 759.5 [M+H]+. Example 13 was synthesised following Scheme 17

[0021] Scheme 17 Step 1 Intermediate 84: methyl 1-(3-((tert-butoxycarbonyl)amino)propyl)-3-methyl-1H-indazole- 6-carboxylate To a solution of methyl 3-methyl-1H-indazole-6-carboxylate (Intermediate 21, 500 mg, 2.50 mmol) in DMF (8 mL) was added NaH (60% in mineral oil, 150 mg, 3.75 mmol) at 0°C. The reaction was then stirred for 30 min at 0 °C. tert-Butyl (3-bromopropyl)carbamate (CAS No: 83948-53-2, 751 mg, 3.00 mmol) was then added and the reaction was stirred at room temperature for 2h. Water (20 mL) was added and the aqueous phase was extracted with EtOAc (2 x 50 mL). The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was then chromatographed on a silica gel column, eluting with MeOH / DCM (2 / 98), to afford methyl 1- (3-((tert-butoxycarbonyl)amino)propyl)-3-methyl-1H-indazole-6-carboxylate (Intermediate 84, 270 mg, 28%) as a colorless oil. Mass spec: m / z: 348.2 [M+H]+. Step 2 Intermediate 85: 1-(3-((tert-butoxycarbonyl)amino)propyl)-3-methyl-1H-indazole-6- carboxylic acid To a stirred solution of methyl 1-(3-((tert-butoxycarbonyl)amino)propyl)-3-methyl-1H- indazole-6-carboxylate (Intermediate 84, 454 mg, 1.18 mmol) in THF (8 mL) and water (2 mL) was added LiOH (141 mg, 5.88 mmol) and the resulting mixture was stirred at 60°C for 2h. The pH value of the solution was adjusted to pH ~5 by dropwise addition of dilute aqueous HCl (1M) and the resulting mixture was extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with brine and dried over anhydrous Na2SO4and then concentrated under reduced pressure to afford 1-(3-((tert-butoxycarbonyl)amino)propyl)-3-methyl-1H-indazole-6- carboxylic acid (Intermediate 85, 230 mg, 52%) as a white solid. Mass spec: m / z: 334.1 [M+H]+. Step 3 Intermediate 86: tert-butyl (3-(6-carbamoyl-3-methyl-1H-indazol-1-yl)propyl)carbamate A 100 mL round-bottom flask was charged with 1-(3-((tert-butoxycarbonyl)amino)propyl)-3- methyl-1H-indazole-6-carboxylic acid (Intermediate 85, 332 mg, 0.896 mmol), NH4Cl (240 mg, 4.48 mmol), DMF (6 mL), HATU (511 mg, 1.34 mmol), DIPEA (348 mg, 2.69 mmol) and the reaction was stirred overnight at room temperature. The mixture was chromatographed on a C18 silica column, eluting with MeCN / water (with 0.5% NH4HCO3) (3 / 7) to afford tert-butyl (3-(6-carbamoyl-3-methyl-1H-indazol-1-yl)propyl)carbamate (Intermediate 86, 280 mg, 89%) as a white solid. Mass spec: m / z: 333.2[M+H]+. Step 4 Intermediate 87: tert-butyl (R)-6-(1-(3-((tert-butoxycarbonyl)amino)propyl)-3-methyl- 1H-indazole-6-carboxamido)-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1- carboxylate A 100 mL round-bottom flask was charged with tert-butyl (3-(6-carbamoyl-3-methyl-1H- indazol-1-yl)propyl)carbamate (Intermediate 86, 120 mg, 0.343 mmol), tert-butyl (R)-6- br...

Claims

1. CLAIMS 1. A compound which is a Proteolysis Targeting Chimera (PROTAC) or a pharmaceutically acceptable salt thereof, wherein the PROTAC has the structure: wherein U is an E3 ubiquitin ligase binding moiety, LINK is a moiety that covalently links M and U, and M is an MLLT1 and / or MLLT3 binder of formula (I): wherein: one of Z1and Z3is -N(H)- and the other is N or -C(R4)-, Y1is N, Y2is N or -C(R6)-, and Y3is N or -C(R5)-; Hy is a 4- to 7-membered heterocyclic ring containing X and at least one N atom, wherein: ring Hy is linked to ring A via a C atom within ring Hy, said C atom also being linked to R2; a N atom within ring Hy is substituted by R1; X is a bond, -N(R11)-, O, S, -S(O)2-, -S(O)(NR11)-, or - C(R11)2-; and the rest of ring Hy is unsubstituted or substituted by one or two R3; L is –C(O)N(H)-, wherein the C atom of L is bonded to R8, and the N atom of L is bonded to ring B; R1is H, C1-4cycloalkyl, or C1-4alkyl which is itself unsubstituted or substituted with one C1-4alkoxy or one, two or three halo; R2is H or methyl; each R3is independently selected from C1-4alkyl, C1-4alkoxy, phenyl, a 5- to 6-membered heteroaryl ring and halo, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring; R4and R6are independently selected from H, halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R5is selected from H, halo, C1-4alkoxy, C3-5cycloalkyl and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R8is an 8- to 10-membered heteroaryl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two R9; each R9is independently selected from halo and C1-4alkoxy; R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 6-membered heterocyclyl ring, and a phenyl ring, the group R10being unsubstituted or substituted by one or two substituents independently selected from C1-4alkyl, C1-4alkoxy, and halo; and each R11is independently selected from H, C1-4alkyl, and C1-4cycloalkyl; wherein M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK.

2. A compound according to claim 1, wherein LINK is (a) a single bond, or (b) a chemical linker group represented by formula (L): wherein: LINK is attached to M via L1; LINK is attached to U via L3; L1 and L3 are each independently selected from a single bond, -N(R’)-, -C(O)N(R’)-, -O-, - N(R’)C(O)-, -C(O)-, -S(O2)N(R’)-, -N(R’)S(O2)-, -(C1-6alkylene)-, ethynylene, -(C2-6alkenylene)-, -C=C=C-, phenylene, a divalent 3- to 6-membered cycloalkyl ring and a divalent 4- to 7-membered heterocyclyl ring, the phenylene, cycloalkyl and heterocyclyl rings being unsubstituted or substituted by one or two C1-4alkyl; L2 is represented by the formula -(L4)m-;each L4 is independently a unit of formula: or each XLis independently selected from a single bond, -N(R’)-, -O-, -C(O)-, -S-, -SO-, -SO2-, - C(R”)=C(R”)- and -C≡C-; each YLis independently selected from a divalent 3- to 6-membered cycloalkyl ring, a divalent 4- to 7-membered heterocyclyl ring, or one of the following structures: , the cycloalkyl and heterocyclyl rings being unsubstituted or substituted by one or two C1-4 alkyl; n is selected from 0 to 4; n’ is selected from 0 or 1; n + n’ ≥ 1; m is selected from 1 to 30; each R’ is independently selected from H and C1-4alkyl; and each R” is independently selected from H and halo.

3. A compound according to claim 1 or 2, wherein U is: (a) a CRBN E3 ubiquitin ligase binding moiety of formula (U1): wherein: RU1is H; Q is selected from -CH(RU6)-, -N(RU6)-, -O-, -C(O)-, -NH-CH(RU6)-, -N=C(RU6)-, or -N=N-; RU6is H or C1-4alkyl; RU2and RU5are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; RU3and RU4are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU2, RU3, RU4and RU5is a single bond to LINK; (b) a CRBN E3 ubiquitin ligase binding moiety of formula (U4): wherein: RU1’is H; W is N or CRU16; Q’ is N and LUis a single bond, or Q’ is CH and LUis selected from a single bond or - C(O)N(H)-, wherein either (i) the C atom of LUis bonded to phenyl, and the N atom of LUis bonded to Q’; or (ii) the C atom of LUis bonded to Q’, and the N atom of LUis bonded to phenyl; RU12, RU13and RU14are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU12, RU13and RU14is a single bond to LINK; RU15and RU16are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN and CF3; (c) a CRBN E3 ubiquitin ligase binding moiety of formula (U5):wherein: RU17is H; RU18, RU19, RU20and RU21are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU18, RU19, RU20and RU21is a single bond to LINK; or (d) a VHL E3 ubiquitin ligase binding moiety of formula (U2):wherein: RU7is a group selected from phenyl, a 5- to 6-membered heteroaryl ring, a 5- to 6-membered heterocyclyl ring, and a 5- to 6-membered cycloalkyl ring, the group RU7being unsubstituted or substituted by C1-4alkyl; RU11is H or C1-4alkyl; RU8is selected from C1-4 alkyl, phenyl and a 3- to 8-membered cycloalkyl ring; and RU9is a single bond to LINK.

4. A compound according to any one of the preceding claims, wherein the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A.

5. A compound according to any one of the preceding claims, wherein Z1is -C(R4)-, Z3is -N(H)-, Y1is N, Y2is -C(R6)- and Y3is -C(R5)-.

6. A compound according to any one of the preceding claims, wherein M is of formula (II):wherein: Z1, Z3, Y1, Y2, Y3, R1, R2, R8, X and L are as defined in any one of the preceding claims; R3aand R3bare independently selected from H, C1-4alkyl, phenyl, a 5- to 6-membered heteroaryl ring and C1-4alkoxy, or R3aand R3bform, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring, R3cand R3dare independently selected from H, C1-4alkyl, halo, phenyl, a 5- to 6-membered heteroaryl ring and C1-4alkoxy, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring, or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, with the proviso that when X is -N(R11)-, O, S, -S(O)2- or -S(O)(NR11)-, then neither R3cnor R3dare halo; wherein at least two of R3a, R3b, R3cand R3dare H; and wherein M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK.

7. A compound according to any one of the preceding claims, wherein M is of formula (III):wherein: R1is H or C1-4alkyl which is itself unsubstituted or substituted with one C1-4alkoxy or one, two or three halo, preferably with one C1-4alkoxy; R2is H or methyl; R3aand R3bare independently selected from H, C1-4alkyl, and C1-4alkoxy, or R3aand R3bform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, with the proviso that when X is -N(Me)- or O, then neither R3cnor R3dare halo; wherein at least two of R3a, R3b, R3cand R3dare H; X is a bond, -N(Me)-, O or -CH2-; R4is selected from H, CN, halo, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R5and R6are independently selected from H, halo, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R8is an 8- to 10-membered heteroaryl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two R9; each R9is independently selected from halo and C1-4alkoxy; R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 6-membered heterocyclyl ring, and a phenyl ring, the group R10being unsubstitutedor substituted by one or two substituents independently selected from C1-4alkyl, C1-4alkoxy, and halo; and wherein M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK.

8. A compound according to claim 1, wherein the PROTAC has a structure selected from: 1-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; rac-1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}octyl)-3-methyl-N-[2- (1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl]indazole-6-carboxamide; 1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}octyl)-3-methyl-N-{2- [(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}octyl)-3-methyl-N-{2- [(2S)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 2-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)-3-methyl-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2H-indazole-6-carboxamide; 3-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindol-5-yl]piperazin-1- yl}methyl)piperidin-1-yl]-1-methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2- c]pyridin-6-yl}indazole-5-carboxamide; 1-[1-(3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}propyl)piperidin-4-yl]-3- methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6- carboxamide; 1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]oxy}octyl)-3-methyl-N-{2-[(2R)- 1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-{8-[3-(2,4-dioxo-1,3-diazinan-1-yl)-2-methylphenoxy]octyl}-3-methyl-N-{2-[(2R)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-{6-[3-(2,4-dioxo-1,3-diazinan-1-yl)-2-methylphenoxy]hexyl}-3-methyl-N-{2-[(2R)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-{7-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-1,3-benzodiazol-4-yl]hept-6-yn-1-yl}-3- methyl-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6- carboxamide; 1-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)octyl)-3-methyl-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)-3-methyl-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide;1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]amino}octyl)-3-methyl-N-{2- [(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]amino}octyl)-3-methyl-N-{2- [(2S)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]amino}octyl)-3-methyl-N-{2- [(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-(8-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]amino}octyl)-3-methyl-N-{2- [(2S)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1-(8-((2-(2,6- dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)-3-methyl-1H-indazole-6- carboxamide; 1-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperazin-1-yl}butyl)-3-methyl- N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperazin-1-yl}butyl)-3-methyl- N-{2-[(2S)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)-3-methyl-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(6-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}hexyl)-3-methyl-N-{2- [(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}indazole-6-carboxamide; 1-(5-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)pentyl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H- indazole-6-carboxamide; 1-(2-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)ethoxy)ethyl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)-1H-indazole-6-carboxamide; 1-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)ethyl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4yl)amino)ethoxy)ethyl)-3-methyl- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)propyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide;1-(3-(1-(4-((2,6-dioxopiperidin-3-yl)carbamoyl)-2-fluorophenyl)piperidin-4-yl)propyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(5-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)pentyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(7-(2-(2, 6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl) hept-6-yn-1-yl)-3-methyl-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(3-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)propyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-3-methyl-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(7-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)hept-6-yn-1-yl)-3-methyl-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(7-(3-((2,6-dioxopiperidin-3-yl)carbamoyl)-2-fluorophenyl)hept-6-yn-1-yl)-3-methyl-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(7-(3-((2,6-dioxopiperidin-3-yl)carbamoyl)-2-methylphenyl)hept-6-yn-1-yl)-3-methyl-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-5-carboxamide; 1-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)-N-(2-((S)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-5-carboxamide; 1-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2-c]pyridin-6-yl)-1H-indazole-5-carboxamide; 1-(9-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5- yl)non-8-yn-1-yl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)-1H-indazole-6-carboxamide; 1-((E)-9-chloro-9-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)non-8-en-1-yl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-((Z)-9-chloro-9-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)non-8-en-1-yl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide;1-(9-chloro-9-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)non-8-en-1-yl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(6-(((S)-2,6-dioxopiperidin-3-yl)carbamoyl)pyridin-3-yl)non-8-yn-1-yl)-3-methyl-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(6-(((S)-2,6-dioxopiperidin-3-yl)carbamoyl)pyridin-2-yl)non-8-yn-1-yl)-3-methyl-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(2-(((S)-2,6-dioxopiperidin-3-yl)carbamoyl)pyridin-4-yl)non-8-yn-1-yl)-3-methyl-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-N-(2-((R)-1- (methyl-d3)pyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(8-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oct-7-yn-1-yl)-3-methyl-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-3-methyl-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(5-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)pentyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-N-(2-((R)-1- ethylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-3-methyl-1H-indazole-6-carboxamide; 1-(5-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)pentyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(2-((6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)oxy)ethyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(9-(3-(((S)-2,6-dioxopiperidin-3-yl)carbamoyl)-2-fluorophenyl)non-8-yn-1-yl)-3-methyl-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(2-(2,6-dioxopiperidin-3-yl)-7-fluoro-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1-(9-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-1H-indazole-6- carboxamide; 1-(10-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl) dec-9-yn-1-yl)-3-methyl-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide;1-(9-(2-(2, 6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl) non-8-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrol[3, 2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-N-(2-((R)-5- methyl-5-azaspiro[2.4]heptan-6-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-N-(3- methyl-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-5-fluoro-3-methyl-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 3-cyclopropyl-1-(9-(2-(2, 6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl) non-8-yn-1-yl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)non-8-yn-1-yl)-3-methyl-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(3-(2, 6-dioxopiperidin-3-yl)-2-fluorophenyl) non-8-yn-1-yl)-3-methyl-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(6-(2, 6-dioxopiperidin-3-yl) pyridin-2-yl) non-8-yn-1-yl)-3-methyl-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl)-1H-indazole-6-carboxamide; (R)-1-(9-(3-(2, 4-dioxotetrahydropyrimidin-1(2H)-yl)-2-fluorophenyl) non-8-yn-1-yl)-3- methyl-N-(2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl)-1H-indazole-6- carboxamide; (R)-1-(9-(6-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)pyridin-2-yl)non-8-yn-1-yl)-3-methyl-N- (2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; (R)-1-(9-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-5-fluoro-1-methyl-1H-indazol-6- yl)non-8-yn-1-yl)-3-methyl-N-(2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)- 1H-indazole-6-carboxamide; N-(3-cyano-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1-(9-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-1H-indazole-6- carboxamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1-(9-(2-(2,6- dioxopiperidin-3-yl)-7-fluoro-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-1H-indazole-6- carboxamide; 1-(1-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)piperidin-4-yl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide;1-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidin-4- yl)methyl)piperidin-4-yl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4- yl)methyl)piperidin-4-yl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4- yl)methyl)piperidin-4-yl)-3-methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)-3-methyl-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(6-(1-(6-(((S)-2,6-dioxopiperidin-3-yl)carbamoyl)pyridin-2-yl)piperidin-4-yl)hexyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(4-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl) pent-4-yn-1-yl) cyclohexyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c] pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(9-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-(9-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1-(9-(2-((rel-S)- 2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-1H-indazole-6- carboxamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1-(9-(2-((rel-R)- 2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-3-methyl-1H-indazole-6- carboxamide; 1-(9-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-5-fluoro-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-(9-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)non-8-yn-1-yl)-5-fluoro-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl) methyl)-3-methyl- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c] pyridin-6-yl)-1H-indazole-6- carboxamide;1-(5-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)pentyl)-3-methyl-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)-3-methyl-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6-carboxamide; 1-((1-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; 1-((1-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide; and 1-(5-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)pentyl)-3- methyl-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-1H-indazole-6- carboxamide.

9. A compound according to any one of claims 1 to 7, wherein M is of formula (IV):wherein R8is an 8- to 10-membered heteroaryl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkyl and R10; R10is a 3-membered cycloalkyl ring; wherein M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK.

10. A compound which is a bicyclic compound of formula (I’) or a pharmaceutically acceptable salt thereof:wherein: one of Z1and Z3is -N(H)- and the other is N or -C(R4)-, Y1is N, Y2is N or -C(R6)-, and Y3is N or -C(R5)-; Hy is a 4- to 7-membered heterocyclic ring containing X and at least one N atom, wherein: ring Hy is linked to ring A via a C atom within ring Hy, said C atom also being linked to R2; a N atom within ring Hy is substituted by R1; X is a bond, -N(R11)-, O, S, -S(O)2-, -S(O)(NR11)-, or - C(R11)2-; and the rest of ring Hy is unsubstituted or substituted by one or two R3; L is –C(O)N(H)-, wherein the C atom of L is bonded to R8, and the N atom of L is bonded to ring B; R1is H, C1-4cycloalkyl, or C1-4alkyl which is itself unsubstituted or substituted with one C1-4alkoxy or one, two or three halo; R2is H or methyl; each R3is independently selected from C1-4alkyl, C1-4alkoxy, phenyl, a 5- to 6-membered heteroaryl ring and halo, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring; R4and R6are independently selected from H, halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R5is selected from H, halo, C1-4alkoxy, C3-5cycloalkyl and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; at least one of R4, R5and R6is not H; R8is an 8- to 10-membered heteroaryl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two R9; each R9is independently selected from halo and C1-4alkoxy; R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 6-membered heterocyclyl ring, and a phenyl ring, the group R10being unsubstitutedor substituted by one or two substituents independently selected from C1-4alkyl, C1-4alkoxy, and halo; each R11is independently selected from H, C1-4alkyl, and C1-4cycloalkyl.

11. A pharmaceutical composition which comprises a compound as defined in any one of claims 1 to 10 and a pharmaceutically acceptable carrier or diluent.

12. A compound as defined in any one of claims 1 to 10 for use in the treatment of the human or animal body by therapy.

13. A compound as defined in any one of claims 1 to 10 for use in the treatment of cancer.

14. The compound for use according to claim 13, wherein the cancer is a transcriptionally addicted cancer, such as breast cancer, acute leukemia, prostate cancer, bladder cancer, cholangiocarcinoma, colon adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, kidney chromophobe, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, pheochromocytoma and paraganglioma, rectum adenocarcinoma, stomach adenocarcinoma, uterine corpus endometrial carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, lung squamous cell carcinoma, neuroblastoma, midline glioma or sarcoma, preferably neuroblastoma or midline glioma.

15. The compound for use according to claim 13, wherein the cancer is acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN) or acute lymphoblastic leukaemia (ALL), for instance wherein the cancer is mixed-lineage leukaemia (MLL) rearranged (also known as KMT2Ar) acute leukemia (AML and ALL), NPM1 mutant acute leukemia, RUNX1-fusion acute leukemia, E2A-fusion acute leukemia, PML-fusion acute leukemia or NUP98-fusion acute leukemia.

Images